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1. Lipids and lipoprotein metabolism
Triglycerides (TG) and cholesterol are hydrophobic lipids that are absorbed by the 
intestine and synthesized by the liver, and have to be transported to other tissues for 
biosynthetic processes (i.e. cholesterol), energy production, heat production or storage 
(i.e. triglycerides). Since TG and cholesterol are insoluble in a hydrophilic environment, 
they circulate in the blood as constituents of water-soluble particles named lipoproteins. 
Lipoproteins consist of a lipid-rich inner core containing TG and cholesteryl esters (CE), 
the storage form of cholesterol, and an amphiphilic surface containing phospholipids 
(PL), unesterified cholesterol and one or more apolipoproteins. According to their 
density, lipoproteins are subdivided into five main classes, namely (from lowest to 
highest density) chylomicrons (CM), very low density lipoproteins (VLDL), intermediate 
density lipoproteins (IDL), low density lipoproteins (LDL) and high density lipoproteins 
(HDL). Lipoprotein metabolism will be discussed in more detail in sections 1.1-1.3, and 
a schematic overview is depicted in Figure 1. 
Figure 1. schematic overview of lipoprotein metabolism. See text for explanation. 
1.1 Chylomicrons




the intestine, the digestion products of dietary TG, i.e. 2-monoacylglycerol (MG) and 
fatty acids (FAs) are taken up by the enterocytes. Intracellularly, TG is reconstituted from 
2-MG and FA at the endoplasmic reticulum (ER) surface. TG droplets are surrounded 
by newly synthesized apolipoprotein B48 (apoB48), mediated by the microsomal 
triglyceride transfer protein (MTP), to form a prechylomicron that moves to the Golgi. 
There mature chylomicrons (CM) are formed by fusion with additional lipids, which are 
exported into the lamina propria of the basolateral membrane to enter the lymphatic 
system and ultimately the thoracic lymph duct 1-4. In addition to apoB48, CMs contain 
other apolipoproteins including apoAI, apoAIV, apoCI, apoCII and apoCIII 5. From the 
lymph system, CMs enter the blood circulation, where their TG are hydrolyzed by 
lipoprotein lipase (LPL) in metabolically active tissues into FAs and glycerol 6. FAs are 
taken up by skeletal muscle and heart for use as energy source, by brown adipose 
tissue (BAT) for thermogenesis, and by white adipose tissue (WAT) for storage of excess 
FAs as TG. As a consequence of lipolysis, CM remnants are produced that are enriched in 
cholesterol and have acquired apoE, through which the remnants are taken up by the 
liver via the apoE-binding receptors and binding sites , such as the LDL receptor (LDLr) 7, 
LDLr-related protein (LRP) 7, heparan-sulphate proteoglycans (HSPGs) 8, and possibly 
also scavenger receptor-class B type I (SR-BI) 9. 
1.2 VLDL, IDL and LDL
VLDL is synthesized and secreted by the liver. ApoB100 (and in rodents also apoB48 10) is 
the key structural protein of VLDL, which is also synthesized at the ER surface. Similarly 
to CM, the nascent apoB100 is partially lipidated to form a lipid-poor primordial VLDL 
particle mediated by MTP 11, and then the primordial VLDL particle fuse with TG-rich 
particles already present in the cytosol. The latter step is not only facilitated by MTP 12 
as for chylomicrons, but also by cideB 13 (a homolog of cell death-inducing DFF45-like 
effector). TGs used for VLDL assembly are synthesized de novo in the ER lumen in a 
preventive response to FA influx as albumin-bound free FA (released from adipose tissue 
or taken up by the intestine via the portal vein), or as TG-derived FA (after uptake of CM 
or VLDL remnants) 14. The most important genes involved in the de novo synthesis of 
TG are the transcription factor sterol regulatory element binding protein-1c (SREBP-1c), 
carbohydrate response element binding protein (ChREBP) 15, fatty acid synthase (FAS) 
and stearyl-Coa desaturase-1 (SCD-1)16, while the rate-limiting enzyme for the de 
novo synthesis of cholesterol is 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase 
(HMGCoA reductase). 
In addition to apoB100, VLDL contains other apolipoproteins such as apoCI, apoCII, 
apoCIII and apoE 17, 18. Like CM, their TGs are lipolyzed by LPL, and the VLDL remnant 
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(i.e. IDL) is taken up by the liver via apoE-binding receptors. In the fasted state when 
CM synthesis is low, LPL activity in adipose tissue is low while LPL activity in heart and 
skeletal muscle remains steady. Therefore, in the fasted state, VLDL-TG derived FA are 
mainly taken up by skeletal muscle and heart for energy use instead of by adipose 
tissue for storage. In addition to being taken up by the liver, IDL can be further lipolyzed, 
resulting in a TG-depleted lipoprotein called LDL6, 19. LDL has lost all apolipoproteins 
apart from apoB100, through which LDL can be taken up via the LDLr by the liver, but 
also by extrahepatic tissues that use cholesterol to maintain membrane integrity or to 
produce steroid hormones (e.g. adrenals, reproductive glands) 20, 21.
ApoB-containing lipoproteins (VLDL, IDL, LDL) are considered to be pro-atherogenic, 
as they can accumulate in the vessel wall, where they are modified and taken up by 
macrophages, initiating the process of atherosclerosis development.
1.3 HDL
Apolipoprotein AI (apoAI), the most abundant apolipoprotein of HDL, is synthesized in 
the liver and intestine, and is released into circulation. Subsequently, apoAI is lipidated 
with phospholipids (PL) via the ATP binding cassette transporter A1 (ABCA1) expressed 
in the liver and intestine to form a nascent discoidal HDL. This HDL particle can take 
up cholesterol from various peripheral tissues and cell types (e.g. from resident 
macrophages) via ABCA1 or from surface remnants (consisting of PL and cholesterol) 
upon lipolysis of TG-rich lipoproteins via phospholipid transfer protein (PLTP) 22, 23.The 
acquired cholesterol is then esterified by lecitin: cholesterol acyltransferase (LCAT), 
which results in CE accumulation in the core of the HDL particle. Under the action of 
LCAT, the nascent HDL becomes a mature spherical HDL containing more cholesterol 
and additional other apolipoproteins, such as apoAII, apoAIV, apoAV, apoCI, apoCII, 
apoCIII, apoE and apoM 24. During maturation, the affinity of HDL for other cholesterol 
export molecules is increased, including the ATP-binding cassette transporter G1 
(ABCG1) and SR-BI, which results in further cholesterol efflux from peripheral tissues 
and further maturation of HDL 25, 26. CE in HDL is selectively taken up via hepatic SR-BI 27, 
while TG and PL in HDL can be lipolyzed by hepatic lipase (HL) and endothelial lipase 
(EL) 28, 29. Alternatively, in humans and some other species, CE in HDL can be transferred 
to apoB-containing lipoproteins in exchange for TG via the cholesteryl ester transfer 
protein (CETP), and CE can subsequently be cleared by LDL receptor-mediated uptake 
of apoB-containing lipoproteins by the liver. Once taken up by the liver, HDL-derived 
cholesterol can be used for storage as CE, for assembly of VLDL, or for excretion into bile 
in the form of bile acids or neutral sterols.  




correlated with cardiovascular disease (CVD), the plasma HDL-cholesterol level is 
inversely correlated with CVD risk 30. However, recent studies suggested that the 
cholesterol efflux capacity of HDL is a better predictor of CVD than the concentration 
of HDL-cholesterol 31, 32. Cholesterol efflux is one of the most important steps of reverse 
cholesterol transport (RCT). This process describes the transport of cholesterol from the 
peripheral tissues like the vessel wall back to the liver, after which cholesterol is secreted 
via the bile into the feces. This RCT pathway is believed to be a major mechanistic basis 
for the protective effect of HDL on CVD. Besides mediating RCT, the antimicrobial, 
antioxidant, antiglycation, anti-inflammatory, nitric oxide-inducing, antithrombotic 
and immune-modulating properties of HDL are believed to also contribute to the anti-
atherogenic actions of HDL. In addition, HDL has recently been described to beneficially 
affect the pathophysiology of diabetes, including glucose homeostasis and energy 
homeostasis 33, 34. 
2. Atherosclerosis and non-alcoholic steatohepatitis
2.1 Atherosclerosis
Atherosclerosis is a multifactorial disease affecting the arteries, where lipids, connective 
tissue elements, smooth muscle cells (SMCs) and immune cells have accumulated, 
leading to a progressive narrowing of the vessel wall. With consequences such as the 
myocardial infarction or stroke, atherosclerosis remains the most common cause of 
death in the Western world 35. 
Atherosclerosis development starts with the infiltration of atherogenic lipoproteins 
such as LDL into the vessel wall. Upon being trapped, LDL can be modified (e.g. by 
oxidation or aggregation), and the modified LDL then stimulates endothelial cell 
(EC) activation and recruitment of immune cells. Within the sub-endothelial space, 
monocyte-derived macrophages take up the oxidized LDL and slowly turn into the 
large lipid-laden “foam cells”. Lesions consisting only of foam cells and other immune 
cells are called fatty streaks or mild lesions that mostly cause no clinical symptoms. 
Foam cells and activated ECs secrete inflammatory cytokines and chemokines that 
activate SMCs to proliferate and migrate into the atherosclerotic lesion. This causes the 
formation of a fibrous cap covering the fatty streak. When foam cells or SMCs die in 
the plaque, a necrotic core will be formed consisting of extracellular lipid and cellular 
debris. Depending on the composition, a plaque can be less or more vulnerable to 
rupture, resulting in different severity of clinical manifestations. Stable plaques usually 
have a thick fibrous cap and low amount of macrophages and lipid content, whereas 
unstable plaques have a thin fibrous cap and a relative high content of macrophages 
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and lipids and/or a necrotic core. Unstable plaques are prone to rupture, which leads 
to immediate blood clotting and the formation of a thrombus that will rapidly slow or 
stop blood flow, thus causing an infarction 36-38. 
2.2 Non-alcoholic steatohepatitis
Non-alcoholic fatty liver disease (NAFLD) is currently the leading cause of chronic liver 
disease in the Western world and the estimated prevalence in the general population 
ranges between 20% and 30%, rising to as high as 90% in morbidly obese individuals 39, 40. 
NAFLD embraces a pathological spectrum of liver diseases, from steatosis with 
virtually no evidence of hepatocellular injury or liver inflammation to non-alcoholic 
steatohepatitis (NASH) 41. NASH is characterized by fat accumulation (steatosis) in 
combination with hepatic inflammation (steatohepatitis) 42.  Although the mechanisms 
underlying the development of NASH are not completely established yet, the so-
called “two-hit hypothesis” postulates a sequential evolution from simple steatosis to 
NASH, with steatosis as the first critical “hit” and a necessary prerequisite for further 
liver damage, such as inflammation 43, 44. However, the “two-hit” model is challenged 
by findings from recent studies, which described that the development of hepatic 
inflammation was independent on the presence of hepatic steatosis 45, 46. In contrast, 
cholesterol or its modified form, trapped inside of hepatic macrophages, is an important 
trigger for NASH.
Liver biopsies are currently the golden standard methods used for the diagnosis 
of NASH. However, there are several severe limitations to liver biopsies, such as 
sampling error, differences in histopathologic interpretation, as well as patient stress 
and discomfort, risk of bleeding and long hospitalizations. Non-invasive imaging 
modalities have been advocated for liver steatosis only (e.g. 1H-magnetic resonance 
spectroscopy; MRS), but they are insufficient to distinguish NASH from just fatty liver 
disease. Although some liver enzymes, such as aminotransferase (ALT) that indicate 
liver damage, are elevated in patients with NASH, none of them yet can replace liver 
biopsy. Therefore, the discovery of a blood marker with a high sensitivity and specificity 
for NASH is eagerly awaited 47-49 .  
2.3 The association between atherosclerosis and NASH
The association between NASH and CVD has been studied in the last decades. 
Although some studies showed no significant association between NASH and markers 
of subclinical CVD (e.g. carotid-artery intimal medical thickness or carotid-artery 
calcium), most studies demonstrate that NASH is strongly associated with increased 




patients with NASH have a higher risk of mortality than the general population, mainly 
due to atherosclerotic diseases 52. However, the biological mechanisms linking NASH 
and CVD are still poorly understood. 
Several etiologies are potentially responsible for both development of 
atherosclerosis and NASH. For example, insulin resistance resulting in increased lipolysis 
is a pathogenic factor in the development and progression of NASH, and also plays 
a major role in the development of CVD 53. Also, dyslipidemia, reflected by increased 
plasma levels of (V)LDL-cholesterol and TG, and decreased level of HDL-cholesterol, is 
a major risk factors for both atherosclerotic diseases and fatty liver disease. In addition 
to impaired glucose and lipid metabolism, inflammation characterized by monocyte/
macrophage infiltration and macrophage foam cell formation also plays a vital role in 
the development of both atherosclerosis and NASH 45, 54-58. Recently, Bieghs et al. 59 put 
forward the hypothesis that NASH and atherosclerosis are actually two aspects of a 
shared disease with same etiology: the infiltration of macrophages.
Since atherosclerosis and NASH are strongly associated and share similar etiologies, 
the current treatment strategies for CVD are also tested for NASH in clinical practice, 
mainly aimed at improving lipid metabolism. Therapeutic options targeted to lowering 
plasma levels of TG and VLDL/LDL-cholesterol are established for treatment of CVD. 
Statins, which inhibit HMGCoA reductase thereby reducing the plasma (V)LDL-
cholesterol level, are the most widely used cholesterol-lowering drugs with a significant 
reduction of major cardiovascular (CV) events 60, 61 up to -50% when LDL-cholesterol is 
reduced by 2-3 mmol/L. However, even aggressive statin therapy does not eliminate 
CVD; in particularly, patients with a low level of HDL-cholesterol still have a significant 
risk for CV events after statin therapy. Therefore, strategies that e.g. can increase the 
plasma HDL-cholesterol level are investigated for the treatment of CVD. Although lipid-
lowering agents (e.g. statins and fibrates), anti-oxidants (e.g. vitamins C, E), and insulin-
sensitizers (e.g. thiazolidinediones, metformin) are considered to have beneficial 
effects in NASH outcomes, none of them have as yet shown adequate and convincing 
benefits 62, 63. Lifestyle modifications, such as weight loss, exercise, and restriction of 
nutrition intake are still the mainstays for the treatment of NASH 64. The search for novel 
pharmacological strategies to treat atherosclerosis and NASH is thus still warranted. 
3. ceTP and HDL-raising strategies, implications for cVD
Since HDL-cholesterol is inversely correlated with the risk of CVD and CETP plays 
a vital role in HDL-cholesterol metabolism (as described in section 1.3), CETP has 
become one of the most important targets for the development of HDL-raising and 
anti-atherosclerotic strategies. Several CETP inhibitors markedly increase plasma HDL-
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cholesterol, but also lipid-lowering compounds such as fibrates and niacin increase 
HDL-cholesterol level by affecting CETP expression and activity. However, the anti-
atherogenic capacity of HDL-raising strategies is still not established. 
3.1 CETP structure and function
Several mammalian species express CETP mRNA, including humans, monkeys, rabbits, 
pigs but not rats and mice 65-67. In humans, the CETP gene is located at chromosome 16 
(16q12-16q21), and consists of 16 exons and 15 introns, with the exons ranging from 
32bp to 250 bp 68, 69. The upstream flanking region of the CETP gene contains several 
regulatory sequences, including binding sites for SREBP, the ubiquitous nuclear factor-1, 
the hepatocyte nuclear factor-1 and a nuclear receptor binding site that is activated by 
liver X receptor (LXR) 70, 71. In humans, CETP mRNA is expressed mainly in the liver and 
adipose tissue, but also to some extent in spleen, heart, small intestine, adrenal gland, 
and skeletal muscle 66, 67, 70, 71. However, the relative contribution of adipose tissue and 
liver to total plasma CETP levels, and the cell types involved in CETP expression, are 
still obscure. CETP is a highly hydrophobic glycoprotein with a molecular mass (Mr) of 
70-74 kDa 68, 69. The crystal structure of CETP protein reveals a curved molecule with N- 
and C- terminal cavities and tunnel spanning the entire length of the protein 72. CETP is 
secreted into plasma where it binds mainly to HDL, and promotes bidirectional transfer 
of CE, TG, and, to a lesser extent, PL between plasma lipoproteins. Because most of CE 
in plasma resides in HDL, after esterification of cholesterol by LCAT, and the majority 
of the TG enters the plasma as a component of CM and VLDL [known collectively as 
triglyceride-rich lipoproteins (TRL)], the overall effect of CETP is a net mass transfer of 
CE from HDL to TRLs and LDL, and in exchange for TG from TRLs to HDL 73. 
3.2 Role of CETP in lipoprotein metabolism and atherosclerosis 
development
The effects of CETP on lipoprotein metabolism and atherosclerosis development in 
humans have been studied in subjects with genetic deficiencies of CETP. In the past 
two decades, at least 13 mutations in the CETP gene have been described in Japan 
and elsewhere 74-76. These mutations result in decreased plasma CETP mass and 
activity, associated with an increase in HDL-cholesterol level. Moreover, subjects with a 
homozygous CETP deficiency have not only elevated plasma levels of HDL-cholesterol, 
apoAI and apoAII, but also decreased plasma LDL-cholesterol and apoB levels 77. These 
observations suggest that inhibiting CETP in humans beneficially affects lipoprotein 




susceptibility to develop atherosclerosis in epidemiological studies are controversial. A 
large meta-analysis of 92 studies involving 113.833 participants showed that subjects 
with CETP polymorphisms that are associated with deceased CETP activity and mass 
have an elevated concentration of HDL-cholesterol and a decreased risk of CVD 78. A 
similar conclusion was drawn from an analysis of a cohort of 18.245 healthy women 
from the Women’s Genome Health Study, where polymorphisms in the CETP gene that 
impact on HDL-cholesterol levels also impact on the future risk of myocardial infarction 79. 
In contrast, other studies suggest that CETP mutations, despite of raising the plasma 
HDL-cholesterol level, do not lower the risk of CVD 80, 81. In fact, the Honolulu Heart 
Study suggested that heterozygote CETP deficiency even increased risk of CVD 82. 
Transgenic mice that express human CETP have significantly decreased plasma 
HDL-cholesterol level and slightly increased (V)LDL-cholesterol level 83-88. In contrast 
to the clear effects on lipoprotein metabolism, the effects of CETP expression on 
atherosclerosis gave conflicting results in those CETP transgenic mice. CETP has been 
shown to be pro-atherogenic in apoE deficient, LDL receptor deficient and APOE*3-
Leiden transgenic mice 84-86, whereas CETP was shown to be anti-atherogenic in APOC3 
and LCAT transgenic mice 87 88. 
3.3 CETP inhibitors as therapeutic HDL-raising agents
Small-molecule CETP inhibitors have been developed to raise the HDL-cholesterol 
level and have been tested for the treatment of CVD. Torcetrapib, one of the first CETP 
inhibitors, at a daily dose of 60 mg, increased the plasma HDL-cholesterol and apoAI 
level by 70% and 25%, respectively, and decreased the plasma LDL-cholesterol and apoB 
level by 25% and 12.5%, respectively, in the ILLUMINATE trial 89. Despite the beneficial 
effects on lipoprotein profiles, this trial was terminated early because of a statistically 
significant excess of deaths from both cardiovascular and noncardiovascular causes 
due to off-target side effects. Another CETP inhibitor, dalcetrapib, at a daily dose of 
900 mg reduced CETP activity by 37%, increased the HDL-cholesterol level by 34% and 
reduced the LDL-cholesterol level by 7% without showing off-target adverse effects 90. 
However, none of the clinical trials with dalcetrapib (dal-PLAQUE, dal-VESSEL, dal-
OUTCOMES) showed beneficial effects on carotid artery wall index, endothelial function 
or CVD outcomes 91-93 . The REVEAL trial, evaluating the effect of another CETP inhibitor, 
anacetrapib, on clinical CVD outcomes is ongoing, and the outcome is expected by 
2017. 
3.4 Other CETP-modulating HDL-raising agents
Fibrates belong to a class of drugs that exert their effects by activating the peroxisome 
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proliferator-activated receptor (PPAR) α and, to a lesser extent PPARβ/δ and PPARγ 94. 
Fibrates decrease plasma VLDL-TG by increasing VLDL-TG clearance and stimulating 
the oxidation of FFA, although fibrates increase VLDL-TG production in the liver 95. In 
clinical trials, fibrates not only reduce plasma TG (up to -50%), but also increase plasma 
HDL-cholesterol (up to +25%) 96-98. One mechanism underlying these effects of fibrates 
on the concentration of HDL-cholesterol could be that fibrates reduce hepatic CETP 
expression and plasma CETP activity 99, but it is unknown how fibrates reduce hepatic 
CETP expression. Fibrates were approved to treat dyslipidemia since 1993, yet there 
remains considerable controversy regarding their clinical efficacy for CVD 100. Two 
trials of gemfibrozil demonstrated improvements in cardiovascular outcomes 101, 102, 
but subsequent trials of bezafibrate and fenofibrate showed no significant overall 
cardiovascular benefit over placebo 103-105. 
Niacin (nicotinic acid) is the most potent HDL-cholesterol-raising drug used in clinic 
practice. In addition to raising HDL-cholesterol (up to +35%), niacin also decreases 
plasma LDL-C and TG levels (up to -25% and -50%, respectively) in humans 106. Niacin 
reduces hepatic CETP expression and plasma CETP activity thereby increasing the HDL-
cholesterol level in CETP Tg mice 107. Like for fibrates, the mechanism underlying the 
reducing effect of niacin on hepatic CETP expression is still unclear. Although niacin 
has been used in clinical practice for many decades for the prevention of CVD and 
numerous studies demonstrated a significant reduction in CV events by the niacin 
intervention 108-112, the clinical efficacy of niacin for the treatment of CVD has been 
challenged by the latest results from the AIM-HIGH (Atherothrombosis Intervention 
in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health 
Outcomes) trial 113 and HPS2-THRIVE (Heart Protection Study 2 Treatment of HDL to 
Reduce the Incidence of Vascular Events) trial, both of which were stopped because of 
failure to show clinical benefits with respect to attenuating CVD. 
Overall, given the fact that CETP inhibition increases the concentration of HDL-
cholesterol, CETP inhibitors and other compounds inhibiting CETP expression were 
thought to protect against the atherosclerosis development. However, the clinical 
efficacy of those compounds is challenged by the recent clinical trials (e.g. ILLUMINATE, 
dal-PLAQUE, dal-VESSEL, dal-OUTCOMES, AIM-HIGH, HPS2-THRIVE). Therefore, the 
hypothesis that raising the HDL-cholesterol level by inhibiting CETP has beneficial 
effects on CV events is at present not supported by clinical trials and further studies 




4. selected novel targets modulating lipoprotein 
metabolism for treatment of cVD and NAsH 
In addition to classical lipid-lowering drugs (e.g. statin, fibrates and niacin) used for 
the treatment of dyslipidemia, atherosclerosis and NASH, other novel strategies are 
currently under investigation, including those targeting the central and peripheral 
regulation of energy homeostasis and food intake (e.g. NPY and GLP-1), as well as those 
targeting inflammation (e.g. glucocorticoids).
 
4.1 NPY
The hypothalamus is considered as the main region of the brain regulating energy 
homeostasis and food intake. It contains a number of discrete neuronal populations 
or nuclei, one of which is the arcuate nucleus (ARC). The ARC contains two distinct 
groups of neurons with opposing effects on energy metabolism and food intake: one 
group consists of neurons with coexpression of neuropeptide Y (NPY) and agouti-
related peptide (AgRP), which activates appetite; the other group consists of neurons 
with coexpression of pro-opiomelanocortin (POMC) and cocaine- and amphetamine-
regulated transcript (CART), which inhibits appetite. 
The 36-amino acid peptides NPY, peptide YY (PYY) and pancreatic polypeptide, 
collectively called the NPY family of peptides, affect food intake by interacting with 
G-protein coupled Y receptors 114, 115. NPY is widely expressed in both the brain and 
the peripheral nervous system. Within the brain, NPY is highly expressed in the 
hypothalamus, especially in the ARC 114, 115. NPY/AgRP-neurons can be activated by a 
diversity of signals, such as leptin and insulin 116. Upon activation, NPY stimulates its 
Y receptors (Y1 and Y5) to activate circuits that increase food intake and fat storage. 
Concomitantly, by antagonizing the melanocortin 3 and 4 (MC3/4) receptors in the 
paraventricular nucleus (PVN), NPY/AgRP prevents the catabolic drive initiated by the 
melanocortin system 117. 
In addition to modulation of food intake and energy expenditure, central NPY 
displays multiple bio-functions in experimental studies. Intracerebroventricular (ICV) 
injection of NPY to rats powerfully increases food intake, causes obesity 118, influences 
glucose metabolism 119, and increases hepatic production of VLDL-TG 120, all of which are 
risk factors for CVD and NASH. Although ICV administration of NPY to mice has similar 
effects on food intake, energy homeostasis and glucose metabolism 121, 122 as in rats, 
the effect of NPY administration on lipid metabolism in mice is less clear. Sympathetic 
nervous system-targeted NPY overexpression in mice enhances neointimal formation in 
response to vascular injury, indicating the direct role of central NPY in the development 




In addition to hypothalamic NPY, numerous peripheral gut hormones show an important 
role in regulating energy homeostasis as well, such as ghrelin 124, 125, cholecystokinin 126, 127, 
oxyntomodulin 128, peptide Y 129 and glucagon like peptide-1 (GLP-1). 
GLP-1 is a cleavage production of the proglucagon molecule which is secreted by 
the intestinal L-cells and the brain 130, 131. It is released in response to food intake to 
stimulate glucose-dependent insulin production 132. In addition, GLP-1 exerts multiple 
other functions, including inhibition of food intake 133, slowing the gastric emptying 134, 
and inhibition of glucagon secretion 135. Moreover, administration of native GLP-1 
beneficially improves glucose metabolism in type 2 diabetes mellitus (T2DM) patients 135, 136, 
which implies GLP-1 as an ideal potential target for treatment of T2DM. GLP-1 mediates 
its effects via the GLP-1 receptor, a 7-transmembrane-spanning G-protein-coupled 
receptor that is abundantly expressed in various tissues 137, including the gastrointestinal 
tract, pancreatic islands, kidneys, heart and central nervous system 138.
However, therapeutic application of GLP-1 is hampered by its short circulating half-
life (<2 minutes), because it is rapidly degraded by dipeptidyl peptidase 4 (DPP-4) that is 
widely expressed in endothelium and intestinal mucosa 139. Therefore, pharmaceutical 
GLP-1 analogues that are resistant to degradation by DPP-4 have been developed with 
an improved pharmacokinetic profile related to a longer half-life, and with retained 
beneficial effects on T2DM, of which exenatide (a synthetic version of exendin-4) was 
approved in 2005 for the treatment of T2DM 140. In addition to reducing body weight and 
improving glucose metabolism, some preliminary studies suggested that exenatide 
also decreases the plasma TG level in patients with T2DM 141, 142, all of which are of clinical 
benefit for fatty liver disease. In addition, exenatide reduces hepatic lipid accumulation 
and reverses diet-induced hepatic steatosis in ob/ob mice 143. Although GLP-1 receptor 
agonism has the potential to treat hepatic steatosis, its impact on hepatic inflammation 
is still uncertain. Besides the clear beneficial effects on fatty liver disease, GLP-1 receptor 
agonism shows controversial effects on atherosclerosis. Several studies showed 
that both native GLP-1 and exendin-4 inhibits atherogenesis in ApoE-/- mice 144, 145. 
However, a recent study demonstrated that taspoglutide, another long-acting GLP-1 
receptor agonist, did not attenuate the development of atherosclerosis. Therefore, 
further studies evaluating the effects of GLP-1 receptor agonism on the development 
of atherosclerosis are warranted. 
4.3 Glucocorticoids
Glucocorticoids (GCs) (cortisol in humans and corticosterone in rodents) are a class 




the necessary behavioral and metabolic adaptations for the individual to be able to 
adequately cope with the stressor 146. GCs influence a wide variety of physiological 
functions, including energy homeostasis, food intake, body weight, glucose and 
lipid metabolism 147. For example, GCs stimulate gluconeogenesis in the liver and 
inhibit glucose uptake in the muscle and adipose tissue 148. Central administration of 
GCs induces hyperphagia and bodyweight gain 149. As a consequence, patients with 
Cushing’s syndrome (CS) who have excess of GCs display increased risk of obesity and 
insulin resistance 150. 
In contrast to the convincing effects on the glucose metabolism, GCs have 
contradictory effects on lipid metabolism. GCs increase circulating level of FAs through 
increasing lipogenesis and VLDL secretion from the liver as well as increasing LPL 
activity. However, GCs appear to have both lipolytic and lipogenic effects in white 
adipose tissue, depending on the dose and duration of exposure 151. Therefore, patients 
with excess GCs have inconsistent lipid levels. In clinical cohorts, the prevalence of 
hyperlipidemia in patients with CS varies from 38% to 71% 152. Moreover, a study by 
Mancini et al 153 has shown that hyperlipidemia does not correlate to the degree of 
hypercortisolism in patients with CS.
In addition, the role of GCs in the development of atherosclerosis is also not yet 
clearly established. On one hand, GCs are shown to induce vasoconstriction 154 and 
endothelial dysfunction 155, both of which can induce atherosclerosis development. 
Human data revealed an association between increased GC levels and a risk of CVD 
even after long-term successful correction of GC exposure 156. On the other hand, GCs 
have strong anti-inflammatory and immunosuppression properties, therefore may 
attenuate vascular inflammation, macrophage proliferation and differentiation 157 and 
thus suppressing atherosclerotic lesion formation 158. Therefore, further studies are 
eagerly required to truly answer whether GCs can be used for the treatment of CVD. 
5. outline of this thesis
In this thesis, we aimed to gain new insights into novel modulators of lipoprotein 
metabolism, as well as their implications for the treatment of atherosclerosis and NASH. 
Firstly, we determined the role of CETP in lipid metabolism, the effect of pharmacological 
and dietary intervention on plasma CETP levels, as well as the cellular origin of CETP. 
Since reconstituted HDL has different effects on VLDL metabolism in humans and 
mice, in chapter 2 we first evaluated the role of CETP in the effect of reconstituted 
HDL on VLDL metabolism by using APOE*3-Leiden (E3L) mice, an established model for 
human-like lipoprotein metabolism, with or without CETP expression. Previous studies 
in mice indicated that lipid-lowering strategies that reduce the hepatic lipid content 
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also reduce the hepatic CETP expression and plasma CETP concentration. To evaluate 
whether a reduction of the liver TG content, demonstrated to reduce hepatic CETP 
expression and plasma CETP levels in CETP transgenic mice, also reduces the plasma 
CETP concentration in humans, in chapter 3 we compared the effects of pioglitazone 
that reduces hepatic TG with that of metformin that has no effect on hepatic TG on 
the plasma CETP concentration. Subsequently, in chapter 4 we studied the effect of 
a lifestyle intervention (i.e. very low calorie diet), that was known to reduce hepatic 
TG, on plasma CETP concentration in obese patients with T2DM. To get more insight in 
the mechanism underlying the relation between liver lipid content and hepatic CETP 
expression, in chapter 5 we evaluated the mechanism underlying the CETP-lowering 
effect of niacin by using CETP transgenic mice. We showed that niacin, besides reducing 
the liver lipid content, also reduces the hepatic CETP expression by reducing the hepatic 
macrophage content. Since these data indicated that macrophages importantly 
contribute to hepatic CETP synthesis, we performed in chapter 6 more in-depth 
studies evaluating the contribution of various tissues and cell types to the plasma CETP 
level, by using both human cohorts and E3L.CETP transgenic mice, and were able to 
conclude that the plasma CETP concentration predicts hepatic macrophage content.
Then we investigated novel strategies for treatment of atherosclerosis and 
NASH. Since hypothalamic NPY influences energy homeostasis, food intake and 
lipid metabolism in rats, we set out to validate the effects of central NPY on hepatic 
VLDL production in wild-type mice in chapter 7, to ultimately investigate whether 
hypothalamic NPY, by inducing dyslipidemia, affects the development of atherosclerosis. 
Since human studies demonstrated that GLP-1 receptor agonism decreases plasma TG, 
we explored the underlying mechanisms in chapter 8 by evaluating the effects of GLP-1 
receptor analogues on hepatic VLDL production and de novo TG synthesis in E3L mice. 
Subsequently, in chapter 9 we studied the therapeutic applications of GLP-1 receptor 
agonist exendin-4 on the development of atherosclerosis and NASH simultaneously 
in E3L.CETP mice, and investigated the potential underlying mechanism. Because 
the effects of long-term glucocorticoid overexposure on the lipid metabolism and 
atherosclerosis development is not well established, in chapter 10 we investigated the 
effects of both transient and continuous glucocorticoid treatment on atherosclerosis 
development in E3L.CETP mice.
Finally, chapter 11 discusses the major findings of this thesis, and addresses the 
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Human data suggest that reconstituted HDL (rHDL) infusion can induce atherosclerosis 
regression. Studies in mice indicated that rHDL infusion adversely affects VLDL levels, 
but this effect is less apparent in humans. This discrepancy may be explained by the 
fact that humans, in contrast to mice, express cholesteryl ester transfer protein (CETP). 
The aim of this study was to investigate the role of CETP in the effects of rHDL on VLDL 
metabolism by using APOE*3-Leiden (E3L) mice, a well-established model for human-
like lipoprotein metabolism. At 1 h after injection, rHDL increased plasma VLDL-C 
and TG in E3L mice, but not in E3L mice cross-bred onto a human CETP background 
(E3L.CETP mice). This initial raise in VLDL was caused by competition between rHDL 
and VLDL for LPL-mediated TG hydrolysis, and was thus prevented by CETP. At 24 h 
after injection, rHDL caused a second increase in VLDL-C and TG in E3L mice, whereas 
rHDL even decreased VLDL in E3L.CETP mice. This secondary raise in VLDL was due to 
increased hepatic VLDL-TG production. Collectively, we conclude that CETP protects 
against the rHDL-induced increase in VLDL. We anticipate that studies evaluating the 
anti-atherosclerotic efficacy of rHDL in mice that are naturally deficient for CETP should 
be interpreted with caution, and that treatment of atherogenic dyslipidemia by rHDL 
should not be combined with agents that aggressively reduce CETP activity.
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iNTroDUcTioN
Dyslipidemia is an important risk factor for cardiovascular disease (CVD). Current 
treatment mainly focuses on lowering of LDL-cholesterol (C), e.g. by statins. LDL-C 
lowering treatment results in a significant reduction in the morbidity and mortality 
of CVD, but can not prevent the majority of cardiovascular events 1, 2. Prospective 
epidemiological studies have demonstrated a strong inverse correlation between 
HDL-C and CVD 3, and recent studies revealed that high HDL-C levels are indeed 
protective against plaque progression 4. Although the exact mechanisms by which 
HDL protects are unclear, HDL has been shown to have antioxidant, antithrombotic and 
anti-inflammatory properties, and to mediate reverse cholesterol transport (RCT) via 
the hepatobiliary route 5. Therefore, new strategies to raise HDL-C are currently being 
developed to prevent and treat CVD. 
Various therapeutic strategies are currently under development to raise HDL levels, 
including cholesteryl ester transfer protein (CETP) inhibition, niacin, upregulation 
of apoAI expression and infusion of apoAI mimetics or reconstituted HDL (rHDL) 6. 
Although still in early stage of development, infusion of (r)HDL seems to be a promising 
strategy for the treatment of CVD. Recent reviews have demonstrated that infusion 
of rHDL improves atherosclerotic plaque characteristics both in animal models and 
in humans 7-9. For example, rHDL, composed of recombinant human apoAIMilano and 
phosphatidylcholine, rapidly mobilized tissue cholesterol and reduced the lipid and 
macrophage content of atherosclerotic plaques after a single injection into apoE-
deficient mice 10. Moreover, it prevented the progression of aortic atherosclerosis 
as well as promoted the stabilization of plaques after 6 weeks of administration 11. 
Recent clinical trials assessed the effect of rHDL consisting of human apoAI and 
phosphatidylcholine (CSL-111) as a potential HDL-raising therapeutic strategy. Short-
term infusion of CSL-111 significantly improved the plaque characterization index and 
coronary score on quantitative coronary angiography 12. In addition, a single dose of 
rHDL led to acute changes in plaque characteristics with a reduction in lipid content, 
macrophage size and inflammatory mediators 13. 
Albeit that rHDL thus seems to beneficially modulate atherosclerosis in mice and 
humans, differences have been observed with respect to modulation of VLDL levels. 
Infusion of rHDL into apoE-deficient mice increased (V)LDL-C in both acute and chronic 
studies 10, 11, whereas rHDL did not adversely affect (V)LDL-C in clinical studies 12, 13. 
This discrepancy may be explained by the fact that, in contrast to mice 14, humans 
express CETP 15, a crucial factor involved in the metabolism of both (V)LDL and HDL by 
mediating the transfer of triglycerides (TG) and cholesteryl esters (CE) between these 
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lipoproteins. Therefore, the aim of this study was to elucidate the role of CETP in the 
effects of rHDL on VLDL metabolism. We used APOE*3-Leiden (E3L) transgenic mice, a 
unique model for human-like lipoprotein metabolism, which have been crossbred with 
mice expressing human CETP under control of its natural flanking regions 16, resulting 
in E3L.CETP mice. This allows distinguishing between the effect of rHDL administration 
on VLDL metabolism in the absence and presence of CETP-mediated lipid transfer. 
mATeriALs AND meTHoDs
Animals
Hemizygous human CETP transgenic (CETP) mice, expressing human CETP under the 
control of its natural flanking regions 16, were purchased from the Jackson Laboratory 
(Bar Harbor, ME) and crossbred with hemizygous E3L mice 17 at our Institutional Animal 
Facility to obtain E3L.CETP mice 18. In this study, female mice were used, housed under 
standard conditions in conventional cages with free access to food and water. At the 
age of 12 weeks, mice were fed a semi-synthetic Western-type diet, containing 1% 
(w/w) corn oil and 15% (w/w) cacao butter (Hope Farms, Woerden, The Netherlands) 
with 0.25% (w/w) cholesterol (E3L mice) or 0.1% (w/w) cholesterol (E3L.CETP mice) 
for three weeks, aimed at yielding comparable VLDL levels between both mouse 
genotypes. Upon randomization according to total plasma cholesterol (TC) and TG 
levels, mice received a single intravenous injection of rHDL (CSL-111; CSL Behring AG, 
Bern, Switzerland) (250 mg/kg in 250 µL PBS) or vehicle. Experiments were performed 
after 4 h of fasting at 12:00 pm with food withdrawn at 8:00 am. The institutional Ethical 
Committee on Animal Care and Experimentation has approved all experiments.
Reconstituted HDL
rHDL (CSL-111) consists of apoAI isolated from human plasma and phosphatidylcholine 
from soybean with a molar ratio of 1:150. Before infusion, rHDL was reconstituted with 
50 mL of sterile water, yielding 62.5 mL of clear, pale yellow solution, pH 7.5, and 10% 
(w/v) sucrose as a stabilizing agent. The final apoAI and PL concentrations were 20 and 
86 mg/mL, respectively.
Plasma lipid and lipoprotein analysis 
Plasma was obtained via tail vein bleeding and assayed for TC, TG and phospholipids 
(PL) using the commercially available enzymatic kits 236691, 11488872 (Roche 
Molecular Biochemicals, Indianapolis, IN, USA) and phospholipids B (Wako Chemicals, 
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Neuss, Germany), respectively. The distribution of lipids over plasma lipoproteins was 
determined using fast protein liquid chromatography (FPLC). Plasma was pooled per 
group, and 50 μL of each pool was injected onto a Superose 6 PC 3.2/30 column (Äkta 
System, Amersham Pharmacia Biotech, Piscataway, NJ, USA) and eluted at a constant 
flow rate of 50 μL/min in PBS, 1 mM EDTA, pH 7.4. Fractions of 50 μL were collected and 
assayed for TC, TG and PL as described above.
Plasma human apoAI concentration
Plasma human apoAI concentrations were determined using a sandwich ELISA. Goat 
anti-human apoAI antibody (Academy Biomedical Co., Inc., Houston, TX; 11A-G2b) 
was coated overnight on to Costar medium binding plate (Costar, Inc., New York, NY) 
(3 µg/mL) at 4°C and incubated with diluted mouse plasma (dilution, 1:100,000) for 
2 h at 37°C. Subsequently, horseradish peroxidase-conjugated goat antihuman apoAI 
(Academy Biomedical; 11H-G1b) was added and incubated for 2 h at 37°C. Horseradish 
peroxidase was detected by incubation with tetramethylbenzidine (Organon Teknika, 
Boxtel, The Netherlands) for 15 min at room temperature. Human apoAI (Academy 
Biomedical; 11P-101) was used as a standard.
In vivo clearance of VLDL-like emulsions 
Glycerol tri[3H]oleate- and [1a,2a(n)-14C]cholesteryl oleate-double labeled VLDL-like 
emulsion particles (80 nm) were prepared as described by Rensen et al. 19. In short, 
radiolabeled emulsions were obtained by adding 200 µCi of glycerol tri[3H]oleate 
and 20 µCi of [14C]cholesteryl oleate to 100 mg of emulsion lipids before sonication 
(isotopes obtained from GE Healthcare, Little Chalfont, U.K.). Mice were fasted for 4 h, 
sedated with 6.25 mg/kg acepromazine (Alfasan), 6.25 mg/kg midazolam (Roche), and 
0.3125 mg/kg fentanyl (Janssen-Cilag) and injected with the radiolabeled emulsion 
particles (0.15 mg TG in 200 µL PBS) via the tail vein. At indicated time points after 
injection, blood was taken from the tail vein to determine the serum decay of glycerol 
tri[3H]oleate and 20 µCi of [14C]cholesteryl oleate.
In vitro LPL activity assay
The effect of rHDL on LPL activity was determined essentially as described 20. First, 
glycerol tri[3H]oleate-labeled VLDL-like emulsion particles (200 µg of TG, corresponding 
to a final concentration of 0.5 mg/mL), prepared as described above, were added to 
the indicated amounts of rHDL (or vehicle containing sucrose or sodium cholate only) 
and heat-inactivated human serum (20 µL, corresponding to a final concentration of 
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5% v/v) in a total volume of 75 µL of phosphate-buffered saline. Subsequently, 0.1 
M Tris.HCl (pH 8.5) was added to a total volume of 200 µL and incubation mixtures 
were equilibrated at 37°C. At t=0, bovine LPL (final concentration 3.5 U/mL, Sigma) 
in 200 µL of 120 mg/mL free fatty acid-free BSA (Sigma), corresponding with a final 
concentration of 60 mg/mL, was added (37°C). At t=15, 30, 60, 90 and 120 min, [3H]
oleate generated during lipolysis by LPL was extracted. Hereto, 50 µL samples were 
added to 1.5 mL extraction liquid (CH3OH: CHCl3: heptane: oleic acid (1410: 1250: 
1000: 1, v/v/v/v). Samples were mixed and 0.5 mL of 0.2 M NaOH was added. Following 
vigorous mixing and centrifugation (10 min at 1000 g), 3H radioactivity in 0.5 mL of the 
aqueous phase was counted. After taking the last samples, 50 µL of the incubations 
were also directly counted, representing the total amount of radioactivity in the assay. 
Lipolysis rate (i.e. LPL activity) was calculated by linear regression between incubation 
time and percentage of [3H]oleate released.
Hepatic VLDL-TG and VLDL-apoB production 
Mice were fasted for 4 h, with food withdrawn at 8:00 a.m., prior to the start of the 
experiment. During the experiment, mice were sedated as described above. At t=0 
min blood was taken via tail bleeding and mice were i.v. injected with 100 µL PBS 
containing 100 µCi Trans35S label to measure de novo total apoB synthesis. After 30 min, 
the animals received 500 mg of tyloxapol (Triton WR-1339, Sigma-Aldrich) per kg body 
weight as a 10% (w/w) solution in sterile saline, to prevent systemic lipolysis of newly 
secreted hepatic VLDL-TG 21. Additional blood samples were taken at 15, 30, 60, and 90 
min after tyloxapol injection and used for determination of plasma TG concentration. 
At 120 min, the animals were sacrificed and blood was collected by orbital puncture for 
isolation of VLDL by density gradient ultracentrifugation. 35S-apoB was measured in the 
VLDL fraction and VLDL-apoB production rate was shown as dpm.h-1 22.
Statistical analysis
All data are presented as means ± SD. Data were analyzed using the unpaired Student’s 
t test. P-values less than 0.05 were considered statistically significant.
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resULTs
Infusion of rHDL transiently increases plasma apoAI and phospholipid 
levels in both E3L and E3L.CETP mice 
To investigate the role of CETP in the effects of rHDL infusion on VLDL metabolism, 
female E3L mice with or without human CETP expression received a single intravenous 
injection of rHDL. To assess the kinetics of rHDL that consists of humans apoAI and 
PL, plasma levels of human apoAI and phospholipid was determined over time (Fig. 1) 
rHDL caused a transient increase in plasma human apoAI and PL levels in both E3L mice 
(Fig. 1A, C) and E3L.CETP mice (Fig. 1B, D). Human apoAI and PL were cleared at a similar 
rate, and were disappeared from plasma after approximately 24 h. At 1 h after injection, 
lipoproteins in plasma were separated and the distribution of human apoAI and PL 
were determined (Fig. 2). rHDL appeared to integrate into the endogenous HDL pool 
in both E3L and E3L.CETP mice, since both human apoAI (Fig. 2A, B) and PL (Fig. 2C, D) 
eluted in fractions representing HDL. In addition, PL derived from rHDL selectively 
integrated into (V)LDL fraction (Fig. 2C, D). The presence of rHDL-PL in (V)LDL is not 
due the presence of large rHDL aggregates that would elute in the void volume, since 
apoAI is not detected in the void volume (Fig. 3A), but is explained by a time-dependent 
transfer of PL to endogenous VLDL as evident from incubation of rHDL with plasma 
from E3L mice (Fig. 3B) and E3L.CETP mice (Fig. 3C) in vitro. 
Figure 1. effect of rHDL on plasma 
human apoAi and phospholipid in 
e3L and e3L.ceTP mice. E3L (A, C) and 
E3L.CETP (B, D) mice were fed a Western-
type diet for 3 weeks. Subsequently, they 
received a single intravenous injection 
of rHDL (250 mg/kg in 250 µL PBS) or 
vehicle. Blood was drawn at the indicated 
time points and plasma was assayed for 
human apoAI (A, B) and phospholipid 
(C, D). Values are means ± SD (n=8-
10); *P<0.05, **P<0.01, ***P<0.001 as 
compared to the control group.
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Figure 2. effect of rHDL on the 
lipoprotein distribution of human 
apoAi and phospholipid at 1 h after 
injection in E3L and E3L.CETP mice. 
E3L (A, C) and E3L.CETP (B, D) mice 
were fed a Western-type diet for 3 
weeks. Subsequently, they received 
a single intravenous injection of rHDL 
(250 mg/kg in 250 µL PBS) or vehicle. 
After 1 h, blood was drawn and 
plasma was pooled per group (n=8-
10). Pooled plasma was fractionated 
using FPLC on a Superose 6 column 
and the individual fractions were 
assayed for human apoAI (A, B) and 
phospholipid (C, D).
Figure 3. effect of in vitro incubation 
of rHDL with E3L and E3L.CETP 
mouse plasma on phospholipid 
distribution. E3L and E3L.CETP 
mice were fed a Western-type diet 
for 3 weeks, and fresh plasma was 
collected. rHDL was incubated (1 h 
at 37°C) without mouse plasma (A) 
or with plasma of E3L mice (B) or E3L.
CETP mice (C). Samples were pooled 
per group (n=8-10) and fractionated 
using FPLC on a Superose 6 column, 
and the individual fractions were 
assayed for phospholipid. 
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Infusion of rHDL affects plasma levels of endogenous lipids 
differentially in E3L and E3L.CETP mice 
Albeit rHDL was cleared at a similar rate in E3L and E3L.CETP mice, its effects on 
endogenous plasma levels of cholesterol and TG were clearly different in both mouse 
types (Fig. 4). At 1 h after injection, rHDL significantly increased plasma cholesterol (C) 
in both E3L mice (+63%; P<0.001) (Fig. 4A) and E3L.CETP mice (+28%; P<0.01) (Fig. 4B). 
However, at 24 h after injection, rHDL still significantly increased plasma cholesterol in 
E3L mice (+26%, P<0.01) (Fig. 4A) but actually decreased plasma cholesterol in E3L.CETP 
mice (-22%, P<0.01) (Fig. 4B). In addition, whereas rHDL caused a significant increase in 
plasma TG levels in E3L mice at both 1 h (+89%; P<0.01) and 24 h after injection (+67%; 
P<0.01) (Fig. 4C), rHDL did not significantly increase plasma TG at any time point in E3L.
CETP mice (Fig. 4D). 
Figure 4. effect of rHDL on plasma 
cholesterol and triglycerides in E3L 
and E3L.CETP mice. E3L (A, C) and E3L.
CETP (B, D) mice were fed a Western-
type diet for 3 weeks. Subsequently, 
they received a single intravenous 
injection of rHDL (250 mg/kg in 250 
µL PBS) or vehicle. Blood was drawn at 
the indicated time points and plasma 
was assayed for total cholesterol (A, 
B) and triglycerides (C, D). Values are 
means ± SD (n=8-10); *P<0.05, **P<0.01, 
***P<0.001 as compared to the control 
group. 
At short term, rHDL raises HDL-C in E3L and E3L.CETP mice, and 
increases VLDL mainly in E3L mice
To investigate the mechanism underlying the early effects of rHDL infusion on plasma 
lipids, plasma was obtained at 1 h after injection and lipoproteins were fractionated by 
FPLC (Fig. 5). rHDL increased HDL-C in both E3L mice (Fig. 5A) and E3L.CETP mice (Fig. 5B), 
indicating that rHDL induces a rapid cholesterol efflux from peripheral tissues into 
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plasma. In addition, rHDL markedly increased VLDL-C (Fig. 5A) and VLDL-TG (Fig. 5C) in 
E3L mice, while its VLDL-increasing effect was only modest in E3L.CETP mice (Fig. 5B, D). 
To investigate whether the raise in VLDL was due to competition between rHDL and 
VLDL for binding and subsequent TG hydrolysis by LPL, we assessed the effect of rHDL 
on the plasma kinetics of intravenously injected glycerol tri[3H]oleate [14C]cholesteryl 
oleate double-labeled VLDL-like emulsion particles (Fig. 6). Indeed, rHDL decreased the 
plasma clearance of the VLDL-like emulsion particles, including glycerol tri[3H]oleate 
and [14C]cholesteryl oleate, in both E3L mice (Fig. 6A, C) and E3L.CETP mice (Fig. 6B, D). 
An in vitro LPL activity assay confirmed that rHDL dose-dependently decreases LPL-
mediated lipolysis of VLDL-like emulsion particles (Fig. 7), whereas sucrose and sodium 
cholate at amounts present at the various rHDL concentrations did not (not shown). 
These data thus indicate that rHDL competes for the binding of VLDL-like emulsion 
particles with LPL in both E3L and E3L.CETP mice, resulting in delayed clearance of 
TG-derived fatty acids (i.e. 3H-activity) as well as the resulting core remnants (i.e. 
14C-activity). The fact that rHDL does not substantially raise VLDL levels in E3L.CETP mice 
is thus probably related to rapid remodeling of VLDL by CETP.
Figure 5. effect of rHDL on 
lipoprotein distribution of 
cholesterol and triglycerides at 1 h 
after injection in E3L and E3L.
CETP mice. E3L (A, C) and E3L.CETP 
(B, D) mice were fed a Western-type 
diet for 3 weeks. Subsequently, they 
received a single intravenous injection 
of rHDL (250 mg/kg in 250 µL PBS) 
or vehicle. Blood was drawn and 
plasma was pooled per group (n=8-
10). Pooled plasma was fractionated 
using FPLC on a Superose 6 column 
and the individual fractions were 
assayed for total cholesterol (A, B) and 
triglycerides (C, D). 
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Figure 6. effect of rHDL on the plasma 
clearance of VLDL-like emulsion 
particles in E3L and E3L.CETP mice. 
E3L (A, C) and E3L.CETP (B, D) mice were 
fed a Western-type diet for 3 weeks, 
and they received a single intravenous 
injection of rHDL (250 mg/kg in 200 µL 
PBS) or vehicle. After 1 min, mice were 
intravenously injected with glycerol 
tri[3H]oleate- and [14C]cholesteryl oleate-
double labeled VLDL-like emulsion 
particles (0.15 mg TG in 200 µL PBS). 
Blood was drawn at the indicated time 
points and 3H and 14C-activity was 
determined. Values are means ± SD 
(n=8); *P<0.05, **P<0.01, ***P<0.001 as 
compared to the control group. 
Figure 7. effect of rHDL on in vitro 
LPL activity Glycerol tri[3H]oleate-
labeled VLDL-like emulsion particles 
were incubated at 37 °C with bovine 
LPL (3.5 U/mL) in 0.1 M Tris.HCl (pH 8.5) 
in the presence of heat-inactivated 
human serum (5%, v/v) and free fatty 
acid-free BSA (60 mg/mL). [3H]oleate 
generated during lipolysis was extracted 
after 15, 30, 60, 90 and 120 min of 
incubation. The lipolysis rate (i.e. LPL 
activity) was calculated by the linear 
regression between incubation time 
and percentage of [3H]oleate generated. 
Values are means ± SD (n=3); **P<0.01, 
***P<0.001 as compared to control 
incubations containing vehicle. 
At long term, rHDL raises VLDL in E3L mice and decreases VLDL in E3L.
CETP mice
To determine the mechanism underlying the divergent long-term effects of rHDL 
infusion on plasma was also obtained at 24 h after administration and lipoproteins 
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were fractionated by FPLC (Fig. 8). In both E3L and E3L.CETP mice, the effect of rHDL 
on increasing HDL-C levels had disappeared (Fig. 8A, B). However, whereas rHDL 
still significantly raised VLDL-C (+60%) (Fig. 8A) and VLDL-TG (+86%) (Fig. 8C) in E3L 
mice, rHDL actually decreased VLDL-C (-25%) in E3L.CETP mice (Fig. 8B). Since it has 
been shown that increasing the flux of HDL to the liver can increase the availability 
of substrate for hepatic VLDL synthesis and subsequently VLDL-TG secretion 23, we 
speculated that rHDL may have increased the VLDL production. Therefore, the effect 
of rHDL on VLDL production was evaluated after injection of Triton WR1339 (tyloxapol) 
to block LPL-mediated lipolysis (Fig. 9). Indeed, at 24 h after administration of rHDL, 
the VLDL-TG production rate was increased in E3L mice (+36%; P<0.01) (Fig. 9A). ApoB 
production was not affected (Fig. 9C), indicating that rHDL increases lipidation of VLDL 
particles rather than increasing the VLDL particle secretion rate. Likewise, rHDL tended 
to increase the VLDL-TG production rate (Fig. 9B) without affecting the apoB production 
rate (Fig. 9D) in E3L.CETP mice.
Figure 8. effect of rHDL on lipoprotein 
distribution of cholesterol and 
triglycerides at 24 h after injection in 
E3L and E3L.CETP mice. E3L (A, C) and 
E3L.CETP (B, D) mice were fed a Western-
type diet for 3 weeks. Subsequently, they 
received a single intravenous injection of 
rHDL (250 mg/kg in 250 µL PBS) or vehicle. 
Blood was drawn and plasma was pooled 
per group (n=8-10). Pooled plasma was 
fractionated using FPLC on a Superose 6 
column and the individual fractions were 
assayed for total cholesterol (A, B) and 
triglycerides (C, D). 
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Figure 9. effect of rHDL on the hepatic 
VLDL-TG production at 24 h after 
injection in E3L and E3L.CETP mice. 
E3L (A, C) and E3L.CETP (B, D) mice were 
fed a Western-type diet for 3 weeks, 
and they received a single intravenous 
injection of rHDL (250 mg/kg in 250 µL 
PBS) or vehicle. At 24 h after rHDL or 
vehicle injection, mice were injected 
with Trans35S label and tyloxapol to 
block VLDL-TG clearance. Blood was 
drawn at the indicated time points 
and plasma TG concentrations were 
determined. VLDL-TG production rate 
was calculated from the slopes of the 
TG-time curves from the individual mice 
(A, B). At 120 after tyloxapol injection, 
mice were exsanguinated and VLDL 
was isolated by ultracentrifugation. 
35S-activity was determined and VLDL-
apoB production rate was calculated as 
dpm.h-1 (C, D). Values are means ± SD 
(n=7-11); **P<0.01 as compared to the 
control group. 
DiscUssioN 
In this study, we investigated the role of CETP in the effects of rHDL on VLDL metabolism 
by using E3L mice with or without human CETP expression. In both E3L and E3L.CETP 
mice, rHDL caused a similar transient increase in plasma human apoAI and PL levels and 
induced a transient increase in the endogenous HDL-C pool. However, rHDL caused an 
increase in VLDL in E3L mice, at both 1 h and 24 h after injection, which was prevented 
by CETP expression in E3L.CETP mice.
We observed that rHDL caused a rapid increase in VLDL-TC and VLDL-TG in E3L mice 
within 1 h after administration. This is in line with previous observations showing that 
rHDL, composed of human apoAIMilano and PL, also increased the VLDL-TC pool in apoE-
deficient mice at 1 h after injection 10. These effects can not be simply explained by 
transfer of lipid compounds from rHDL to VLDL, since rHDL does not contain cholesterol 
or triglycerides. Rather, we speculated that infusion of a substantial amount of rHDL 
may interfere with endogenous VLDL catabolism. Indeed, rHDL decreased the plasma 
clearance of VLDL-like emulsion particles, including the clearance of both glycerol 
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tri[3H]oleate and [14C]cholesteryl oleate. Apparently, rHDL competes with endogenous 
VLDL for binding to triacylglycerol hydrolases, resulting in impaired hydrolysis of TG 
within VLDL. Indeed, rHDL dose-dependently inhibited LPL activity in an in vitro assay. 
At an rHDL concentration of 0.625 mg/mL, resulting in an rHDL: TG ratio similar to the 
in vivo situation, rHDL inhibited LPL activity by as much as 80%. Sucrose and sodium 
cholate, both present in rHDL, did not inhibit LPL activity in vitro and are thus unlikely 
to inhibit LPL in vivo. As a consequence of LPL inhibition by rHDL in vivo, the clearance 
of core remnants is attenuated and plasma VLDL levels are increased. Our finding that 
normalization of elevated PL levels at 8 h after injection also normalized plasma TG 
levels in E3L mice is consistent with such a mechanism.
In addition to increasing VLDL at 1 h after injection, rHDL caused a second raise in 
VLDL-TC and VLDL-TG in E3L mice at 24 h after administration. Since competition of rHDL 
for VLDL clearance mechanisms can be excluded at this time point, as rHDL has been 
cleared from the circulation, we hypothesized that rHDL may have caused an increase 
in hepatic VLDL production. Indeed, we observed that rHDL increased the production 
rate of VLDL-TG without affecting the production rate of VLDL-apoB. Since each VLDL 
particle contains a single molecule of apoB, this indicates that rHDL infusion increases 
the lipidation of hepatic apoB rather than increasing the number of VLDL particles 
produced. Interestingly, it has previously been observed that increasing the flux of HDL 
to the liver by hepatic overexpression of SR-BI also increases the VLDL-TG production 
rate, and that HDL-derived cholesterol can be re-secreted from the liver within VLDL 
particles 23. Therefore, we postulate that, in a similar manner, infusion of rHDL causes 
an increased net flux of lipids to the liver. We did show that rHDL transiently enhanced 
HDL-C, which may at least partly be attributed by efflux of cholesterol from peripheral 
tissues. This increased HDL-C may subsequently be taken up by the liver via SR-BI, 
which could then be re-secreted within VLDL. However, it is even more likely that a high 
flux of rHDL-associated PL to the liver enhances the amount of hepatic TG available 
for secretion as VLDL-TG. Indeed, it has been demonstrated that HDL-associated 
phosphatidylcholine that has been taken up by hepatocytes is converted to TG after 
phosphatidylcholine-phospholipase C-mediated hydrolysis of phosphatidylcholine 
resulting in diacylglycerol that is subsequently converted into TG by DGAT2 24.
Although rHDL infusion caused a clear hyperlipidemic side-effect in E3L mice, 
there was no increase in VLDL in E3L.CETP mice at any time point, albeit rHDL induced 
a significant decrease of VLDL clearance at short term and tended to increase VLDL 
production at long term in E3L.CETP mice similarly to E3L mice. Expression of CETP 
thus clearly prevents the adverse effects of rHDL on VLDL levels. These data are in line 
with various human studies in which infusion of rHDL was used as an experimental 
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treatment of CVD 12, diabetes 25 and inflammation 26. In these clinical studies, no specific 
adverse VLDL increasing effects have been reported, which is in line with our data that 
human CETP may protect against rHDL-induced elevation of VLDL.
It is interesting to speculate on the mechanism(s) underlying the protective effect 
of CETP on the rHDL-induced raise in VLDL. It is well-known that CETP mediates the 
transfer of CE from HDL particles to LDL and VLDL particles in exchange for TG, and 
that this reciprocal neutral lipid transfer approaches equilibrium under physiological 
conditions. However, under conditions of increased VLDL levels as observed at 1 and 
24 h after administration of rHDL to E3L mice, the increase in VLDL results in elevated 
acceptor activity for CETP, which would result in an increased net rate of TG transfer 
from VLDL particles to both HDL and LDL particles 27. Both TG-enriched HDL and LDL 
particles are avidly bound to hepatic lipase (HL) that effectively hydrolyzes TG (as well 
as PL) to form small dense LDL and HDL, respectively 28, thereby effectively eliminating 
TG from plasma. 
Based on our data and literature studies, we propose the following mechanism by 
which CETP has a protective effect on rHDL-induced increase in VLDL. Infusion of rHDL 
initially decreases VLDL clearance via blocking of LPL-mediated lipolysis and, at a later 
stage, increases VLDL production via HDL-mediated delivery of lipids to the liver, both 
of which processes increase plasma VLDL levels. The transient accumulation of VLDL 
particles leads to an increase of the CETP activity, resulting in an accelerated transfer 
of TG from VLDL to HDL and LDL, in which TG is hydrolyzed quickly through the action 
of HL.
Since our primary research question was to examine the effect of CETP on the rHDL-
induced increase on VLDL metabolism, we used saline as a control for rHDL treatment 
similarly as applied in clinical trials. It should be noted that such a study set-up does not 
allow evaluating the individual contributions of apoAI versus lipids. As the cholesterol-
efflux properties of rHDL could largely depend on the apoAI moiety, it would be 
interesting to investigate the effect of rHDL as compared to apoAI-free lipid micelles 
on cholesterol mobilization into plasma as well as VLDL metabolism in future studies.
In addition to rHDL infusion therapy, other strategies to raise HDL-C are currently 
being developed to prevent and treat CVD, alone or combined with LDL-lowering drugs, 
among which CETP inhibitors. The first CETP inhibitor torcetrapib increased HDL-C 
levels by approximately 60% 29, but failed to demonstrate any effect on the primary 
atherosclerotic burden as assessed by carotid intima-media thickness and coronary 
intravascular ultrasound imaging 30, 31 and even increased cardiovascular events and 
mortality, accompanied by off-target effects 32. However, other CETP inhibitors such 
as dalcetrapib 33 and anacetrapib 34 have now progressed into phase III clinical trails 
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without showing any off-target toxicity. Additionally, niacin effectively increases HDL 
by 25-30% 35 and improves carotid intima-media thickness 36. We recently showed that 
the HDL-raising effect of niacin is caused by reducing the hepatic CETP expression and 
plasma CETP protein 37. Since the HDL-raising effects of CETP inhibitors and niacin thus 
both depend on reducing CETP activity in plasma, whereas CETP activity now appears 
crucial to prevent the raise in VLDL as induced by rHDL infusion, combining rHDL with 
these HDL-raising agents could reveal adverse VLDL effects, and as a consequence 
counteract the potentially protective effect of rHDL in CVD. 
In conclusion, our results show that rHDL infusion induces an increase in VLDL 
levels, which is prevented by CETP expression. Therefore, we anticipate that studies 
evaluating the anti-atherosclerotic efficacy of rHDL in mouse models that are naturally 
deficient for CETP should be interpreted with caution, and that treatment of atherogenic 
dyslipidemia as a risk factor for CVD by rHDL should not be combined with agents that 
aggressively reduce CETP activity.
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Thiazolidinediones reduce hepatic steatosis and increase HDL cholesterol levels. 
In mice with human-like lipoprotein metabolism (APOE*3-Leiden.CETP transgenic 
mice), a decrease in hepatic triglyceride (TG) content is associated with a decrease in 
plasma cholesteryl ester transfer protein (CETP) mass and an increase in high-density 
lipoprotein (HDL)-cholesterol levels. Therefore, the aim of the present study was to 
assess the effects of pioglitazone on CETP mass in patients with type 2 diabetes mellitus 
(T2DM). We included 78 men with T2DM (age 56.5 ± 0.6 years; HbA1c 7.1 ± 0.1%) who 
were randomized to treatment with pioglitazone (30 mg/day) or metformin (2000 mg/
day) and matching placebos, in addition to glimepiride. At baseline and after 24 weeks 
of treatment plasma HDL cholesterol levels and CETP mass were measured, and hepatic 
TG content was assessed by proton magnetic resonance spectroscopy. Pioglitazone 
decreased hepatic TG content (5.9 [interquartile range 2.6-17.4] versus 4.1 [1.9-12.3]%, 
P<0.05), decreased plasma CETP mass (2.33±0.10 vs. 2.06±0.10 μg/ml, P<0.05) and 
increased plasma HDL-cholesterol levels (1.22±0.05 vs. 1.34±0.05 mmol/l, P<0.05). 
Metformin did not significantly change any of these parameters. In conclusion, a 
decrease in hepatic TG content by pioglitazone is accompanied by a decrease in plasma 
CETP mass and associated with an increase in HDL-cholesterol levels. These results in 





Hepatic steatosis is a prevalent condition in patients with type 2 diabetes mellitus (T2DM) 
and is associated with an increased cardiovascular risk 1, 2. Furthermore, many patients 
with T2DM display dyslipidemia characterized by high plasma levels of apolipoprotein 
(apo) B-lipoproteins and triglycerides (TG) and low plasma levels of high-density 
lipoprotein (HDL) cholesterol. Recently, Toledo et al. 3 showed that hepatic steatosis is 
associated with more severe hyperlipidemia in T2DM, which might contribute to the 
increased risk of cardiovascular disease.
To reduce this increased cardiovascular risk in T2DM, regular treatment algorithms 
include lipid lowering drugs. Our previous studies in APOE*3-Leiden.CETP transgenic 
mice, a well-established model for human-like lipoprotein metabolism, showed that 
treatment with either statins 4, fibrates 5 or niacin 6 resulted in a reduction in plasma 
apoB-lipoprotein and TG levels and an increase in HDL cholesterol. Moreover, these 
treatments reduced hepatic lipid content (i.e., both TG and cholesterol) as well as the 
hepatic expression and plasma levels of cholesteryl ester transfer protein (CETP) 4-6. 
CETP is a protein that mediates the heteroexchange of cholesteryl esters from HDL to 
(V)LDL with a simultaneous exchange of triglycerides from (V)LDL to HDL. These studies 
thus suggest that lowering of hepatic TG content in APOE*3-Leiden.CETP mice increased 
HDL cholesterol levels by reduction of plasma CETP mass.
Because the correlation between hepatic TG content and plasma CETP mass has not 
been studied in humans, the aim of this study was to evaluate whether the relationship 
between lowering of hepatic TG content and decreased plasma CETP mass also exists 
in humans. Hepatic TG content can be lowered by thiazolidinediones, including 
pioglitazone 7. Indeed, in a previous study, we reported that both antidiabetic drugs 
pioglitazone and metformin improved insulin sensitivity in men with T2DM, whereas 
only pioglitazone reduced hepatic TG content 8. Therefore, we used pioglitazone 
treatment as a model to study the effects of a change in hepatic TG content on CETP 
mass in patients with T2DM and used metformin treatment as a negative control. 
mATeriALs AND meTHoDs
Study design
This study used the data from the Pioglitazone Influence on tRiglyceride Accumulation 
in the Myocardium in Diabetes (PIRAMID) study. This was a prospective, randomized, 
double-blind, intervention study, which compared the effects of pioglitazone and 
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metformin on cardiac function and metabolism. The results were reported previously 8. 
The study design will be summarized here. The study included male patients with T2DM 
without cardiovascular disease or diabetes related complications. Inclusion criteria 
were body mass index (BMI) 25-32 kg/m2, age between 45-65 years, and diabetes well 
controlled with metformin, a sulfonylurea or both (HbA1c 6.5-8.5%). Patients were 
excluded on the following criteria: uncontrolled hypertension (blood pressure > 150/85 
mmHg), medical history of diabetes-related complications, liver disease, cardiovascular 
disease, or use of thiazolidinediones or insulin before the study. This study was executed 
at two hospitals in the Netherlands (Leiden University Medical Center, Leiden and VU 
University Medical Center, Amsterdam), and both local ethics committees gave their 
approval. All participants signed informed consent. 
If patients met the inclusion criteria, their glucose-lowering medication was switched 
to glimepiride monotherapy, untill a stable dose was reached 2 weeks before the start 
of the intervention. At baseline, patients were randomized to metformin (500 mg twice 
daily, titrated to 1000 mg twice daily) or pioglitazone (15 mg once daily, titrated to 30 
mg once daily after 2 weeks) in addition to glimepiride. In both the metformin and 
pioglitazone groups, 39 patients were included. In the pioglitazone group 34 and in the 
metformin group 37 patients completed the study. 
Patients were studied at baseline and after 24 weeks treatment. Blood sampling and 
magnetic resonance spectroscopy were performed after an overnight fast. 
Hepatic triglyceride content
Hepatic TG content was measured by proton (1H) magnetic resonance spectroscopy 
on a 1.5 Tesla whole-body magnetic resonance scanner (Gyroscan ACS/NT15; Philips, 
Best, the Netherlands). The technical details were described previously 8. The voxel 
was placed in the hepatic parenchyma, carefully preventing placement of the voxel in 
vascular structures. Java Magnetic Resonance User interface software (jMRUI version 
2.2, Leuven, Belgium) was used for fitting of the spectra. Technical details of spectra 
acquisition and spectra quantification were formerly described 8, 9. Spectra with and 
without water suppression were acquired to calculate hepatic TG content relative to 
water (signal amplitude of triglyceride/ signal amplitude water x 100%). 
Plasma cholesterol and CETP mass analysis
All plasma samples were obtained in the postabsorptive state on the day of randomization 
and at 24 weeks and analyzed in one laboratory (Leiden, the Netherlands). To ascertain 
that we could make adequate correlations, these measurements were performed 




determined using a commercially available enzymatic kit (1488872 and 236691; Roche 
Molecular Biochemicals, Indianapolis, IN, USA). This cholesterol assay was also used for 
determination of plasma HDL cholesterol after precipitation of apoB-lipoproteins from 
20 µl of plasma by adding 10 µl of heparin (500 unites/ml; LEO Pharma, The Netherlands) 
and 10 µl of 0.2 mol/l MnCl2 
6. Plasma apoB100 was determined with a Human ApoB 
ELISA kit (3715-1H; Mabtech, Nacka Strand, Sweden). The plasma CETP mass was 
quantified using a CETP ELISA Daiichi kit (Daiichi Pure Chemicals, Tokyo, Japan).
Statistical analysis
Data are expressed as means ± standard error of the mean (SEM) or as median 
(interquartile range) because hepatic TG content and plasma TG were not normal 
distributed. Paired t tests or Wilcoxon signed-ranks tests were used for within-group 
differences. We used ANOVA to assess between-group differences. For correlation 
analysis, Spearman correlation analyses were used. We used SPSS software (version 16.0, 
SPSS, Chicago, Illinois, USA) for statistical analyses. P < 0.05 was considered statistically 
significant.
resULTs
At baseline, patients in both treatment groups were well-matched for age (pioglitazone 
56.8 ± 1.0 years and metformin 56.4 ± 0.9 years, between group P> 0.05), duration of 
diabetes (pioglitazone 4 [3-6] years and metformin 3 [1-5] years, P> 0.05), and body 
mass index (pioglitazone 28.2 ± 0.5 kg/m2 and metformin 29.3 ± 0.6 kg/m2, between 
group P> 0.05) 8. 
Table 1. Hepatic triglyceride content, plasma ceTP mass, cholesterol, triglycerides, and apoB100 at 
baseline and after 24 weeks of treatment
Pioglitazone Metformin P value between 
groupsBaseline 24weeks Baseline 24weeks
Hepatic TG content (%) # 5.9 (2.6-17.4) 4.1 (1.90-12.3)* 7.7 (3.7-23.9) 10.7 (5.1-22.0) < 0.01
CETP mass (µg/ml) 2.33 ± 0.10 2.06 ± 0.10* 2.44 ± 0.08 2.24 ± 0.12 NS
HDL cholesterol (mmol/l) 1.22 ± 0.05 1.34 ± 0.05* 1.22 ± 0.06 1.23 ± 0.06 0.02
Total cholesterol (mmol/l) 4.90 ± 0.16 5.19 ± 0.22* 5.15 ± 0.18 4.99 ± 0.18 < 0.01
Triglycerides (mmol/l) 1.74(0.97-3.09) 1.37(0.88-1.80) 2.08(1.08-2.74) 1.23(0.68-1.92) NS
ApoB100 (mg/dl) 84.88 ± 5.08 75.41 ± 4.03* 89.72 ± 5.01 74.58 ± 4.22* NS
Data are means ± SEM or median (interquartile range). # Data from van der Meer et al 8. 




The effects of treatment on hepatic TG content and plasma lipid profiles are presented 
in Table 1. As we showed before 8, treatment with pioglitazone for 24 weeks decreased 
hepatic TG content [5.9 (2.6-17.4) vs. 4.1 (1.9-12.3)%, P< 0.05)]. This was accompanied by 
a decrease in plasma CETP mass (2.33±0.10 vs. 2.06±0.10 µg/ml, P< 0.05) and an increase 
in plasma HDL cholesterol levels (1.22 ± 0.05 vs. 1.34 ± 0.05 mmol/l, P< 0.05). Treatment 
with metformin did not significantly affect either of these parameters. Treatment with 
pioglitazone and metformin both decreased plasma TG and apoB100 significantly; 
however, there was no difference in the reduction between the groups (Table 1). 
Correlations 
Changes in plasma CETP mass after 24 weeks in the pioglitazone-treated patients 
correlated with changes in hepatic TG content (r= 0.34, P <0.05), although this association 
was not present in the metformin group. 
Effect of statin use in the pioglitazone-treated group
In the pioglitazone group, 19 of the 39 patients used a statin at start of the study. 
Table 2 compares the changes in lipid levels and hepatic TG content between statin 
users versus non-statin users in the patients treated with pioglitazone. In nonstatin 
users, pioglitazone decreased liver TG content [6.4 (2.5-18.9) vs. 4.9 (1.9-14.7)%, 
P< 0.05], increased HDL cholesterol levels (1.14 ± 0.06 vs. 1.32 ± 0.06 mmol/l, 
P< 0.05), and decreased CETP mass (2.64 ± 0.14 vs. 2.16 ± 0.12 µg/ml, P< 0.05). However, 
remarkably, in statin users, pioglitazone also reduced liver TG content [8.0 (2.8-16.5) vs. 
3.7 (1.9-10.9)%, P< 0.05], but did not affect either HDL cholesterol levels or CETP mass. 
ApoB100 decreased significantly only in the statin users (83.07 ± 8.29 vs. 68.77 ± 5.34 
mg/dl, P< 0.05)  
Table 2. Hepatic triglyceride content, plasma ceTP mass, cholesterol, triglycerides, and apoB100 in 
patients treated with pioglitazone, selected on the use of statins at baseline
No statin use Statin use P value 
between 
groupsBaseline 24weeks Baseline 24weeks
Hepatic TG content (%) 6.4 (2.5-18.9) 4.9 (1.90-14.7)* 8.0 (2.8-16.5) 3.7 (1.9-10.9)* NS
CETP mass (µg/ml) 2.64 ± 0.14 2.16 ± 0.12* 1.98 ± 0.09 1.96 ± 0.15 0.03
HDL cholesterol (mmol/l) 1.14 ± 0.06 1.32 ± 0.06* 1.30 ± 0.06 1.36 ± 0.08 NS
Total cholesterol (mmol/l) 5.32 ± 0.22 5.87 ± 0.35 4.44 ± 0.19 4.55 ± 0.19 NS
Triglycerides (mmol/l) 1.74(0.82-3.11) 1.32(0.80-3.02) 1.61(1.02-2.41) 1.46(0.99-1.69) NS
ApoB100 (mg/dl) 86.59 ± 6.22 82.06 ± 5.77 83.07±8.29 68.77 ± 5.34* NS
Data are means ± SEM or median (interquartile range). 





In this study, we assessed the associations among changes in hepatic TG content, 
plasma CETP mass, and lipid profiles in patients with T2DM. The results show that 
pioglitazone decreased hepatic TG content, associated with decreased plasma CETP 
mass and increased HDL cholesterol levels. These findings are in full concordance 
with our recent studies in APOE*3-Leiden.CETP mice, which showed that classical lipid-
lowering drugs concurrently lowered hepatic lipid content and decreased hepatic CETP 
mRNA expression, resulting in decreased plasma CETP mass 4-6. 
In this study, plasma TG and plasma apoB100 decreased equivalently in both 
the pioglitazone and metformin group. Accordingly, other studies have shown that 
pioglitazone and metformin both decrease plasma TG 10-13. Given the generally observed 
inverse relationship between plasma TG and HDL cholesterol found in epidemiological 
studies, a decrease in plasma TG may induce an increase in HDL cholesterol only. 
However, in the present study the decrease in plasma TG was not different between 
groups and plasma HDL cholesterol only increased in the pioglitazone group, indicating 
that another mechanism may be responsible for eliciting this difference, i.e., the 
reduction in CETP.  
It is intriguing to speculate on the mechanism underlying the correlation between 
hepatic lipid content and plasma CETP mass. It is known that cholesterol derivatives are 
agonists for the nuclear receptor liver X receptor α (LXRα). Activation of LXRα results 
in increased transcription of CETP and sterol regulatory element-binding proteins-1c 
(SREBP-1c) 14. Thus, our studies in APOE*3-Leiden.CETP mice suggest that a decrease in 
the hepatic cholesterol content, associated with a decrease in cholesterol derivatives, 
such as oxysterols, reduces LXRα activation, thereby further downregulating CETP 
mRNA transcription.  It is therefore likely that in our study pioglitazone decreased 
hepatic cholesterol content in addition to TG content, thereby downregulating LXRα-
activity. Although it is not possible at this time to noninvasively measure hepatic 
cholesterol content in humans, studies in APOE*3-Leiden.CETP mice with a human-like 
protein profile generally demonstrate a strong relation between hepatic cholesterol 
and hepatic TG content. 
Notably, thiazolidinediones such as pioglitazone, can also upregulate LXRα 
expression via activation of peroxisome proliferator-activated receptor-γ, which is most 
dominantly expressed in adipose tissue 15. Moreover, CETP expression is prominent 
in adipose tissue. Radeau et al. 16 have shown that CETP mRNA expression in adipose 
tissue correlates with plasma CETP concentrations. The increased subcutaneous fat 
mass as induced by pioglitazone treatment may contribute to increased plasma CETP 
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levels, thereby potentially counteracting the decrease in plasma CETP levels due to the 
decrease in hepatic lipid content by pioglitazone. Therefore, the observed decrease in 
plasma CETP mass due to the decrease in hepatic TG content may, in fact, be larger.
To our knowledge only one other study evaluated the effect of thiazolidinediones 
on CETP expression, but the hepatic TG content was not studied. Chappuis et al. 17 
performed a cross-over study comparing pioglitazone versus rosiglitazone in 17 
patients with T2DM. They found that rosiglitazone increased total cholesterol levels and 
decreased plasma CETP activity in accordance with our study. However, pioglitazone did 
not have any effect on these parameters. The differences in their results on the effects of 
pioglitazone compared with our study may be due to the shorter treatment duration of 
12 weeks and/or to the smaller sample size in the previous study.
Finally, we found that pioglitazone did not further decrease CETP mass in 
patients who already used a statin. Experimental studies in APOE*3-Leiden mice have 
demonstrated that statins decrease plasma CETP mass by decreasing hepatic mRNA 
expression, again related to decreased hepatic cholesterol content 4. Apparently 
the effect of statins is dominant over the effect of pioglitazone. We hypothesize that 
statins specifically decrease hepatic cholesterol content and downregulate CETP mRNA 
expression. Therefore, additional lowering of hepatic TG content will not result in an 
additional decrease in CETP expression. However, the current study was not designed 
to assess the effects of statins on these parameters. 
A limitation of this study is that only men were included. Kinoshita et al. 18 showed 
that men have lower CETP activity than women; thus, these data may not be readily 
extrapolated to women with T2DM.
In summary, this study shows that in male patients with T2DM a decrease in hepatic 
TG content by pioglitazone is associated with a decrease in CETP mass and an increase 
in HDL cholesterol levels. Furthermore, we confirmed that use of statins is associated 
with a decreased plasma CETP mass. Both findings are in full agreement with our recent 
findings in APOE*3-Leiden.CETP mice and support the validity of these mice as a model 
for human-like lipoprotein metabolism.
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Using a mouse model for human-like lipoprotein metabolism we previously observed 
that reduction of the hepatic triglyceride (TG) content resulted in a decrease in plasma 
cholesteryl ester transfer protein (CETP) and an increase in HDL levels. The aim of the 
present study was to investigate the effects of prolonged caloric restriction in obese 
patients with type 2 diabetes mellitus, resulting in a major reduction in hepatic TG 
content, on plasma CETP and HDL levels. We studied 27 obese (BMI: 37.2±0.9 kg/m2) 
insulin-dependent patients with type 2 diabetes mellitus (14 men, 13 women, age 
55±2 years) who received a 16-week very low calorie diet (VLCD). At baseline and after 
a 16-week VLCD, plasma lipids, lipoproteins and CETP were measured. Furthermore, 
functionality of HDL with respect to inducing cholesterol efflux from human monocyte 
cells (THP-1) was determined. A 16-week VLCD markedly decreased plasma CETP 
concentration (-18%, P<0.01) and increased plasma apoAI levels (+16%, P<0.05), 
without significantly affecting plasma HDL-cholesterol and HDL-phospholipids. 
Although a VLCD results in HDL that is less lipidated, the functionality of HDL with 
respect to inducing cholesterol efflux in vitro was unchanged. In conclusion, the 
marked decrease in hepatic TG content induced by a 16-week VLCD is accompanied 
by a decrease in plasma CETP concentration and an increase in ApoAI levels, without 
improving the cholesterol efflux properties of HDL in vitro.
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CALORIC RESTRICTION DECREASES CETP AND INCREASES APOAI
iNTroDUcTioN
Patients with type 2 diabetes mellitus display a typical atherogenic dyslipidemia 
marked by increased plasma triglycerides (TG) and very low density lipoprotein 
(VLDL)-cholesterol concentrations, and decreased high density lipoprotein (HDL)-
cholesterol levels. Furthermore, hepatic steatosis, which is also strongly associated 
with cardiovascular disease (CVD) risk 1, 2 is frequently observed in patients with type 2 
diabetes mellitus 3-5.
Previously, we demonstrated that the HDL-raising effect of various classical lipid-
lowering drugs was caused by a reduction in plasma cholesteryl ester transfer protein 
(CETP) that mediates the net transfer of cholesteryl esters from HDL to (V)LDL. In 
APOE*3-Leiden.CETP mice, a well-established animal model for human-like lipoprotein 
metabolism, statins 6, fibrates 7, and niacin 8 decrease the hepatic lipid content (i.e. both 
TG and cholesterol) resulting in a decreased hepatic CETP expression accompanied by 
decreased plasma CETP levels, and a consequently increased plasma HDL. Recently, we 
showed that a similar mechanism may account for the HDL-raising effect of pioglitazone 
in humans. In patients with type 2 diabetes mellitus, pioglitazone decreased hepatic TG 
content 9, accompanied by a decrease in plasma CETP concentration and increase in 
HDL level 10. In contrast, metformin did not affect either hepatic TG, plasma CETP or 
HDL levels 10.
Lifestyle interventions such as diet-induced weight reduction and exercise are very 
important in the treatment of obese patients with type 2 diabetes mellitus. Recently, 
we reported that a 16-week very low calorie diet (VLCD) in obese patients with type 
2 diabetes mellitus significantly decreased plasma total cholesterol and TG levels and 
markedly reduced hepatic TG content 11, but the potential beneficial effect of a VLCD 
on plasma CETP and HDL levels has not been studied. Therefore, using plasma samples 
from that study 11, we now investigated whether prolonged caloric restriction reduces 




The study protocol has previously been described in detail 11. Twenty-seven obese 
patients with insulin-dependent type 2 diabetes mellitus (14 men and 13 women) were 
included (mean ± standard error of the mean: age: 55±2 years, BMI: 37.2±0.9 kg/m2. 
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HbA1c: 7.8±0.2%). At baseline patients used 82±11 units of insulin per day with or 
without concomitant use of metformin and/or sulfonyl ureum derivates. Exclusion 
criteria were: smoking, unstable weight during 3 months before inclusion or any other 
chronic disease. In the previously published paper 11, we described only 12 out of the 
27 patients, from whom 1H-MRS scans could be obtained. The local ethics committee 
approved this protocol. All patients gave written informed consent and the study was 
performed in accordance with the Declaration of Helsinki.
Study design
Patients were studied before start and after completion of the 16-week VLCD. Three 
weeks before start of the VLCD all oral blood glucose lowering medication was stopped 
and insulin therapy was intensified. The day before the start of the VLCD intervention, 
only short-acting insulin was prescribed. Patients did not use any blood glucose-
lowering medication, including insulin, during the 16-week VLCD. The VLCD consisted of 
3 liquid food shakes (Modifast Intensive; kindly provided by Nutrition & Santé, Antwerp, 
Belgium) containing a total of 450 kcal/day and all essential micro- and macronutrients. 
Thirteen of the 27 subjects simultaneously followed an exercise program in addition to 
the VLCD. Since exercise had no effect on outcome parameters (Supplemental Table 1), 
data of all subjects were pooled for the present analyses.
supplemental Table 1. changes in plasma ceTP and (apo)lipoprotein values induced by 16 weeks of 







Δ CETP (µg/mL) -0.41 ± 0.14 -0.49 ± 0.23 0.7651
Δ Total cholesterol (mM) -0.67 ± 0.34 -0.86 ± 0.20 0.6356
Δ Triglycerides (mM) -0.87 ± 0.19 -1.32 ± 0.50 0.4128
Δ Phospholipids (mM) -0.37 ± 0.08 -0.45 ± 0.12 0.5822
Δ LDL-C (mM) -0.64 ± 0.30 -0.63 ± 0.24 0.9866
Δ ApoB100 (mg/dL) -11.3 ± 7.4 -26.8 ± 7.3 0.1477
Δ HDL-C (mM) 0.00 ± 0.09 0.15 ± 0.06 0.1896
Δ HDL-PL (mM) -0.03 ± 0.08 0.05 ± 0.05 0.4477
Δ ApoAI (mg/dL) 34.5 ± 12.2 8.2 ± 11.3 0.1270
Changes (Δ) are calculated by subtracting values obtained after VLCD from those obtained at baseline. Data 
are presented as means ± SEM. P-values are calculated using Unpaired Student’s t test. CETP, cholesteryl ester 
transfer protein; VLCD, very low calorie diet; PL, phospholipids; LDL-C, low density lipoprotein-cholesterol; 
HDL-C, high density lipoprotein-cholesterol; HDL-PL, high density lipoprotein-phospholipids. 
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Hepatic triglyceride content
Hepatic TG content was measured in supine position using 1H-MRS on a 1.5 Tesla 
whole-body MR scanner (Gyroscan ACS/NT15; Philips, Best, The Netherlands), exactly 
as previously described 11.
Plasma (apo)lipoprotein and CETP analyses
All plasma samples were obtained after an overnight fast before the start (i.e. after 
stopping all glucose-lowering medication including insulin) and after the 16-week 
VLCD protocol, stored in aliquots at -80°C, and analyzed after thawing once in a single 
laboratory (Leiden, The Netherlands). To ascertain that we could make adequate 
correlations, all analyses were performed within the same blood samples in the 
same assay runs. Plasma cholesterol and TG concentrations were determined using 
enzymatic kits (no. 236691 and 11488872, respectively, Roche Molecular Biochemicals, 
Indianapolis, IN, USA). Plasma phospholipids were determined using the phospholipids 
B kit (Wako Chemicals, Neuss, Germany). Plasma CETP concentration was quantified 
using kit ‘CETP ELISA Daiichi’ (Daiichi Pure Chemicals Co, Ltd, Tokyo, Japan). HDL 
fractions were obtained after precipitation of ApoB-lipoproteins from 50 µL plasma by 
adding 25 µL 36% polyethylene glycol 6000 (PEG6000, no.81260, Sigma Aldrich, Inc, 
USA.) The HDL-cholesterol and phospholipids were determined as described above. 
Plasma ApoAI and ApoB100 levels were determined with the ’Human ApoAI ELISA kit‘ 
(no. 3710-1H, Mabtech AB, Sweden) and ’Human ApoB ELISA kit‘ (no. 3715-1H; Mabtech 
AB, Sweden), respectively. 
Cholesterol efflux study
Cholesterol efflux to total plasma and ApoB-depleted human plasma were determined 
using the human monocyte cell line THP-1 as cholesterol donor. THP-1 cells were 
obtained from European Collection of Cell Cultures (ECACC), and maintained in medium 
A (RPMI 1640 with 25 mM HEPES Buffer, supplemented with 10% fetal bovine serum, 
1% L-glutamine, 100 U/mL penicillin and 100 µg/mL streptomycin) at 37°C in 5% CO2. 
Before the experiment, THP-1 cells were seeded into 24 well plates at density of 5x105 
cells per well and differentiated into macrophages with 0.1 µM phorbol 12-myristate-
13-acetate (PMA; no. P1585, Sigma Aldrich, Inc, USA) within 3 days. Macrophages were 
washed three times with PBS and incubated in medium B (RPMI 1640 with 25 mM 
HEPES buffer, supplemented with 2% fetal bovine serum, 1% L-glutamine, 100 U/mL 
penicillin, 100 µg/mL streptomycin, 50 µg/mL acetyl-LDL and 10 µCi/ml [1α,2α(n)-3H]-
cholesterol (no.NET139001MC, Perkin Elmer, Netherlands) for 1 day at 37°C in 5% CO2. 
After incubation, cells were washed 3 times with PBS and the efflux assay was started 
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by adding total human plasma or ApoB-depleted human plasma diluted to 1% in 
medium C (RPMI 1640 with 25 mM HEPES buffer, supplemented with 1% L-glutamine, 
100 U/ml penicillin, 100 µg/ml streptomycin, and 0.5 mg/ml BSA). The whole assay was 
carried out in triplicate. To be able to normalize results between series of experiments 
and to correct for plate-to-plate variation, efflux to a standard preparation of HDL (50 
µg protein/mL) was determined in triplicate. After 4 hours incubation, medium was 
collected and centrifuged. Subsequently, [3H]cholesterol was quantified by liquid 
scintillation counting. Total cellular 3H-cholesterol was determined after extraction 
of the cells with 0.1 M NaOH. Cholesterol efflux rate was calculated by dividing the 
3H-activity in the medium by the sum of the 3H-activity in the medium and the cell 
extract. Background values (the efflux in the absence of plasma) were subtracted. 
Statistical analysis
Data are expressed as means ± SEM. Paired t-tests were used for the statistical 
comparisons between measurements at baseline and after 16 weeks of caloric 
restriction. For correlation analysis, Pearson’s correlation analysis was used. A P-value < 
0.05 was considered statistically significant. 
resULTs
In line with our previous observations in 12 patients 11, a subset of the 27 patients who 
were included in the present study, the VLCD profoundly reduced bodyweight from 
113.1±3.7 to 87.7±2.9 kg (P<0.05) and decreased BMI from 37.2±0.9 to 28.9±0.8 kg/m2 
(P<0.05). In addition, in the 12 patients from whom 1H-MRS scans could be obtained, 
hepatic TG content considerably reduced from 21.2±4.2 to 3.0±0.9% (n =12, P<0.001) 
as reported previously 11.
Plasma CETP and (apo)lipoproteins
Compared to baseline, VLCD decreased plasma CETP concentration (-18.2%, P<0.01). 
In addition, VLCD reduced plasma levels of total cholesterol (-13.1%, P<0.001), TG 
(-45.1%, P<0.001), phospholipid (-15.2%, P<0.0001), LDL-cholesterol (-15.8%, P<0.01) 
and ApoB100 (-13.9%, P<0.01). VLCD did not alter plasma HDL-cholesterol and 
HDL-phospholipids, but increased ApoAI (+16.2%; P<0.05) (Table 1). The change 
in bodyweight after 16 weeks of VLCD did not correlate with the change in either 
plasma triglycerides (R2=0.0000; P=0.9952), total cholesterol (R2=0.0471; P=0.2769), 
phospholipid (R2=0.0305; P=0.3837), LDL-cholesterol (R2=0.0320; P=0.3717), HDL-
cholesterol (R2=0.0086; P=0.6460) or HDL-phospholipid (R2=0.0013; P=0.8570).
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Table 1. Plasma ceTP and (apo)lipoprotein levels in obese patients with type 2 diabetes mellitus and 
hepatic steatosis in response to 16 weeks of VLcD.
Plasma parameters Baseline After VLCD Delta (%) P value
CETP (µg/mL) 2.48 ± 0.15 2.03 ± 0.14 -18.2 0.0021
Total cholesterol (mM) 5.76 ± 0.30 5.00 ± 0.22 -13.1 0.0007
Triglycerides (mM) 2.41 ± 0.28 1.32 ± 0.10 -45.1 0.0003
Phospholipids (mM) 2.69 ± 0.11 2.28 ± 0.07 -15.2 0.0000
LDL-C (mM) 3.99 ± 0.27 3.36 ± 0.20 -15.8 0.0028
ApoB100 (mg/dL) 130 ± 6 111 ± 5 -13.9 0.0016
HDL-C (mM) 0.84 ± 0.04 0.91 ± 0.06 - NS
HDL-PL (mM) 0.98 ± 0.03 0.98 ± 0.05 - NS
ApoAI (mg/dL) 135 ± 10 156 ± 11 +16.2 0.0174
Delta-values are calculated by comparing values obtained after VLCD to those obtained at baseline from 
obese patients with T2DM. Data are presented as means ± SEM (n=27). P-values are calculated using Paired 
Student’s t test. CETP, cholesteryl ester transfer protein; VLCD, very low calorie diet; PL, phospholipids; LDL-C, 
low density lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; HDL-PL, high density 
lipoprotein-phospholipids; NS, not significant.
Figure 1. cholesterol efflux to total plasma 
and apoB-depleted plasma. THP-1 cells were 
loaded with [3H]cholesterol and incubated for 
4 h at 37°C with total plasma (1% v/v) (A) or 
ApoB-depleted plasma (1% v/v) (B), obtained 
before and after VLCD from 27 obese patients 
with T2DM. Cholesterol efflux rate is calculated 
by dividing 3H-activity in the medium by the 
sum of the 3H-radioactivity in the medium and 
cell extract. Data are means ± SEM. P-values 
are calculated using Paired Student’s t test. 
***P<0.001 as compared to baseline. ApoB, 
Apolipoprotein B; HDL, high density lipoprotein; 




VLCD decreased cholesterol efflux from THP-1 cells to total plasma obtained from 
patients compared to plasma from baseline (-14.5%, P<0.001) (Fig. 1A). Similarly, the 
capacity of apoB-depleted plasma obtained after VLCD to promote cholesterol efflux 
was lower than that of apoB-depleted plasma obtained at baseline (-14.9%; P<0.001) 
(Fig. 1B).
supplemental Figure 1. correlation between cholesterol efflux and plasma lipids. THP-1 cells were 
loaded with [3H]cholesterol and incubated for 4 h at 37°C with total plasma (1% v/v) obtained at baseline and 
after VLCD from 27 obese patients with T2DM. Cholesterol efflux rate was calculated by dividing 3H-activity in 
the medium by the sum of the 3H-radioactivity in the medium and cell extract. Cholesterol efflux was plotted 
against total cholesterol (TC, A), phospholipid (PL, B), HDL-C (C), HDL-PL (D), Non-HDL-C (E), and Non-HDL-PL 
(F), and correlations were calculated. 
Correlation analysis showed that cholesterol efflux to total plasma positively 
correlated with plasma total cholesterol (R2=0.2416; P<0.001) and plasma total 
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phospholipid (R2=0.3499; P<0.001). Cholesterol efflux to total plasma positively 
correlated with non-HDL-cholesterol (R2=0.2339; P<0.001) and non-HDL-phospholipid 
(R2=0.2855; P<0.001) rather than HDL-cholesterol or HDL-phospholipid (both P>0.05) 
(Supplemental Fig. 1). Moreover, no significant correlation was observed between 
cholesterol efflux to plasma and apoAI (Supplemental Fig. 2).
supplemental Figure 2. correlation between cholesterol efflux and plasma apoAi. THP-1 cells were 
loaded with [3H]cholesterol and incubated for 4 h at 37°C with total plasma (1% v/v) obtained at baseline and 
after VLCD from 27 obese patients with T2DM. Cholesterol efflux rate was calculated by dividing 3H-activity in 
the medium by the sum of the 3H-radioactivity in the medium and cell extract. Cholesterol efflux was plotted 
against apoAI, and correlations were calculated. 
DiscUssioN
A main finding from the present study is that prolonged caloric restriction by a 16-
week VLCD in obese patients with type 2 diabetes mellitus and hepatic steatosis, which 
considerably reduces hepatic TG content (-85%) 11, also markedly decreases plasma 
CETP concentration (-18.2%). This observation corroborates our recent finding that 
a reduction of the hepatic lipid content (-30.5%), as induced by pioglitazone, also 
associates with a reduction in plasma CETP concentration (-11.6%) in patients with type 
2 diabetes mellitus 10. However, the potency of prolonged caloric restriction to reduce 
hepatic lipid content and plasma CETP concentration exceeds that of pioglitazone 
treatment considerably.
These data are in full accordance with our previous observations that lowering 
hepatic lipids (i.e. TG as well as cholesterol) in APOE*3-Leiden.CETP mice by classical 
lipid-lowering drugs decreased hepatic CETP mRNA expression, resulting in decreased 
plasma CETP concentration 6-8. Since CETP expression is regulated by liver X receptor 
alpha (LXRα) for which oxysterols are natural ligands 12 and the liver cholesterol level 
determines LXRα activation 13, we concluded from those studies that a decrease in 
hepatic cholesterol content, associated with a decrease in cholesterol derivatives, 
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reduces hepatic LXRα activation, thereby downregulating CETP mRNA transcription. 
Although it is unknown whether hepatic TG levels reflect levels of hepatic cholesterol 
and oxysterols in the present study, as we cannot assess hepatic (oxy)sterols 
noninvasively in humans, hepatic TG and cholesterol levels were highly correlated 
(r=0.867) in 33 Chinese subjects (Dr. P. Parini, personal communication). Therefore, it is 
likely that the reduction in plasma CETP concentration induced by VLCD also reduces 
hepatic LXRα-activated CETP mRNA transcription thereby reducing plasma CETP. 
Our data corroborate those of Laimer et al. 14 who showed that substantial weight 
loss in morbidly obese women induced by laparoscopic gastric banding surgery also 
decreased plasma CETP mass (-8.3%) at 1 year after surgery.
The effect of caloric restriction on HDL levels is still under debate. Although a single 
study reported that an average of 6 years of caloric restriction in 18 subjects increased 
HDL-cholesterol 15, other studies demonstrated that both 6 months and 2 years of caloric 
restriction in 8 subjects in fact decreased plasma HDL-cholesterol 16, 17. Moreover, caloric 
restriction had conflicting effects on HDL-cholesterol among different diet groups 
even in one study: HDL-cholesterol was either increased or unaffected 18. The current 
study is the first to show that caloric restriction by a VLCD increased the plasma level 
of the main HDL protein constituent ApoAI (+16.2%), which is supposed to be a good 
(negative) predictor of CVD risk 19. However, the VLCD did not increase HDL-cholesterol 
levels. Our previous studies in mice 6-8 and in patients with type 2 diabetes mellitus 10 
showed that reduction of hepatic lipids and plasma CETP, as induced by drugs, were 
in fact related to increased plasma HDL-cholesterol levels. In fact, treatment of only 
20 patients with type 2 diabetes mellitus with pioglitazone resulted in a significant 
increase in HDL-cholesterol despite less pronounced decreases in hepatic lipid and 
plasma CETP 10, suggesting that our present study including 27 patients would not be 
underpowered to detect an potential effect on HDL-C. It is known that the LXRα target 
ATP binding cassette A1 (ABCA1) plays a crucial role in HDL maturation by mediating 
the lipidation of plasma ApoAI 20. Furthermore, hepatic ABCA1 is the main contributor 
to the loading of HDL with cholesterol as evidenced by studies in mice that selectively 
lack ABCA1 from the liver 21. Collectively, it is thus conceivable that the dramatic 
reduction in hepatic lipids largely downregulates the hepatic expression of ABCA1, 
resulting in reduced lipidation of plasma ApoAI with liver-derived cholesterol, thereby 
counteracting the expected rise in HDL-cholesterol due to the reduction in CETP. 
The reduced ratio of HDL-cholesterol over apoAI as induced by VLCD may be 
expected to result in an increased ability of total plasma and ApoB-depleted plasma to 
induce cholesterol efflux from cholesterol-laden macrophages. However, we observed 
that the VLCD actually reduced the capacity of total plasma and ApoB-depleted plasma 
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to induce cholesterol efflux from THP-1 cells, even after discarding the three subjects 
showing the largest decrease in cholesterol efflux from the analysis. Correlation analysis 
revealed that HDL constituents (cholesterol, phospholipid and apoAI) did not correlate 
with cholesterol efflux to plasma. Instead, the decrease in cholesterol efflux to plasma 
was mainly related to the decrease in total phospholipid levels in plasma. Collectively, 
these data indicate that the total lipoprotein surface area in plasma, rather than the 
HDL level, determines the capacity of plasma to induce cholesterol efflux.
Our findings are in line with those of a recent study showing that the cholesterol 
efflux capacity of plasma was independent of total HDL-C or ApoAI levels 22. In fact, 
independently of HDL-cholesterol, sera with high efflux capacity had a significant 
increase in ABCA1-mediated efflux due to the presence of preß-1 HDL. Likewise, another 
study showed that, although both pioglitazone and statins increase HDL-cholesterol, 
pioglitazone but not statins increases the cholesterol efflux capacity of plasma, and 
no correlation was noted between the change in HDL-cholesterol and the change 
in cholesterol efflux capacity 23. Overall, the cholesterol efflux capacity of plasma is 
thus not simply related to HDL-cholesterol or apoAI, although the capacity of HDL to 
mediate cholesterol efflux from macrophages has recently been established to strongly 
inversely associate with carotid intima-media thickness and likelihood of angiographic 
coronary artery disease 23. The fact that we were unable to detect a correlation between 
cholesterol efflux and HDL-cholesterol or apoAI thus probably indicates that VLCD does 
not improve the functionality of HDL with respect to mediating cholesterol efflux.
A limitation of the current study may be the small study group. Although we initially 
included 27 patients for the VLCD intervention, hepatic TG quantification by MRS was 
possible in only 12 patients, mainly related to limitations for maximum weight and 
circumference of the MRI scanner. Secondly, the design of the current human study 
does not permit to assess causal relationships between hepatic lipid content and 
plasma CETP or ApoAI level. Nonetheless, the results are in accordance with data 
obtained from mechanistic studies in a mouse model relevant for human lipoprotein 
metabolism 6-8. 
In conclusion, this study indicates that prolonged caloric restriction, which 
considerably reduces hepatic TG content, also markedly decreases plasma CETP 
concentration. This is in full accordance with our previous findings in APOE*3-Leiden.
CETP mice, in which we showed that classical lipid-lowering drugs concurrently 
lowered hepatic lipids resulting in decreased plasma CETP concentration. Furthermore, 
the VLCD increased plasma apoAI levels without improving functionality of HDL with 




This research was supported by the Center for Translational Molecular Medicine 
(CTMM), project PREDICCt (grant 01C-104), by the Netherlands Heart Foundation 
(grant 2007B081) and by Roba Metals B.V., IJsselstein, The Netherlands. P.C.N.R.is an 
Established Investigator of the Netherlands Heart Foundation (grant 2009T038).
4
75
CALORIC RESTRICTION DECREASES CETP AND INCREASES APOAI
reFereNces
 1 Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 
2007;191:235-40.
 2 Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: 
causal effect or epiphenomenon? Diabetologia 2008;51:1947-53.
 3 Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC. Fatty liver in type 2 diabetes mellitus: relation to 
regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 2003;285:E906-E916.
 4 Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, 
Hafeezunnisa. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004;19:854-8.
 5 Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep 2002;2:210-5.
 6 de HW, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM, Romijn JA, Jukema JW, 
Havekes LM, Rensen PC. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed 
APOE*3-Leiden.CETP mice. Atherosclerosis 2008;197:57-63.
 7 van der Hoogt CC, de HW, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijn JA, Princen HM, Jukema JW, 
Havekes LM, Rensen PC. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein 
expression. J Lipid Res 2007;48:1763-71.
 8 van der Hoorn JW, de HW, Berbee JF, Havekes LM, Jukema JW, Rensen PC, Princen HM. Niacin increases HDL 
by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. 
Arterioscler Thromb Vasc Biol 2008;28:2016-22.
 9 van der Meer RW, Rijzewijk LJ, de Jong HW, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de RA, Kamp O, Paulus 
WJ, Heine RJ, Lammertsma AA, Smit JW, Diamant M. Pioglitazone improves cardiac function and alters myocardial 
substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism 
in patients with well-controlled type 2 diabetes mellitus. Circulation 2009;119:2069-77.
 10 Jonker JT, Wang Y, de HW, Diamant M, Rijzewijk LJ, van der Meer RW, Lamb HJ, Tamsma JT, de RA, Romijn 
JA, Rensen PC, Smit JW. Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a 
decrease in hepatic triglyceride content, in patients with type 2 diabetes. Diabetes Care 2010;33:1625-8.
 11 Hammer S, Snel M, Lamb HJ, Jazet IM, van der Meer RW, Pijl H, Meinders EA, Romijn JA, de RA, Smit JW. Prolonged 
caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and 
improves myocardial function. J Am Coll Cardiol 2008;52:1006-12.
 12 Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. 
J Clin Invest 2000;105:513-20.
 13 Jiang XC, Agellon LB, Walsh A, Breslow JL, Tall A. Dietary cholesterol increases transcription of the human 
cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. J Clin Invest 
1992;90:1290-5.
 14 Laimer MW, Engl J, Tschoner A, Kaser S, Ritsch A, Tatarczyk T, Rauchenzauner M, Weiss H, Aigner F, Patsch JR, 
Ebenbichler CF. Effects of weight loss on lipid transfer proteins in morbidly obese women. Lipids 2009;44:1125-30.
 15 Fontana L, Meyer TE, Klein S, Holloszy JO. Long-term calorie restriction is highly effective in reducing the risk for 
atherosclerosis in humans. Proc Natl Acad Sci U S A 2004;101:6659-63.
 16 Verdery RB, Walford RL. Changes in plasma lipids and lipoproteins in humans during a 2-year period of dietary 
restriction in Biosphere 2. Arch Intern Med 1998;158:900-6.
 17 Walford RL, Harris SB, Gunion MW. The calorically restricted low-fat nutrient-dense diet in Biosphere 2 
significantly lowers blood glucose, total leukocyte count, cholesterol, and blood pressure in humans. Proc Natl Acad 
Sci U S A 1992;89:11533-7.
4
76
 18 Tapsell L, Batterham M, Huang XF, Tan SY, Teuss G, Charlton K, Oshea J, Warensjo E. Short term effects of energy 
restriction and dietary fat sub-type on weight loss and disease risk factors. Nutr Metab Cardiovasc Dis 2010;20:317-
25.
 19 Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, 
and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 
2001;358:2026-33.
 20 Wang N, Silver DL, Costet P, Tall AR. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma 
membrane morphology in cells expressing ABC1. J Biol Chem 2000;275:33053-8.
 21 Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, Gebre AK, Coutinho JM, Colvin PL, Smith 
TL, Hayden MR, Maeda N, Parks JS. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia 
and kidney hypercatabolism of apoA-I. J Clin Invest 2005;115:1333-42.
 22 Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux 
via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove 
cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010;30:796-801.
 23 Khera AV, Cuchel M, Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, 
Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and 
atherosclerosis. N Engl J Med 2011;364:127-35.
5
niacin reduces PlasMa cetP levels BY diMinishinG 
liver MacroPhaGe content in cetP transGenic Mice
zhaosha li, Yanan Wang, ronald J. van der sluis, 
José W.a. van der hoorn, hans M.G. Princen, Miranda van eck, 
theo J.c. van Berkel, Patrick c.n. rensen, Menno hoekstra




The anti-dyslipidemic drug niacin has recently been shown to reduce the hepatic 
expression and plasma levels of CETP. Since liver macrophages contribute to hepatic 
CETP expression, we investigated the role of macrophages in the CETP-lowering effect 
of niacin in mice. In vitro studies showed that niacin does not directly attenuate CETP 
expression in macrophages. Treatment of normolipidemic human CETP transgenic 
mice, fed a Western-type diet with niacin for 4 weeks, significantly reduced the hepatic 
cholesterol concentration (-20%), hepatic CETP gene expression (-20%), and plasma 
CETP mass (-30%). Concomitantly, niacin decreased the hepatic expression of CD68 
(-44%) and ABCG1 (-32%), both of which are specific markers for the hepatic macrophage 
content. The decrease in hepatic CETP expression was significantly correlated with the 
reduction of hepatic macrophage markers. Furthermore, niacin attenuated atherogenic 
diet-induced inflammation in liver, as evident from decreased expression of TNF-alpha 
(-43%). Niacin similarly decreased the macrophage markers and absolute macrophage 
content in hyperlipidemic APOE*3-Leiden.CETP transgenic mice on a Western-type 
diet. In conclusion, niacin decreases hepatic CETP expression and plasma CETP mass 
by attenuating liver inflammation and macrophage content in response to its primary 




NIACIN DECREASES CETP BY REDUCING LIVER MACROPHAGES
iNTroDUcTioN
The anti-dyslipidemic drug niacin, also known as nicotinic acid, lowers plasma levels 
of pro-atherogenic lipids/lipoproteins, including very-low-density lipoproteins (VLDL) 
and low-density lipoproteins (LDL) as well as triglycerides (TG). The lipid-lowering 
effect of niacin has been widely recognized as an action on adipose tissue, where it 
reduces the mobilization and flux of free fatty acids from adipocytes into the plasma by 
inhibiting intracellular lipolysis 1, 2. In addition to lowering pro-atherogenic lipoprotein 
levels, niacin increases the level of anti-atherogenic high-density lipoprotein (HDL) in 
normolipidemic as well as hypercholesterolemic subjects 3. Several clinical trials have 
shown that niacin reduces cardiovascular disease and myocardial infarction incidence, 
providing an emerging rationale for the use of niacin in the treatment of atherosclerosis 4, 5. 
 Previously, we have shown that niacin increases HDL by reducing the hepatic 
expression and plasma levels of the pro-atherogenic cholesteryl ester transfer protein 
(CETP) in APOE*3-Leiden.CETP transgenic mice that exhibit a human-like lipoprotein 
profile 6. Importantly, a similar effect of niacin treatment on plasma CETP has also been 
detected in the human clinical setting (25-30% decrease; Chapman et al., unpublished 
data). CETP, as a lipid transfer protein, has an established role in cholesterol metabolism 7. 
It modifies the arterial intima cholesterol content via altering the concentration and 
function of plasma lipoproteins. Human population investigations favor low CETP as 
atheroprotective; this is supported by animal models where overexpression of CETP 
increased concentration of apoB-lipoprotein-cholesterol and atherosclerosis 8. Since 
CETP expression is driven by liver X receptor (LXR) activation, the reduction in hepatic 
CETP expression may be secondary to reduced liver lipid levels. However, the exact 
mechanism behind the hepatic CETP-lowering effect of niacin is still unresolved.
The liver consists of several different types of cells, including hepatocytes and non-
parenchymal cells such as resident macrophages, also known as Kupffer cells. Kupffer 
cells reside in the sinusoidal space of the liver and represent approximately 80-90% of 
the body’s resident macrophages 9, 10. Kupffer cells are derived from monocytes that 
arise from bone marrow progenitors and migrate from the circulation 11. Interestingly, 
Van Eck et al. 12 have shown a 47-fold higher expression of CETP mRNA in liver Kupffer 
cells than in hepatocytes of CETP transgenic mice. Furthermore, immunolocalization 
studies by Pape et al. 13 have also suggested that non-parenchymal cells are the primary 
site of CETP expression in livers from cynomolgus monkeys. Combined, these studies 
indicate that bone marrow-derived CETP is an important contributor to hepatic CETP 
expression and plasma CETP mass. Since the niacin receptor GPR109A is expressed 
in macrophages 14, 15 and niacin has been shown to exhibit potent anti-inflammatory 
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activities independent of its lipid lowering action 16-18, it is important to determine 
whether there is a direct action of niacin on liver macrophages. The aim of the current 
study was therefore to investigate whether macrophages are involved in the hepatic 




Twelve to fourteen week old female CETP transgenic mice expressing the human CETP 
transgene under the control of its natural flanking regions (CETP Tg; strain 5203; C57BL/6J 
N10) 19 were used. The animals were fed a semi-synthetic Western-type diet containing 
15% (w/w) fat and 0.25% (w/w) cholesterol (Diet W, Special Diet Services, Witham, UK) for 
3 weeks (run-in), after which the diet for the treatment group was supplemented with 
2% niacin (Sigma-Aldrich) for 4 weeks. Given the ~7-fold higher total metabolic rate 20, 21 
and ~6-fold higher glomerular filtration rate 22 in mice as compared to humans, the 2% 
dose of niacin given to the mice corresponds to approximately 18 g/day for an average 
70 kg human subject. Although this dosage is higher than the therapeutic dose of 
niacin used in the clinical setting 23, in pharmaceutical literature a relatively high dose of 
dietary niacin is commonly used dose to study the biological effect of niacin in mice 24-26. 
After an overnight fast, mice were euthanized, bled via orbital exsanguination, and 
perfused in situ through the left cardiac ventricle with ice-cold PBS (pH 7.4) for 20 
minutes. Tissues were dissected and snap-frozen in liquid nitrogen. One lobe of the 
liver was dissected free of fat and stored in 3.7% neutral-buffered formalin (Formal-fixx, 
Shandon Scientific Ltd., UK) for histological analysis. Animal care and procedures were 
performed in accordance with the national guidelines for animal experimentation. All 
protocols were approved by the Ethics Committee for Animal Experiments of Leiden 
University.
Some of the data reported here are derived from post-hoc analyses on samples from 
a previous study executed in APOE3*Leiden.CETP mice 6. In the indicated study, female 
APOE3*Leiden.CETP mice were fed a semi-synthetic cholesterol-rich diet for 3 weeks to 
obtain similar total cholesterol levels. After matching, mice received a Western-type 
diet without or with 1% niacin (Sigma) for 3 weeks.
Culture of bone marrow-derived macrophages
Bone marrow from female CETP Tg mice was harvested by flushing the femurs and 
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tibias with PBS (pH 7.4). Single-cell suspensions were prepared by passing the cells 
through a 70 μm cell strainer (BD, Breda, The Netherlands). Cell concentration was 
adjusted to 8 x 106 cells/mL, and cells were placed on a non-tissue culture treated 
Petri dish in RPMI1640 (PAA Laboratories) containing 20% (v/v) fetal calf serum (FCS), 
2 mM/L L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, 1% (v/v) non-
essential amino acids, 1% (v/v) pyruvate, and 30% (v/v) L929-conditioned media for 
7 days to specifically induce macrophage differentiation. Optimal differentiation was 
confirmed microscopically by visual examination of cell morphology (i.e. shape) and 
using routine blood cell analysis (Sysmex XT-2000iV Veterinary Hematology analyzer; 
Sysmex Corporation). Macrophages were harvested and cultured on 12-well plate in 
DMEM (PAA Laboratories) containing 10% (v/v) FCS, 2 mM/L L-glutamine, 100 U/mL 
penicillin, and 100 µg/mL streptomycin at a density of 0.5 x 106 cells/mL. After 24 hours, 
non-adherent cells were removed, and macrophages were incubated in the absence or 
presence of niacin (Sigma-Aldrich) at a concentration of 0.1 μM, 1 μM, 10 μM, and 100 
μM for 24 hours.
Tissue lipid analysis
Lipids were extracted from liver using the Folch method. Briefly, 100 mg of tissue was 
homogenized with chloroform/methanol (1:2). The homogenate was centrifuged to 
recover the upper phase, which was further washed with chloroform-0.9% NaCl (1:1, pH 1.0). 
After centrifugation, the lower chloroform phase containing lipids was evaporated and 
the retained lipids were solubilized in 2% Triton X-100 by sonication. Protein content 
of the tissue homogenates was analyzed by BCA assay (Pierce Biotechnology, Thermo 
Fisher Scientific BV, IL, USA). Total cholesterol and triglyceride contents of the lipid 
extract were determined using enzymatic colorimetric assays (Roche Diagnostics, 
Mannheim, Germany). Data were expressed relative to the protein content.
RNA isolation and gene expression analysis
Total RNA was isolated using acid guanidinium thiocyanate (GTC)-phenol-chloroform 
extraction. Briefly, 500 µL of GTC solution (4 M guanidine isothiocyanate, 25 mM sodium 
citrate, 0.5% N-lauroylsarcosine; Sigma-Aldrich) was added to each sample, followed 
by acid phenol:chloroform extraction. The RNA in aqueous phase was precipitated 
with isopropanol. The quantity and purity of the isolated RNA were examined using 
ND-1000 Spectrophotometer (Nanodrop, Wilmington, DE, USA). One microgram of 
the isolated RNA from each sample was converted into cDNA by reverse transcription 
with RevertAid™ M-MuLV Reverse Transcriptase (Promega, Madison, WI, USA). Negative 
controls without addition of reverse transcriptase were prepared for each sample. 
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Quantitative real-time PCR was carried out using ABI Prism 7700 Sequence Detection 
system (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s 
instructions using the primers in Table 1. 36B4, Beta-actin, and GAPDH were used as 
internal housekeeping genes. Amplification curves were analyzed using 7500 Fast 
System SDS software V1.4 (Applied Biosystems, Foster City, CA, USA). Transcripts that 
showed Ct>35 were considered not detectable. The relative expression of each gene 
was expressed as comparative numerical fold changes 2−(ΔΔCT). Standard error of the 
mean (SEM) and statistical significance were calculated using ΔΔCt formula.
Table 1: Primers used for quantitative real-time Pcr
Gene Accession Forward Primer Reverse Primer
36B4 NM007475 GGACCCGAGAAGACCTCCTT GCACATCACTCAGAATTTCAATGG
ABCA1 NM013454 GGTTTGGAGATGGTTATACAATAGTTGT TTCCCGGAAACGCAAGTC
ABCG1 NM009593 AGGTCTCAGCCTTCTAAAGTTCCTC TCTCTCGAAGTGAATGAAATTTATCG
APOA1 NM009692 ACTCTGGGTTCAACCGTTAGTCA TCCCAGAAGTCCCGAGTCA
ATGL NM025802 TGCCCTCAGGACAGCTCC TTGAACTGGATGCTGGTGTTG
Beta-actin X03672 AACCGTGAAAAGATGACCCAGAT CACAGCCTGGATGGCTACGTA
CD68 NM009853 CCTCCACCCTCGCCTAGTC TTGGGTATAGGATTCGGATTTGA
CETP NM000078 CAGATCAGCCACTTGTCCAT CAGCTGTGTGTTGATCTGGA
CHOP MMCHOP10 CTCTTGACCCTGCGTCCCTAG TGGGATGTGCGTGTGACCT
FAS NM007988 GGCGCGGCACCTATGGCGAGG CTCCAGCAGTGTGCGGTGGTC
GAPDH NM008084 TCCATGACAACTTTGGCATTG TCACGCCACAGCTTTCCA
HSL NM001039507 CTGACAATAAAGGACTTGAGCAACTC AGGCCGCAGAAAAAAGTTGAC
LPL NM008509 CCAGCAACATTATCCAGTGCTAG CAGTTGATGAATCTGGCCACA
SREBP-1C NM011480 GGAGCCATGGATTGCACATT CCTGTCTCACCCCCAGCATA
TNF-alpha X02611 GCC AGC CGA TGG GTT GTA AGGTTGACTTTCTCCTGGTATGAGA
CETP mass determination in plasma
Plasma CETP mass was determined by ELISA, using a commercially available 
immunoturbidimetry kit (Daiichi Pure Chemicals, Tokyo, Japan) according to the 
manufacturer’s instructions. Endogenous CETP activity was determined by a fluorescent 
method using donor liposomes enriched with nitrobenzoxadiazole-labeled cholesteryl 
esters (RB-CETP; Roar Biomedical, New York, NY) as described 27.
Immunohistochemistry
Macrophage content in livers of APOE*3-Leiden.CETP mice treated with or without 
niacin 6 was analyzed by immunohistochemistry staining. The liver was embedded 
in O.C.T™ Compound (Tissue-Tek, Sakura finetek, Tokyo, Japan), and subsequently 
sectioned using a Leica CM 3050S cryostat at 8 μm intervals. After incubation with 
blocking solution (5% goat serum), macrophages were detected using a rat anti-
murine F4/80 antibody (AbD Serotec, Oxford, UK). A rabbit anti-rat IgG/HRP was used as 
second antibody (Dako, Heverlee, Belgium). Sections were developed using NovaRED 
Peroxidase Substrate Kit (Vector Laboratories, Peterborough, UK) according to the 
manufacturer’s instructions. Slides were counterstained with hematoxylin (Sigma-
Aldrich). Apoptotic cells were detected by terminal deoxynucleotidyl transferase–
mediated dUTPbiotin nick-end labeling (TUNEL) with an in situ cell death detection kit 
(Roche). Nuclei were counterstained with 0.3% Methylene Green.
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Statistical analysis
Statistical analyses were performed by the unpaired Student’s t-test for independent 
samples (Instat GraphPad software, San Diego, USA). Statistical significance was defined 
as P<0.05. Data are expressed as means±SEM.
Figure 1. effect of niacin on plasma lipoprotein concentrations, hepatic ceTP expression, and plasma 
ceTP mass in CETP Tg mice. CETP Tg mice were fed a Western-type diet with or without supplementation 
of niacin (w/w) for 3 weeks before analysis. Values are means±SEM. ns, not significant. *P<0.05; ***P<0.001.
resULTs
Niacin lowers VLDL/LDL levels and reduces plasma CETP mass in CETP 
Tg mice
In agreement with its established lipid lowering capacity in the human situation, 
four weeks of niacin treatment induced a significant decrease in plasma levels of 
pro-atherogenic apoB-containing lipoproteins VLDL (-40%; P<0.05) and LDL (-24%; 
P<0.05) in Western-type diet fed CETP Tg mice (Fig. 1). Although a CETP-dependent 
increase in plasma HDL levels has previously been noted upon niacin treatment in our 
APOE3*Leiden mouse model 6, we did not observe a significant change in plasma HDL-
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cholesterol levels in CETP Tg mice upon feeding the diet supplemented with niacin 
(Fig. 1), probably because of low (V)LDL levels as acceptor of CETP-mediated HDL-CE 
transfer. In line with our previous data from APOE*3-Leiden.CETP transgenic mice 6, 
niacin treatment did result in a significant reduction in hepatic CETP gene expression 
(-20%: P<0.05) and plasma CETP mass (-30%; P<0.001) in CETP Tg mice (Fig. 1). Probably 
due to the low amount of substrate available for CETP action, i.e. relatively low plasma 
VLDL/LDL levels, and associated low CETP activity already under basal (non-niacin) 
conditions we did not observe a concomitant decrease in the endogenous plasma 
CETP activity upon niacin treatment in our CETP Tg mouse model (0.35±0.03 mmol/
mL/h for niacin vs 0.37±0.03 mmol/mL/h for controls; P>0.05).
Gene expression analysis on livers revealed that the relative mRNA expression level 
of the primary protein moiety of HDL, apolipoprotein A1 (APOA1), was as expected 
28 markedly stimulated (+84%; P<0.05) by niacin treatment (Fig. 2). Li et al. 26 recently 
showed that activation of the niacin receptor GPR109A diminishes the hepatic 
expression of ABCA1 and impairs the efflux of cholesterol from hepatocytes to APOA1. 
In accordance, we also detected a significant decrease in hepatic ABCA1 expression 
(-45%; P<0.05) in mice subjected to niacin treatment (Fig. 2).
Figure 2. effect of niacin on HDL-associated gene expression in liver of CETP Tg mice. Relative expression 
levels as fold compared to control of apolipoprotein A1 (APOA1) and ATP-binding cassette transport A1 
(ABCA1). Values are means±SEM. *P<0.05.
Niacin treatment does not affect LXR activity in livers of CETP Tg mice
As evident from the Oil red O stainings depicted in Fig. 3A, Western-type high 
cholesterol/high fat diet feeding was associated with the appearance of neutral lipid 
stores within hepatocytes of control mice. In contrast, livers of niacin-treated mice 
showed virtually no lipid droplets (Fig. 3A). Quantification of intra-hepatic lipid levels 
revealed that the effect on neutral lipids stores upon niacin treatment coincided with a 
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reduction in hepatic total cholesterol levels (-20%; P<0.01; Fig. 3B).
Figure 3. effect of niacin on hepatic neutral lipid stores in CETP Tg mice. (A) Neutral lipid content was 
visualized by Oil red O staining. (B) Liver cholesterol and triglyceride concentrations corrected for cellular 
protein content. Values are means±SEM. ns, not significant. **P<0.01.
The cholesterol sensor liver X receptor (LXR) is able to directly stimulate CETP 
and ABCA1 transcription through specific LXR responsive elements in their promoter 
regions 29, 30. To evaluate whether niacin decreased hepatic CETP expression and ABCA1 
by attenuating LXR activation, we measured the effect of niacin on the expression of the 
other established LXR target genes SREBP-1C, APOE, and LPL. The hepatic expression 
of these three genes remained unchanged after niacin treatment (data not shown), 
indicating that the reduction of hepatic CETP expression was not due to a change in 
LXR activation upon niacin treatment.
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Niacin does not change macrophage CETP expression in vitro
Previous studies using cultured peritoneal macrophages have indicated that niacin at 
a concentration of 100 µM can directly affect macrophage function by altering their 
calcium flux 31 or gene expression profile 32 to a similar extent as observed in vivo in mice 
treated with doses of 0.3-1% niacin. To assess whether niacin directly attenuates CETP 
expression in macrophages, bone marrow-derived macrophages from CETP Tg mice 
were exposed to various concentrations of niacin (0.1 µM, 1 µM, 10 µM, and 100 µM) 
for 24 hours. Niacin treatment did not significantly alter CETP expression. Furthermore, 
niacin did not affect relative mRNA expression levels of the LXR-regulated targets 
SREBP-1C or APOE, or the cholesterol metabolism-related genes ABCA1, ABCG1, SR-B1, 
CD36 in cultured bone marrow-derived macrophages (data not shown).
Figure 4. effect of niacin on hepatic macrophage gene expression in CETP Tg mice. (A) Relative expression 
levels as fold compared to control of macrophage marker CD68, the ATP binding cassette transporter G1 
(ABCG1), and tumor necrosis factor-alpha (TNF-alpha). (B) Ratios between the expression level of CETP and 
CD68, ABCG1 and CD68, TNF-alpha and CD68 were calculated. (C) Correlation between hepatic CETP and 
CD68/ABCG1 expression was linearly plotted. Values are means±SEM. ns, not significant. *P<0.05; **P<0.01.
Niacin reduces the liver macrophage content in CETP Tg mice
Since these data indicate that niacin may reduce hepatic CETP expression by reducing 
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the liver macrophage content, we evaluated the effect of niacin on the established 
macrophage markers CD68 and ABCG1 33-35. Niacin treatment significantly decreased 
hepatic expression of CD68 by 44% (P<0.05) and ABCG1 by 32% (P<0.01) (Fig. 4A). 
However, niacin did not affect the CETP/ABCG1 and ABCG1/CD68 expression ratios (Fig. 
4B). Combined, these findings suggest that niacin - in line with our in vitro data - does 
not directly reduce the expression of CETP on macrophages, but in fact reduces hepatic 
CETP expression by diminishing the liver content of (CETP-expressing) macrophages.
In accordance with a decreased liver macrophage content, gene expression of 
the pro-inflammatory M1 macrophage subtype marker TNF-alpha decreased by 43% 
(P<0.05) after niacin treatment (Fig. 4A). Since the TNF-alpha/CD68 ratio did not change 
after niacin treatment (Fig. 4B) and the anti-inflammatory M2 macrophage marker 
interleukin-10 (IL-10) could not be detected in either treatment group (Ct>35; data not 
shown), it seems that treatment of CETP Tg mice with niacin did not affect the in vivo 
macrophage phenotype.
The comparable reductions of hepatic CETP, liver macrophage markers, and liver 
inflammation markers suggest that the decrease of hepatic CETP expression is caused 
by a reduced amount of inflammatory macrophages in liver. Indeed, as evident from 
Fig. 4C linear regression showed a significant and strong positive correlation between 
hepatic CETP and CD68 expression (P<0.01; R2=0.78), as well as between hepatic CETP 
and ABCG1 expression (P<0.05, R2=0.68). 
Consistent with these results, post-hoc analysis on livers of APOE*3-Leiden.CETP 
mice treated with niacin, from our previous study, in which the CETP-lowering effect 
of niacin was first observed 6, revealed similar significant reductions in hepatic gene 
expression of the macrophage markers CD68 (-51%; P<0.01) and ABCG1 (-45%; P<0.01) 
(Fig. 5A). In addition, there were also significant correlations between hepatic CETP 
and CD68 (P<0.001; R2=0.75) or ABCG1 (P<0.001; R2=0.85) expression (Fig. 5A). The 
reduction of hepatic macrophage content was further visualized by staining of F4/80-
positive cells, where niacin significantly reduced the number of macrophages in the 
liver by 28% (P<0.01) (Fig. 5B).
In agreement with a prominent contribution of the liver macrophage-derived CETP 
to total plasma CETP levels, we observed a significant positive correlation between 
the plasma CETP level and hepatic CD68 mRNA expression in CETP Tg mice treated 
with niacin (P<0.05; Supplemental Fig. 1A) and between the plasma CETP level and 
the number of macrophages in livers of APOE*3-Leiden.CETP mice treated with niacin 
(P<0.05; Supplemental Fig. 1B).
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Figure 5. effect of niacin on hepatic macrophage gene expression and number of macrophages in 
APOE*3-Leiden.CETP mice. (A) Relative expression levels as fold compared to control of macrophage marker 
CD68 and the ATP binding cassette transporter G1 (ABCG1). Correlation between hepatic cholesteryl ester 
transfer protein (CETP) and CD68/ABCG1 expression was linearly plotted. (B) Macrophage content in the liver 
was visualized via immunohistochemistry staining with F4/80 antibody, and the number of positive cells 
were counted and expressed as percentage of control group. Representative pictures are shown. Values are 
means±SEM. **P<0.01.
supplemental Figure 1. correlations between the plasma ceTP level and hepatic cD68 mrNA 
expression in CETP Tg mice treated with 2% niacin (A) and the plasma ceTP level and the number of 
macrophages in livers of APOE*3-Leiden.CETP mice treated with 1% niacin (B).
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Niacin does not induce apparent liver toxicity in CETP Tg mice
Mild hepatic toxicity is a known side-effect of high dose niacin treatment in humans 36. 
In addition, a case of severe liver toxicity, i.e. fulminant hepatic failure, upon niacin 
treatment has been reported 37. We therefore evaluated possible hepatotoxic effects 
of niacin treatment in the current study. The liver structure of CETP Tg mice fed the 
diet without or with niacin appeared normal. In addition, no TUNEL-positive apoptotic 
cells were noted in livers of either treatment group (Fig. 6A). In fact, niacin decreased 
the hepatic mRNA expression level of the pro-apoptotic molecule C/EBP homologous 
protein (CHOP; -66%; P<0.01; Fig. 6B) that is highly sensitive to endoplasmatic 
reticulum stress 38. Combined, these findings suggest that niacin may actually diminish 
hepatotoxicity. In line with an overall lower hepatic stress level upon niacin exposure, 
plasma aspartate aminotransferase (AST/GOT) and alanine aminotransferase (ALT/GPT) 
levels both tended to decrease (P=0.08 for both) in APOE*3-Leiden.CETP mice subjected 
to niacin treatment (Fig. 6C).
Figure 6. effect of niacin on liver 
toxicity in CETP Tg mice and APOE*3-
Leiden.CETP mice. (A) No TUNEL-positive 
apoptotic cells could be detected in 
livers CETP Tg mice treated with or 
without niacin, while our positive control 
(parallel stained vain graft material) did 
show TUNEL-positive staining (black 
nuclei; inset). (B) Relative expression 
levels as fold compared to control of 
C/EBP homologous protein (CHOP) in 
CETP Tg mice treated with niacin. (C) 
Plasma aspartate aminotransferase (AST/
GOT) and alanine aminotransferase (ALT/
GPT) in APOE*3-Leiden.CETP mice treated 




Niacin modulates white adipose tissue gene expression and lipids in 
CETP Tg mice
Niacin executes its primary lipid lowering action in adipocytes within white adipose 
tissue, where it via GPR109a-mediated modulation of intracellular signalling pathways 
inhibits lipolysis by decreasing the activity of adipose triglyceride lipase (ATGL) and 
hormone-sensitive lipase (HSL) 39. We did not detect a change in the relative mRNA 
expression level of ATGL and HSL in abdominal white adipose tissue of niacin-treated 
mice, excluding a direct transcriptional effect of niacin on the ATGL-HSL axis (Fig. 7A). 
In contrast to what one would expect in response to the diminished lipolytic activity, 
a marked decrease in the white adipose tissue triglyceride content (-70%; P<0.01; 
Fig. 7B) was noted upon niacin treatment. However, in agreement with similar 
observations in patients with impaired glucose tolerance treated with extended release 
niacin 40, a significant decrease (-38%; P<0.01) in the white adipose tissue expression of 
fatty acid synthase (FAS) was also observed upon niacin exposure (Fig. 7A). Since we 
subjected the mice to an overnight fast, both groups of mice contained low levels of 
abdominal white adipose tissue at sacrifice. As a result, we did not see an apparent 
change in the body weight of niacin-treated mice (data not shown).
Figure 7. effect of niacin on abdominal white adipose tissue triglyceride content and gene expression 
in CETP Tg mice. (A) Relative expression levels as fold compared to control of adipose triglyceride lipase 
(ATGL), hormone-sensitive lipase (HSL), and fatty acid synthase (FAS). (B) White adipose tissue triglyceride 
concentration corrected for cellular protein content. (C) Relative expression levels as fold compared to 
control of macrophage marker CD68 and CETP. Values are means±SEM. ns, not significant. **P<0.01.
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The relative expression levels of CD68 and CETP in abdominal white adipose tissue 
were unaffected by niacin treatment (Fig. 7C). This suggests that the effect of niacin 
treatment on plasma CETP levels can be attributed to attenuation of the macrophage-
derived CETP expression specifically in the liver and argues against a niacin-induced 
general cytotoxic (i.e. apoptotic/necrotic) effect on macrophages in vivo.
DiscUssioN
Niacin lowers plasma CETP levels both in mice 6 as well as in the human clinical setting 
(unpublished data; Chapman et al.). However, the mechanism behind the niacin-
induced decrease in CETP levels has thus far not been delineated.
To explain the CETP-lowering effect of niacin, we set out to investigate the effect 
of niacin on macrophages. Our observations in vitro showed that niacin at various 
concentrations did not reduce CETP expression in cultured macrophages derived 
from CETP Tg mice. Neither did niacin alter cholesterol metabolism-related genes in 
macrophages, such as ABCA1, ABCG1, and SR-B1. We thus conclude that niacin does 
not directly regulate expression of CETP or other lipid-related genes in macrophages.
Luo et al. 29 have previously demonstrated that CETP is trans-activated by nuclear 
receptor LXR, suggesting its role in regulating CETP expression in vivo. Therefore, we 
proposed in our previous study that niacin may decrease the hepatic CETP mRNA 
expression via LXR responsive element in the CETP promoter following decreased 
hepatic cholesterol content 6. However, our current showed that niacin did not 
directly regulate expression of LXR-regulated target genes, such as ABCA1, in cultured 
macrophages in vitro. Our in vivo data further confirmed that niacin did not regulate 
the hepatic expression of classical LXR targets such as SREBP-1C, APOE, or LPL. In 
addition, although niacin treatment reduced the gene expression of ABCG1 in liver, it 
did not affect the ABCG1/CD68 expression ratio, indicating that niacin does not reduce 
the relative expression level of ABCG1 per macrophage. The reduction in ABCG1 in vivo 
is thus probably not simply the consequence of reduced LXR activation. Therefore, it is 
suggested that either direct or indirect regulation of LXRs in the liver is not the main 
mechanism by which niacin reduces CETP expression.
The liver is a unique immunological site responding to inflammation. Antigen-
rich blood from the gastrointestinal tract and the peripheral circulation enters the 
hepatic parenchyma, passes through a network of liver sinusoids and is scanned by 
immune cells including macrophages and lymphocytes 41. Thus, liver macrophages 
have profound implications in many aspects of the hepatic inflammatory response 42. 
Plasma pro-atherogenic lipoproteins, mainly (V)LDLs, are important determinants of 
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liver inflammation. Recent evidence has indicated an increased hepatic inflammation 
and macrophage content upon high-fat diet-induced hyperlipidemia. In C57Bl/6J mice 
fed a high fat diet, upregulation of hepatic expression of CD68 was found associated 
with increased hepatic lipid content 43. Another study showed that in the LDL receptor 
knockout mice fed a high fat diet containing cholesterol, an increase of CD68 expression 
in the liver was correlated with increased plasma VLDL cholesterol levels. Omitting 
cholesterol from the diet rapidly reduced plasma triglyceride and VLDL-cholesterol 
accumulation, associated with significantly lowered CD68 expression in liver together 
with other inflammatory genes 44. In humans, a similar correlation between increased 
presence of CD68-positive Kupffer cells and the histological severity of human hepatic 
lipid content in fatty liver has been reported 45. Such correlations between altered 
macrophage content and circulatory inflammatory factors define macrophage 
infiltration as a common response against hepatic and circulatory inflammation. 
In the current study, niacin treatment reduced cholesterol content in the liver. 
In line with this attenuated liver fat accumulation, we further observed a significant 
reduction of the pro-inflammatory M1 macrophage marker TNF-alpha in liver. TNF-
alpha is critically involved in the pathophysiology of liver steatosis, and this cytokine is 
primarily secreted by Kupffer cells and liver-infiltrating macrophages 46. Taken together, 
the results suggested an attenuated liver inflammation after niacin treatment.
In line with the attenuated diet-induced inflammation in the liver, the hepatic gene 
expression of CD68 and ABCG1 were also reduced upon niacin treatment. CD68 has 
been defined as a reliable macrophage marker and widely used for quantification of 
macrophage content in numerous studies 47-49. ABCG1 has also been shown to be a 
reliable marker to assess Kupffer cell content in the liver, since ABCG1 is not expressed in 
hepatocytes 50, 51. In the current study, a reduction in the hepatic TNF-alpha expression 
coincided with decreased CD68 and ABCG1 gene expression in liver, and also a reduced 
number of macrophages in liver, indicating an attenuated macrophage infiltration into 
the liver and/or an increased macrophage efflux/emigration from the liver and thus an 
overall decreased liver macrophage content. More importantly, the significant positive 
correlation between hepatic CETP and both CD68 and ABCG1 expression observed in 
both the current study and in the present post-hoc analysis of our previous study 6 
suggests that the liver macrophage is a primary contributor to hepatic and total plasma 
CETP mass, and that the hepatic CETP reduction induced by niacin treatment is a direct 
consequence of a reduced macrophage content of the liver. 
Fig. 8 illustrates the proposed mechanism underlying the action of niacin on 
hepatic CETP expression. We propose that the primarily reduced hepatic cholesterol 
accumulation via the lipid-lowering effect of niacin leads to attenuated hepatic 
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inflammation, and thus less macrophage infiltration into and/or increased macrophage 
efflux/emigration out of the liver. The decreased amount of hepatic macrophages leads 
to an overall reduction in hepatic CETP expression and a lower plasma CETP level.
Figure 8. Proposed mechanism underlying the action of niacin on hepatic ceTP expression and plasma 
ceTP mass. We propose that the primarily reduced hepatic cholesterol accumulation via the lipid-lowering 
effect of niacin leads to attenuated hepatic inflammation, and thus less macrophage infiltration into and/or 
increased macrophage emigration out of the liver. The decreased amount of hepatic macrophages, which are 
significant contributors of CETP, leads to an overall reduction in hepatic CETP expression and a lower plasma 
CETP level.
In conclusion, our study sheds new light on the mechanism underlying the CETP-
lowering effect of niacin. We have shown that niacin does not directly alter macrophage 
CETP expression, but attenuates liver inflammation and the macrophage content in 
response to its primary lipid-lowering effect, which leads to a decrease in hepatic CETP 
expression and plasma CETP mass. These findings further substantiate our working 
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Cholesteryl ester transfer protein (CETP) reduces HDL-cholesterol and is a pharmaceutical 
target for treating dyslipidemia. However, the cellular origin of plasma CETP in humans 
is uncertain. We aimed to elucidate the relative contribution of adipose tissue and liver 
to plasma CETP pools and the cellular origin of plasma CETP. To assess the association 
between adipose tissue mass and CETP, waist circumference and plasma CETP were 
measured in 1434 subjects from a general population. To further characterize the source 
of CETP, biopsies of liver and adipose tissue from 94 subjects were analysed for gene and 
protein expression, and these were correlated with plasma CETP and lipid parameters. 
Detailed mechanistic studies on the cellular origin of CETP and mode of action of lipid-
lowering drugs that lower plasma CETP were performed using APOE*3-Leiden.CETP 
(E3L.CETP) transgenic mice, a well-established model for human-like lipoprotein 
metabolism. Plasma CETP did not correlate with waist circumference, suggesting 
that central adipose tissue does not contribute to plasma CETP. Microarray analysis 
of liver and adipose tissue biopsies showed that CETP expression was highest in 
liver. Immunohistochemistry revealed that hepatic CETP is primarily expressed by 
macrophages. CETP expression in liver, but not adipose tissue, positively correlated 
with plasma CETP, and inversely correlated with plasma HDL-cholesterol. Selective 
elimination of macrophages from liver versus adipose tissue in E3L.CETP mice virtually 
abolished hepatic CETP expression, accompanied by largely reduced plasma CETP 
and increased plasma HDL-cholesterol. Lipid-lowering drugs that are known to reduce 
plasma CETP and to increase HDL in humans, reduced the hepatic macrophage content, 
simultaneously reducing plasma CETP and increasing HDL-cholesterol in E3L.CETP mice. 
In conclusion, plasma CETP is predominantly derived from hepatic macrophages, and 




CETP: A BIOMARKER FOR HEPATIC MACROPHAGES
iNTroDUcTioN
The metabolic syndrome (MetS) is a complex disorder defined by interrelated risk factors 
for type 2 diabetes and cardiovascular disease, including central obesity, hyperglycemia, 
hypertension and dyslipidemia. In particular, many patients with the clinical diagnosis 
of MetS show a pro-atherogenic lipid profile with increased very low density lipoprotein 
(VLDL)-triglycerides (TG) and decreased high density lipoprotein (HDL)-cholesterol (C) 1. 
Cholesteryl ester (CE) transfer protein (CETP) plays a pivotal role in the metabolism of 
VLDL and HDL by mediating the transfer of TG from VLDL to HDL in exchange for CE, 
resulting in increased (V)LDL-C and decreased HDL-C 2. Genetic deficiency for CETP 
increases HDL-C and lipid-lowering compounds that reduce plasma CETP induce a 
beneficial lipoprotein profile including reduced VLDL-TG and raised HDL-C 3, 4. Therefore, 
CETP inhibition is a current target for the treatment of low HDL and the pro-atherogenic 
lipid profile associated with MetS to reduce cardiovascular disease risk 5.
Previous studies have demonstrated that liver and adipose tissue are the two major 
sources of circulating CETP in several mammalian species. Other tissues, such as spleen, 
heart, small intestine, adrenal gland and skeletal muscle express CETP mRNA to only a 
minor extent 6-10. However, the relative contribution of liver and adipose tissue to total 
plasma CETP, and the cell types involved in CETP synthesis, remain to be unambiguously 
determined. Few studies have suggested that hepatocytes may be responsible for the 
expression and secretion of CETP from the liver 6. However, other studies suggested that 
nonparenchymal cells including Kupffer cells are the principal source of CETP in the liver 6, 11. 
Although adipose tissue CETP expression was shown to be associated with plasma CETP 
in a small cohort of 13 men 12, an association between plasma CETP and adiposity has 
not been conducted in large general populations as yet.
To design novel CETP-target strategies and to understand their ability to reduce 
cardiovascular disease risk, it is crucial to understand the cellular origin of plasma 
CETP. Therefore, in this study we aimed to elucidate the cellular origin of CETP in the 
APOE*3-Leiden.CETP mouse model and in a translational setting using human cohorts. 
These mice express the human CETP gene under control of its natural regulatory flanking 
regions, ensuring a similar CETP expression pattern as in humans 13-16. Our data show 
that the liver, rather than adipose tissue, predominantly contributes to plasma CETP, 
and that hepatic CETP is exclusively produced by macrophages. Moreover, specific lipid-
lowering drugs decrease the hepatic macrophage content and thus increase HDL-C via 
reduction of hepatic CETP production. We therefore conclude that plasma CETP is a 





Design of human studies
Two independent populations were selected. The first cohort was obtained from the 
general population in Rijswijk, The Netherlands, consisting of 1434 non-diabetic 
subjects between 40-70 years of age (654 males, 780 females). Exclusion criteria included 
diagnosed diabetes, known terminal disease, and a history of psychiatric disorder or 
substance abuse. Waist circumference was measured and venous blood samples were 
taken after overnight fasting (approx. 12 h) for measurement of the plasma CETP 
concentration. The Rijswijk study was approved by the review board of South West 
Holland and performed in accordance with the Declaration of Helsinki.  
The second study consisted of 93 severely obese subjects (BMI 30-74 kg/m2) who 
underwent elective bariatric surgery from 2006 to 2009 at the Dept. of General Surgery, 
Maastricht University Medical Center, Maastricht, The Netherlands, as described 17. 
Subjects using anti-inflammatory drugs or having acute or chronic inflammatory 
diseases, degenerative diseases, and subjects reporting alcoholic intake >10 g/day, were 
excluded. During surgery, biopsies from liver, subcutaneous adipose tissue (SAT) and 
visceral adipose tissue (VAT) were taken for mRNA isolation and hybridization. Venous 
blood samples were obtained after overnight fasting (approx. 8 h) on the morning of 
surgery for analysis of the plasma CETP concentration and lipid parameters. This study 
was approved by the Medical Ethics Board of Maastricht University Medical Centre, in 
line with the Declaration of Helsinki. All participants provided informed written consent.
Details of all parameters measured in both population cohorts are provided in the 
Methods section in the Supplementary Appendix.
Design of mouse studies
Female APOE*3-Leiden.CETP (E3L.CETP) transgenic mice expressing the human CETP 
gene under the control of its natural flanking regions 18 were used, and housed under 
standard conditions with a 12 h light/dark cycle with free access to food and water 
unless indicated otherwise. Mice were fed a semi-synthetic Western-type diet (WTD), 
containing 0.1% (w/w) cholesterol, 1% (w/w) corn oil and 15% (w/w) cocoa butter (Hope 
Farms, Woerden, The Netherlands). 
In a first experiment, mice were fed WTD for 4 weeks, randomized according to 
body weight, plasma total cholesterol (TC) and triglyceride (TG) levels, and received 
two intraperitoneal injections of liposomal clodronate (4 ml/kg bodyweight; purchased 
from Dr. N. van Rooijen, VUmc, Amsterdam) at a 3-day interval to deplete macrophages 
from the liver 19, 20, and were terminated 3 days after the second injection. In a second 
6
103
CETP: A BIOMARKER FOR HEPATIC MACROPHAGES
experiment, mice were fed WTD, without (control) and with 0.04% (w/w) fenofibrate 
or 1% (w/w) niacin (both from Sigma, St. Louis, MO, USA) for 4 additional weeks 
before sacrificing. Experiments were performed after 4 h of fasting at 12:00 pm with 
food withdrawn at 8:00 am. The institutional Ethical Committee on Animal Care and 
Experimentation from the Leiden University Medical Center, Leiden, The Netherlands 
had approved all animal experiments.
In both experiments, blood was obtained via tail vein bleeding into heparin-coated 
capillary tubes. The tubes were placed on ice and centrifuged, and the obtained plasma 
was snap-frozen in liquid nitrogen and stored at -20°C until further analysis. Plasma was 
assayed for CETP and lipid concentrations and lipoprotein profiles (see the Methods 
section in the Supplementary Appendix). After mice had been sacrificed, liver and 
gonadal adipose tissue samples were collected to measure the expression of selected 
genes by quantitative real-time PCR and proteins by immunohistochemistry (see the 
Methods section in the Supplementary Appendix).
Statistical Analysis 
Categorical variables are presented as frequencies and percentages, and continuous 
variables as means and standard deviations, or medians and interquartile ranges for 
variables with skewed distributions. Pearson correlation was used to estimate the 
association between waist circumference and plasma CETP in Rijswijk study. In the 
bariatric surgery cohort, Spearman correlation was used to determine the correlation 
between expression of CETP and MARCO in the liver, SAT, VAT; the association between 
CETP expression in liver, SAT, VAT and plasma CETP level; as well as the association 
between CETP expression in liver, SAT, VAT and plasma HDL-C level, respectively. 
Statistical differences between groups were assessed with the nonparametric Mann-
Whitney U test for two independent groups or two-way ANOVA with Tukey’s post-hoc 
test for multiple comparisons. All reported P values are two-tailed, and P values of less 
than 0.05 were considered statistically significant.
resULTs
Waist circumference is not associated with plasma CETP concentration 
in humans
The characteristics of 1434 subjects (654 males and 780 females) from a non-diabetic 
population in Rijswijk are shown in Supplementary Table 1. Mean (±SD) waist 
circumference was 99 ± 11 cm for males (n=654) and 89 ± 12 cm for females (n=780). The 
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median value for plasma CETP concentration was significantly lower in males [2.31 (1.90-
2.72) µg/ml] compared to females [2.44 (2.02-2.86) µg/ml] (P<0.001). However, plasma 
CETP did not differ between quintiles of waist circumference in either males (Fig. 1A; 
P=0.328) or females (Fig. 1B; P=0.571), and no correlation between waist circumference 
and plasma CETP concentration was observed in either males (Fig. 1C; r=0.007, P=0.857) 
or females (Fig. 1D; r=-0.024, P=0.509). Excluding subjects who received lipid-lowering 
medication (statins) (82 males and 61 females) did not change the results for males 
(r=0.023, P=0.583) and females (r=-0.003, P=0.930). Our findings suggest that central 
obesity measured as waist circumference does not correlate with the plasma CETP in a 
general population.
supplementary Table 1 characteristics of the non-diabetic population cohort in rijswijk study. * 
Characteristic Male (N=654) Female (N=780)
Age — yr 54.0±8.2 53.7±8.3
Current smoking — no. (%) 189 (28.9) 202 (25.9)
Metabolic Syndrome † — no. (%) 293 (45) 245 (32)
Medication — no. (%)
  Statin





Blood pressure — mmHg
  Systolic blood pressure 





Waist circumference — cm 99±11 89±12
Total cholesterol — mmol/liter
  Median





HDL-cholesterol — mmol /liter
  Median





Triglycerides — mmol /liter
  Median





Glucose – mmol/liter 5.44±1.16 5.13±0.77
CETP — µg/ milliliter
  Median





* Plus-minus values are means±SD. To convert values for cholesterol to milligrams per deciliter, divide by 
0.02586. To convert values for triglycerides to milligrams per deciliter, divide by 0.01129. HDL denotes high-
density lipoprotein; CETP denotes cholesteryl ester transfer protein. 
† The diagnosis of metabolic syndrome is based on the IDF criteria.36 Therefore two or more of the following 
criteria in addition to an increased waist circumference (male ≥ 94 cm, female ≥ 80 cm), had to be present: 
triglycerides ≥ 1.7 mmol/l (≥ 150mg/dl), HDL-cholesterol < 1.03 mmol/l (<40 mg/dl) in male and < 1.29 mmol/l 
(<50 mg/dl) in female, fasting glucose ≥ 5.6 mmol/l (150 mg/dl), blood pressure ≥ 130/85 mmHg or the use of 
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Figure 1. Waist circumference is not associated with plasma ceTP concentration in a general population. 
In 1434 subjects that were enrolled in the Rijswijk study, median plasma CETP concentration over quintiles of 
waist circumference in male (A) and female (B) subjects, associations between plasma CETP concentration and 
waist circumference in male (C) and female (D) subjects were determined.  
Hepatic CETP expression, specifically in macrophages, determines the 
plasma CETP concentration and HDL-cholesterol level in humans
The characteristics of 93 severely obese patients who underwent elective bariatric 
surgery are shown in Table 1. Biopsies from livers and adipose tissue [i.e. subcutaneous 
adipose tissue (SAT) and visceral adipose tissue (VAT)] were taken during surgery 
and gene expression profiles were determined by micro-array analyses as described 
previously.17 These profiles revealed that the CETP mRNA transcript is much more 
abundant in liver than in VAT and SAT (P=2.22x10-33 and P=1.9x10-27, respectively). 
Next, the associations between the expression of CETP and other genes in VAT, SAT 
and liver was evaluated. Strikingly, the top genes that correlated highest with hepatic 
CETP expression are specific macrophage markers including TIMD4 (r=0.631) and 
MARCO (r=0.590). In contrast, CETP did not correlate with macrophage-specific genes 
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in adipose tissue. For example, expression of CETP and MARCO were correlated in 
liver (r=0.590; P<0.0001; Fig. 2A) in liver but not in SAT (r=-0.092, P=0.388; Fig. 2B) or 
VAT (r=0.035, P=0.750; Fig. 2C). Using a publicly available considerably larger dataset 
undergoing bariatric surgery (1008 subjects) 21, we were able to replicate the strong 
association between CETP expression and MARCO in liver (r=0.624, P=1.7391e-71), but 
not in VAT (e.g. omental adipose tissue, r=-0.0423, P=0.2183) or SAT (r=0.043, P=0.2448) 
(Supplementary Fig. 1). Immunohistochemical stainings revealed that, in the liver, CETP 
specifically co-localized with CD68+ macrophages (Fig. 2D).
Table 1 characteristics of severely obese subjects underwent the bariatric surgery 
Age — yr 44.2±9.7
Male sex — no. (%) 26 (28.0%)
Body mass index† 46.1±9.5
Glucose- mmol/liter 46.45±1.98







Triglycerides — mmol /liter 2.22±1.98
CETP — µg/ milliliter 2.70±1.02
Importantly, hepatic CETP expression positively correlated with plasma CETP 
(r=0.519, p<0.0001; Fig 2E), and inversely correlated with plasma HDL-C (r=-0.204, 
p=0.075; Fig 2H). In contrast, no significant correlation between expression of CETP in 
VAT and plasma CETP (p=0.140; Fig 2G) or HDL-C (p=0.250; Fig 2J) was noted. Although 
CETP expression in SAT correlated with plasma CETP (P<0.01; Fig 2F), it did not correlate 
with plasma HDL-C (p=0.123; Fig 2I). These data suggest that CETP expression in hepatic 
macrophages determines plasma CETP levels as well as the CETP-induced effects on 
HDL levels.  
supplementary Figure 1. Association of expression of ceTP and mArco in liver and adipose tissue
Scatter plots of the correlation between mRNA level of CETP and MARCO in liver (A), subcutaneous adipose 
tissue (SAT) (B) and omental adipose (OA) (C) obtained from 1008 subjects undergoing bariatric surgery.21
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Figure 2. Hepatic ceTP expression in macrophages is associated with plasma ceTP concentration 
and HDL-cholesterol level in humans. Biopsies from visceral adipose tissues (VAT), subcutaneous adipose 
tissues (SAT) and livers and were taken during bariatric surgery from 97 severely obese patients, and assayed 
for genome-wide gene expression profiles. The expression of CETP was correlated with MARCO in liver (A), 
but not in SAT (B) and VAT (C). Panel D shows representative pictures of double stainings of CD68 (red) and 
CETP (green) in a liver section. Hepatic CETP expression positively correlated with plasma CETP level (E), and 
reversely correlated with plasma HDL-cholesterol level (H). The correlation between plasma CETP level and 
the expression of CETP in the SAT (F) and VAT (G), and the correlation between plasma HDL-C level and the 
expression of CETP in the SAT (I) and VAT (J) are shown.  
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Figure 3. elimination of hepatic macrophages abolishes hepatic ceTP expression and largely reduces 
plasma ceTP in E3L.CETP mice. APOE*3-Leiden.CETP (E3L.CETP) mice fed a western-type diet (WTD) were 
treated with or without liposomal clodronate. Livers were assayed for mRNA expression of F4/80 (A) and CETP 
(C), as well as for F4/80 (B) and CETP (D)-positive cells. Gonadal adipose tissues were assayed for expression 
of F4/80 (E) and CETP (F). The expression levels of ß-2 microglobulin (ß-2) and CETP were compared between 
livers and adipose tissue (G). Plasma was assayed for CETP concentration (H) and the cholesterol distribution 
over lipoproteins (I). 
Elimination of hepatic macrophages abolishes hepatic CETP expression 
and largely reduces plasma CETP concentration in E3L.CETP mice
To further investigate the contribution of CETP expression in hepatic macrophages 
to plasma CETP as well as lipoprotein metabolism, E3L.CETP mice were injected with 
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liposomal clodronate, a well-established method to deplete macrophages from liver, 
but not adipose tissue in rodents 19, 20. Indeed, as compared with controls, liposomal 
clodronate markedly reduced hepatic F4/80 expression (-88%, P<0.001; Fig. 3A) and 
F4/80+ cells (-74%, P<0.001; Fig. 3B). Concomitantly, depletion of hepatic macrophages 
almost completely abolished hepatic CETP expression (Fig. 3C, -96%, P<0.001) as well as 
CETP+ macrophages (Fig. 3D, -96%, P<0.001). In contrast to the liver, liposomal clodronate 
did not alter the mRNA expression of F4/80 (Fig. 3E) or CETP (Fig. 3F) in adipose tissue. 
Strikingly, CETP expression in the liver is 113-fold higher than in adipose tissue (Fig. 3G, 
P<0.001), despite a comparable expression of the reference gene ß-2 microglobulin. This 
corroborates the human studies suggesting that the liver, as opposed to adipose tissue, 
is the main source of CETP. In further support of this notion, elimination of hepatic 
macrophages largely reduced plasma CETP levels (-71%, P<0.001; Fig. 3H), accompanied 
by a decreased VLDL-C (-49%; Fig. 3I) and increased HDL-C level (+130%; Fig. 3I).
Lipid-lowering agents reduce plasma CETP concentration by reducing 
the hepatic macrophage content in E3L.CETP mice 
Fibrates and niacin, which are used for the treatment of dyslipidemia in humans 22, 23, both 
decrease plasma CETP and increase HDL-cholesterol 15, 16. Since our data show that CETP 
is largely derived from hepatic macrophages, we hypothesized that these lipid-lowering 
drugs could act by decreasing hepatic macrophages. In line with our previous findings 15, 16, 
treatment of E3L.CETP mice with fenofibrate and niacin for 3 weeks decreased plasma 
CETP level (-49% and -51%, both P<0.001; Fig. 4A) and hepatic expression of CETP 
(-74% and -56%, both P<0.001; Fig. 4B). It also lowered plasma TG (-80% and -54%, both 
P<0.001; Fig. 4C) and cholesterol level (-60% and -55%, both P<0.001; Fig. 4D), explained 
by a reduction in VLDL-TG (Fig. 4E) and VLDL-C (Fig. 4F), and an increase in HDL-C 
(Fig. 4F). Indeed, fenofibrate and niacin decreased hepatic macrophage content 
reflected by a reduction in hepatic F4/80 expression (-38% and -29%, both P<0.001; 
Fig. 4G), as well as F4/80+ macrophages (-54% and -28%, both P<0.001; Fig. 4H 
and Fig. 4I). Taken together, these data indicate that fenofibrate and niacin reduce the 
hepatic macrophage content, thereby decreasing hepatic CETP production, resulting in 
a decreased plasma CETP concentration and increased HDL-cholesterol. 
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Figure 4. Lipid-lowering agents reduce plasma ceTP concentration by reducing the hepatic macrophage 
content in E3L.CETP mice. E3L.CETP mice fed a WTD were treated without (Con) or with fenofibrate (Fen) or 
niacin (Nia) for 4 weeks. Plasma was assayed for CETP concentration (A), triglycerides (C) and cholesterol (D) 
as well as the distribution of triglycerides (E) and cholesterol (F) over lipoproteins. Livers were assayed for 
expression of CETP (B) and F4/80 (G), and for F4/80-positive cells (H) with representative pictures shown (I).
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DiscUssioN
In this study, we show that liver is the main source of plasma CETP, and that the cells 
responsible for expression of CETP are the hepatic macrophages. Adipose tissue does 
not appear to contribute significantly to the plasma CETP pool because central adiposity 
is not associated with the plasma CETP level in the general population. 
Previous studies have shown that CETP mRNA is abundantly expressed in the liver and 
adipose tissue in several mammalian species 24. A small human cohort study also found a 
correlation between adipose tissue CETP expression and plasma CETP concentration 12. 
In contrast, our data show much more prominent CETP expression in the liver as 
compared to adipose tissue. In addition, we found no association between waist 
circumference and plasma CETP level in a large cohort study (n~1,500). Furthermore, 
by analyzing liver biopsies from obese patients undergoing bariatric surgery, we found 
that the plasma CETP was strongly correlated with the CETP expression in the liver but 
not in adipose tissue, indicating that liver is the main site of CETP expression and is a 
determinant of the total plasma CETP pool in humans. Some studies have suggested 
that changes in the degree of adiposity induced by body weight reduction reduced 
CETP expression and improved lipoprotein metabolism, implying that a reduction in 
adipose tissue reduces plasma CETP 25, 26. However, in addition to reducing adiposity, 
body weight reduction significantly attenuates hepatosteatosis 27, 28. Since we recently 
demonstrated that a decrease in hepatic lipid content is accompanied by a decrease 
in plasma CETP level 28, it is thus tempting to speculate that body weight reduction via 
attenuation of hepatosteatosis reduces the production of CETP by the liver. 
Since the liver consists of multiple cell types including hepatocytes, endothelial 
cells and macrophages, also known as Kupffer cells, we set out to evaluate the cell 
type responsible for the expression of CETP. In the present study, we found that the 
expression of established macrophage markers strongly associated with the expression 
of hepatic CETP, and CETP was specifically co-localized with the CD68+ macrophages 
in liver. Mechanistic studies in E3L.CETP mice showed that depleting the macrophages 
from liver by clodronate liposomes virtually abolished hepatic CETP expression and 
largely reduced plasma CETP, fully corroborating our findings in humans that hepatic 
macrophages, rather than hepatocytes, are the main cellular source of hepatic CETP 
expression and the plasma CETP pool. In contrast to Kupffer cells, we could hardly 
detect any CETP expression in extrahepatic macrophages, including peritoneal 
macrophages and macrophages in adipose tissue. It has been reported that CETP 
expression is regulated by the activation of liver X receptor α (LXRα) 29, which is highly 
expressed in multiple organs. Recently, Gautier et al. 30 demonstrated that in addition 
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to an LXRα responsive element in the CETP promotor, the CETP gene contains an ER8 
farnesoid X receptor (FXR) response element in the first intron. Therefore, bile acids that 
are the natural ligand for FXR and are produced by hepatocytes may be essential for 
maintaining high expression of CETP in hepatic versus extrahepatic macrophages. In 
fact, treatment of E3L.CETP mice with the bile acid taurocholic acid greatly increased the 
hepatic CETP transcript as well as the plasma CETP level 30. 
Previously, hepatic expression of CETP in mice has been attributed to both 
macrophages and hepatocytes, based on studies assessing hepatic CETP expression 8 
weeks after transplantation of bone marrow from wild-type (WT) littermates into human 
CETP transgenic (Tg) mice and vice versa, suggesting that hepatic macrophages 
contribute ≈ 50% to the total hepatic CETP expression 31. However, it should be realized 
that the replacement of liver macrophages after bone marrow transplantation occurs 
slowly. In the same study, it was found that only 50% of Kupffer cells were replaced by 
the donor cells 8 weeks after bone marrow transplantation, accompanied by a 50% 
reduction in plasma CETP as well as a 2-fold lower hepatic CETP expression in WT   CETP Tg 
mice as compared to control transplanted CETP Tg  CETP Tg mice 31. Interestingly, we 
found hepatic CETP expression decreased by approximately -90% 12 weeks after 
transplantation when more Kupffer cells were replaced (data not shown), confirming 
that hepatic macrophages are the predominant source of CETP expression. 
So far, no plasma biomarkers exist for assessing hepatic macrophage content. 
Therefore, quantification of the accumulation of hepatic macrophages, for example in 
studies on non-alcoholic steatohepatitis (NASH), is performed by immunohistochemical 
analysis of liver biopsies. Our present data, showing that CETP is mainly produced by 
hepatic macrophages, and that hepatic CETP mRNA correlates with plasma CETP, imply 
that plasma CETP is a plasma biomarker for the hepatic macrophage content. It is 
therefore attractive to hypothesize that the extent of hepatosteatosis or the extent of 
inflammation are the main determinants of hepatic macrophage CETP expression. 
Our findings that CETP expression in the hepatic macrophages determines the plasma 
CETP and affects lipoprotein metabolism provides new avenues for the development 
of new strategies of CETP inhibition. Although the precise mechanism by which CETP 
inhibitors (e.g. torcetrapib, dalcetrapib and anacetrapib) decrease CETP activity is not 
known, they all change the conformation of the plasma CETP protein and induce tight 
binding of CETP with HDL particles 32. However, tight binding of CETP with HDL particles 
by torcetrapib for instance might compromise the function of HDL to generates large 
CE-rich HDL particles instead of small HDL particles and nascent discoidal HDL 33. To 
avoid the potentially adverse effects of the current CETP inhibitors on HDL function, 
strategies focusing on inhibiting CETP synthesis at its cellular origin may be a promising 
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alternative. In fact, depletion of hepatic macrophages by liposomal clodronate or 
decreasing hepatic macrophage content by lipid-lowering drugs including fenofibrate 
and niacin reduce hepatic expression and plasma level of CETP, consequently generating 
a less atherogenic lipid phenotype, e.g. decreasing TG and increasing HDL-C.
In conclusion, we demonstrate that hepatic macrophages are the main cellular 
source of CETP in humans. Therefore, we propose that plasma CETP concentration 
measurement can be developed as a diagnostic and predictive test for hepatic 
macrophage content. Moreover, CETP expression in hepatic macrophages determines 
plasma CETP concentration and affects lipoprotein metabolism. We propose that 
elimination of hepatic macrophages resulting in decreasing hepatic expression and 
plasma level of CETP would be a promising strategy for the treatment of dyslipidemia 
and cardiovascular disease.     
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sUPPLemeNTArY APPeNDix 
Assessment for Rijswijk study 
A cross-sectional observational study was performed in a general population in 
Rijswijk, The Netherlands. All non-diabetic subjects between 40-70 years of age of four 
general practitioners were identified using computer assisted screening. In addition 
to known diabetes, persons with known terminal disease, a history of psychiatric 
disorder or substance abuse were excluded. Screening was carried out in 2079 of the 
2942 considered eligible subjects (response rate 70.6%) after written informed consent. 
During the screening visit, medical history including use of medication was taken, if 
necessary additional information was retrieved from the medical record. Subsequently, 
waist circumference was measured in standing position, midway between the lower 
limit of the rib cage and the iliac crest using a Seca 200 circumference measuring 
tape (Seca Gmbh, Hamburg, Germany). Venous blood samples were taken after a 12 
h overnight fast. Storage of samples for plasma CETP was performed after evaluation 
of the first 645 subjects. The Rijswijk study was approved by the review board of South 
West Holland and performed in accordance with the Declaration of Helsinki.
Statistical analysis was performed using SPSS for Windows (version 17.0; SPSS, 
Chicago, Illinois, USA). Data are expressed as mean ± standard deviation or median 
(interquartile range). To compare plasma CETP between quintiles of waist circumference 
a Kruskal-Wallis test for non-parametric continues variables was used.
Assessment for bariatric surgery study
Tissue sampling, histology preparation, and mRNA isolation
Tissue sampling and mRNA isolation were performed as described earlier 17. Wedge 
biopsies from liver, subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) 
were taken during bariatric surgery. mRNA was isolated using the Qiagen Lipid Tissue 
Mini Kit (Qiagen, Hilden, Germany, 74804) and mRNA quality and concentration were 
assessed with an Agilent Bioanalyzer (Agilent Technologies,Waldbronn, Germany, 5067-
1521). mRNA integrity numbers (RIN) of these samples ranged between 4.5 and 9.3 
(average 7.5), 5.8 and 8.7 (average 7.5), and 6.2 and 9.4 (average 7.6) for liver, SAT, and 
VAT respectively.
mRNA pre-hybridization processing and hybridization
mRNA pre-hybridization processing and hybridization were performed as described 
earlier 17. Starting with 200 ng of mRNA, the Ambion Illumina TotalPrep Amplification 
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Kit was used for anti-sense RNA synthesis, amplification, and purification, according 
to the manufacturer’s protocol (Applied Biosystems/Ambion, Austin, TX, USA). 750 ng 
of complementary RNA was hybridized to Illumina HumanHT12 BeadChips (Illumina, 
San Diego, CA, USA) and scanned on the Illumina BeadArray Reader. These micro 
arrays contain 48813 different probes targeting 37812 different genes; some genes are 
targeted by more than one probe.
Data normalization and quality control
Quantile-quantile normalization was applied to all genome-wide data from liver, VAT and 
SAT using LIMMA package (version 3.4.5) in R (version 2.11.1) (R foundation for statistical 
computing, Vienna, Austria). Only samples were included that passed quality control 
filtering, which was based on the median probe intensity, general behavior of known 
housekeeping genes, and principal component analysis over the samples. Available 
genome-wide genotype data were used to rule out sample mix-ups 34, and qRT-PCR was 
performed to estimate the technical quality of the micro array 17. We obtained reliable 
RNA measures for 82 liver samples, 90 SAT samples and 84 VAT samples. All expression 
data has been made freely available by submission to GEO under GSE22070 (SAT data), 
and GSE22071 (VAT data). Liver expression data will be made available soon.
Calculations and data visualization
Two probes targeting CETP were present on the micro array. Values of these probes 
were very strongly correlated (r= 0.82, 0.87, and 0.80 in liver, SAT and VAT respectively). 
We determined the expression of CETP as the average value of these two probes. 
Plasma CETP concentration, lipid and lipoprotein profiles analysis 
Plasma CETP concentration was measured using the DAIICHI CETP ELISA kit according 
to manufacturer’s instructions (Daiichi, Tokyo, Japan).
Plasma cholesterol and triglycerides were assayed using the commercially available 
enzymatic kits 236691, 11488872 (Roche Molecular Biochemicals, Indianapolis, IN, USA), 
respectively. The distribution of lipids over plasma lipoproteins was determined using 
fast protein liquid chromatography (FPLC). Plasma was pooled per group, and 50 μL of 
each pool was injected onto a Superose 6 PC 3.2/30 column (Äkta System, Amersham 
Pharmacia Biotech, Piscataway, NJ, USA) and eluted at a constant flow rate of 50 μL/min 
in PBS, 1 mM EDTA, pH 7.4. Fractions of 50 μL were collected and assayed for cholesterol 
and triglycerides as described above.
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RNA extraction, reverse transcription and quantitative RT-PCR
Total RNA was extracted from frozen liver and adipose tissue pieces using the Nucleospin 
RNAII kit (Macherey-Nagel, Düren, Germany) according to manufacturer’s instructions. 
RNA quality was examined by the lab-on-a-chip method using Experion Std Sens 
analysis kit (Biorad, Hercules, CA) and RNA concentration was determined by Nanodrop 
technology (Thermo Scientific, Wilmington, USA). Total RNA was reverse-transcribed 
with iScript cDNA synthesis kit (1708891, Bio-Rad), and the obtained cDNA was 
purified with Nucleospin Extract II kit (636973, Macherey-Nagel, Bioké). Real-time PCR 
was performed on a CFX96 machine (Bio-Rad), the reaction mixture consisting of iQTM 
SYBR® Green Super mix (Bio-Rad), cDNA, primers (Biolegio, Nijmegen, The Netherlands; 
see Supplementary Table 2 for primer sequences), and nuclease-free water in a total 
reaction volume of 10 µL. mRNA values of each gene were normalized to mRNA levels 
of ß-2 microglobulin and hypoxanthine ribosyltransferase (Hprt). Data were expressed 
as relative expression using the dCt method (Pfaffl, 2001, Nucleic Acids Res).
supplementary Table 2 primer sequences used for rT-qPcr 






ß-2m, ß-2 microglobulin; Cd68, cluster of differentiation 68; CETP, cholesteryl ester transfer protein; Hprt, 
hypoxanthine ribosyltransferase. 
Immunohistochemistry (IHC) 
Paraffin-embedded human liver sections (5 µm) were stained for macrophage marker 
CD68 (M0814; 1/800, Dako, California, USA) and CETP (ab51771; 1/1000, Abcam, 
Cambridge, UK). 
Paraffin-embedded sections of E3L.CETP mouse liver and adipose tissue (5 µm) were 
stained for macrophage marker F4/80 (MCA497; 1/600, Serotec, Oxford, UK) as described 
previously 35, and human CETP (ab51771; 1/1000, Abcam, Cambridge, UK).
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Central neuropeptide Y (NPY) administration stimulates food intake in rodents. In 
addition, acute modulation of central NPY signaling increases hepatic production of 
very low-density lipoprotein (VLDL)-triglyceride (TG) in rats. As hypertriglyceridemia is 
an important risk factor for atherosclerosis, for which well-established mouse models 
are available, we set out to validate the effect of NPY on hepatic VLDL-TG production 
in mice, to ultimately investigate whether NPY, by increasing VLDL production, 
contributes to the development of atherosclerosis. Male C57Bl/6J mice received an 
intracerebroventricular (i.c.v.) cannula into the lateral ventricle (LV) or third ventricle 
(3V) of the brain. One week later, after a 4 h fast, the animals received an intravenous 
(i.v.) injection of Tran35S (100 μCi) followed by tyloxapol (500 mg/kg BW), enabling the 
study of hepatic VLDL-apoB and VLDL-TG production, respectively. Immediately after 
the i.v. injection of tyloxapol, the animals received either an i.c.v. injection of NPY (0.2 
mg/kg bodyweight (BW) in artificial cerebrospinal fluid; aCSF), synthetic Y1 receptor 
antagonist GR231118 (0.5 mg/kg BW in aCSF) or vehicle (aCSF), or an i.v. injection of 
PYY3-36 (0.5 mg/kg BW in PBS) or vehicle (PBS). Administration of NPY into both the 
LV and 3V increased food intake within one hour after injection (+164%, P<0.001 and 
+367%, P<0.001, respectively). NPY administration neither in the LV nor in the 3V 
affected hepatic VLDL-TG or VLDL-apoB production. Likewise, antagonizing central 
NPY signaling by either PYY3-36 or GR231118 administration did not affect hepatic VLDL 
production. In conclusion, in mice, as opposed to rats, acute central administration of 
NPY increases food intake without affecting hepatic VLDL production. These results are 
of great significance when extrapolating findings on the central regulation of hepatic 
VLDL production between species.
7
123
CENTRAL NPY AND HEPATIC VLDL PRODUCTION IN MICE
iNTroDUcTioN
The metabolic syndrome is referred to as a cluster of physiological abnormalities 
correlated with obesity and type 2 diabetes mellitus 1. Hallmarked by insulin resistance, 
hyperglycemia, hypertension, low high-density lipoprotein-cholesterol (HDL-C) and 
elevated very low-density lipoprotein-triglyceride (VLDL-TG) levels, this cluster of 
cardiometabolic risk factors is a strong risk factor for type 2 diabetes and cardiovascular 
disease 1, 2. Furthermore, due to the strong interlinkage between its individual 
components, effective treatment of the metabolic syndrome has shown to be extremely 
challenging 2. 
Obesity develops when long-term energy intake exceeds energy expenditure. The 
brain plays an important role in mediating energy intake, with the hypothalamus being 
its key regulator 3, 4. Two major neuronal populations within the hypothalamic arcuate 
nucleus (ARC) exert opposing effects on energy intake. Proopio-melanocortin (POMC) 
neurons are activated upon food intake to exert anorectic effects by inhibiting food 
intake and promoting a negative energy balance. In contrast, when energy levels are 
low, neuropeptide Y (NPY)/Agouti-related peptide (AgRP) neurons are activated to 
stimulate food intake and promoting a positive energy balance 5-7. 
The 36-amino acid peptides NPY, peptide YY (PYY) and pancreatic polypeptide, 
collectively called the NPY family of peptides, affect food intake by interacting with 
G-protein-coupled Y receptors 8, 9. NPY is widely expressed in both the brain and 
the peripheral nervous system. Within the brain, NPY is highly expressed in the 
hypothalamus, especially in the ARC 8. NPY-neurons co-expressing AgRP are only 
found in this hypothalamic nucleus, as AgRP is uniquely expressed in the ARC 10. NPY/
AgRP neurons can be activated by a diversity of signals, such as leptin and insulin 11. 
Upon activation, NPY stimulates its Y receptors to activate circuits that increase food 
intake and fat storage 5. Concomitantly, by antagonizing the melanocortin 3 and 4 
(MC3/4) receptors in the paraventricular nucleus (PVN), AgRP prevents the catabolic 
drive initiated by the melanocortin system 5. In this fashion, NPY/AgRP neurons exert a 
so-called double-anabolic drive.
In addition to modulation of food intake, NPY may also be involved in the regulation 
of lipid metabolism. A recent study in rats showed that acute modulation of central 
NPY signaling, either by NPY or by an Y5 receptor agonist, increased hepatic VLDL-
TG production. Accordingly, central administration of a Y1 receptor antagonist 
decreased hepatic VLDL-TG production 12. In mice, central NPY administration 
prevented the peripheral insulin-induced inhibition of glucose production by the 
liver, and reversed the insulin-induced inhibition of hepatic VLDL-TG production 
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under hyperinsulinemic conditions 13. Hypertriglyceridemia, associated with increased 
hepatic VLDL-TG production and/or decreased VLDL-TG clearance, is an important risk 
factor for cardiovascular diseases such as arterial atherosclerosis (for review 14). Since 
atherosclerosis is generally studied in hyperlipidemic mice rather than in rats, we set out 
to validate the effect of NPY on hepatic VLDL-TG production in mice, with the ultimate 




For all experiments, 15 weeks old male C57Bl/6J mice were used, housed in a temperature 
and humidity-controlled environment with free access to food and water. Experiments 
were performed after 4 h of fasting at 12:00 pm with food withdrawn at 8:00 am, unless 
indicated otherwise. Food intake and body weight were measured weekly during 
experiments. All animal experiments were approved by the Animal Ethics Committee of 
the Leiden University Medical Center, Leiden, The Netherlands.
Intracerebroventricular surgery
For i.c.v. cannula implantation, mice were anaesthetized with 0.5 mg/kg BW 
Medetomidine (Pfizer, Capelle a/d IJssel, The Netherlands), 5 mg/kg BW Midazolam 
(Roche, Mijdrecht, The Netherlands) and 0.05 mg/kg BW Fentanyl (Janssen-Cilag, 
Tilburg, The Netherlands) and placed in a stereotactic device (TSE systems, Homburg, 
Germany). A 25-gauge guide cannula was implanted into the left lateral ventricle using 
the following coordinates from Bregma: 1.0 mm lateral, 0.46 mm posterior and 2.2 mm 
ventral. For third ventricle cannulations the following coordinates from Bregma were 
used: 0.0 mm lateral, 1.3 mm posterior and 5.7 mm ventral. The guide cannula was 
secured to the skull surface with dental cement (GC Europe N.V., Leuven, Belgium) and 
the anesthesia was antagonized using 2.5 mg/kg BW Antipamezol (Pfizer, Capelle a/d 
IJssel, The Netherlands), 0.5 mg/kg BW Flumazenil (Roche, Mijdrecht, The Netherlands) 
and 1.2 mg/kg BW Naloxon (Orpha, Purkersdorf, Austria). Animals were single housed 
after the surgery. 
Food intake measurement
After a recovery period of at least 1 week, the mice received a pre-weighed amount 
of food after which basal food intake was measured for two hours, starting from 
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09:00 a.m. One day later, mice received an i.c.v. injection of NPY (0.2 mg/kg in 1 µL of 
artificial cerebrospinal fluid, aCSF) under light isoflurane anesthesia (1.5% in air). Food 
was weighed before and one and two hours after waking up from the anesthesia to 
determine NPY-induced food intake.
Hepatic VLDL-TG and VLDL-apoB production
In experiments performed under complete anesthesia, 4 h fasted mice were anesthetized 
with 6.25 mg/kg Acepromazine (Alfasan, Woerden, The Netherlands), 6.25 mg/kg 
Midazolam (Roche, Mijdrecht, The Netherlands), and 0.31 mg/kg Fentanyl (Janssen-
Cilag, Tilburg, The Netherlands). In other experiments, mice were awake throughout the 
whole experiment, except for the lateral ventricle (LV) or third ventricle (3V) injections, 
which were performed under light isoflurane sedation (1.5% in air). 
A basal blood sample was taken from the tail tip in a chilled capillary, and mice 
received an intravenous injection of 100 µl PBS containing 100 µCi Tran35S label (MP 
Biomedicals, Eindhoven, the Netherlands) via the tail vein, resulting in incorporation 
of 35S into newly produced VLDL-apolipoprotein B. After 30 min, the animals received 
an intravenous injection of tyloxapol (500 mg/kg body weight; Triton WR-1339, Sigma), 
as a 10% (w/w) solution in sterile saline, to prevent systemic lipolysis of newly secreted 
hepatic VLDL-TG 15.
 Immediately after the tyloxapol injection, mice received an injection of either NPY 
(0.2 mg/kg BW, Bachem, St. Helens, UK in 1 µL aCSF) or vehicle (aCSF, 1 µL) into the 
lateral ventricle (LV) or third ventricle (3V). In the dose-finding study, mice received an 
LV injection of NPY (0.0002, 0.002, 0.02, 0.2 or 2.0 mg/kg BW in 1 µL aCSF) or vehicle. In 
the antagonist study, mice received either an LV injection of Y1 antagonist GR231118 
(0.5 mg/kg in 1 µL aCSF) or vehicle (aCSF, 1 µL) or an i.v. injection of PYY3-36 (0.5 mg/kg in 
100 µL PBS) or vehicle (PBS, 100 µL). 
Blood samples were taken from the tail tip into chilled capillaries at the indicated 
time points up to 90 min after tyloxapol injection. The tubes were kept on ice after 
which they were centrifuged at 4°C. Plasma TG concentration was determined using 
a commercially available kit according to the instructions of the manufacturer (no. 
11488872, Roche Molecular Biochemicals, Indianapolis, IN) At 120 min, the animals 
were sacrificed and blood was collected by orbital puncture for isolation of VLDL by 
density gradient ultracentrifugation 16. 35S-activity was measured in the VLDL fraction 
and VLDL-apoB production rate was calculated as dpm.h-1 17. 
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Verification of cannula position
After termination of mice, brains were taken out and fixed by submerging in 4% 
paraformaldehyde for 48 hours (Sigma-Aldrich, Zwijndrecht, the Netherlands) followed 
by 30% sucrose (Sigma-Aldrich, Zwijndrecht, the Netherlands) in PBS for at least 24 
hours, until the brain has sank to the bottom of the container. Cannula position was 
verified in 30 μm thick brain cryosections mounted on microscopic slides. The sections 
were fixated and defatted in CARNOY solution (100% ethanol, chloroform and acetic 
acid in a 6:3:1 ratio), hydrated by descending ethanol concentrations (100-96-70%) in 
MilliQ (MQ) water, and a Nissl staining was performed using cresyl violet (Sigma-Aldrich, 
Zwijndrecht, the Netherlands): 0.9 g cresyl violet, 300 mL MQ, 2.25 mL 10% acetic 
acid, pH 4.5. The sections were then dehydrated in ascending ethanol concentrations 
(70-96-100-100%) followed by 2 times isopropanol and 2 times Histo-Clear (National 
diagnostics, Atlanta, USA). Cover slips were mounted using xylene, and the cannula 
position was verified by locating the end of the cannula track observed in the tissue.
Statistical analysis
Differences between two groups were determined with Mann-Whitney non-parametric 
tests for two independent samples. Differences between multiple groups were 
determined with the Kruskal-Wallis non-parametric test for k independent samples. 
When significant differences were found, the Dunn’s Multiple Comparisons test was 
used as a follow-up test to determine differences between two independent groups. A 
P-value of less than 0.05 was considered statistically significant. Data are presented as 
means ± SD.
resULTs
Lateral ventricle NPY administration stimulates food intake in mice
To verify that central administration of NPY stimulates food intake, both basal and NPY-
induced food intake were assessed during two hours, starting at 09:00 a.m. with all 
mice serving as their own control. Administration of NPY (0.2 mg/kg BW) in the left 
lateral ventricle (LV) increased food intake during the first hour after injection by +164% 
(0.34±0.19 vs 0.90±0.40 g, P<0.001, Fig. 1). Food intake during the second hour after 
injection was similar to the basal food intake in this specific time frame (0.40±0.17 vs 
0.49±0.20 g, n.s., Fig. 1).
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Figure 1. NPY administration into the lateral 
ventricle acutely increases food intake. NPY (0.2 
mg/kg) was administered in the left lateral ventricle 
under light isoflurane anaesthesia, and food intake 
was measured for two hours, starting at 09:00 a.m. 
All animals served as their own controls (basal food 
intake). Values are means ± SD (n = 9), ***P<0.001 
compared to basal.
Lateral ventricle NPY administration does not affect hepatic VLDL 
production
Figure 2. NPY administration into the lateral 
ventricle does not affect hepatic VLDL 
production in anesthetized mice. After a 4 hour 
fast, mice were fully anesthetized and hepatic VLDL 
production was assessed. Mice received an i.v. 
injection of Tran35S label (t=-30 min), followed by an 
injection of tyloxapol (t=0 min), directly followed by 
an LV injection of NPY (0.2 mg/kg BW) or artificial 
cerebrospinal fluid (control). Plasma triglyceride 
(TG) levels were determined at indicated time 
points (A). VLDL-TG production rate was calculated 
from the slopes of the individual TG-time graphs 
(B). At t=120 min, mice were exsanguinated and 
VLDL fractions were isolated from serum by 
ultracentrifugation. 35S-apoB production was 
determined by scintillation counting of the isolated 
VLDL fraction (C). Values are means ± SD (n = 8-10). 
Next, we assessed the effects of a single injection of NPY (0.2 mg/kg BW) into the left 
lateral ventricle on VLDL production in 4 h-fasted anaesthetized mice. Acute central 
administration of NPY did not affect VLDL-TG production rate in mice (7.7±0.6 vs 
7.3±1.1 μmol/h, n.s., Fig. 2A, B). Accordingly, hepatic VLDL-35S-apoB production was 
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also unchanged upon NPY administration (84±11 vs 79±21 x103 dpm/h, n.s., Fig. 2C). 
Thus, although this dose of NPY increased food intake, it did not affect hepatic VLDL 
production.
Subsequently, we performed a dose-finding study to assess whether either higher or 
lower dosages of NPY (0.0002, 0.002, 0.02, 0.2 or 2.0 mg/kg BW) were capable of increasing 
hepatic VLDL-TG production. Again, we did not observe any difference between the 
VLDL-TG production rate in controls (6.2±0.5 μmol/h) and that in mice treated with NPY 
(6.9±0.1, 6.2±0.1, 6.9±0.3, 6.8±0.5 or 6.9±0.5 μmol/h at 0.0002, 0.002, 0.02, 0.2 or 2.0 
mg /kg BW, respectively, n.s., Fig. S1). Since the use of anesthetics theoretically could 
interfere with the modulation of central NPY signaling, we repeated the experiment 
in conscious mice. However, NPY (0.2 mg/kg BW) did not increase hepatic VLDL-TG or 
VLDL-apoB production in conscious mice (data not shown).
supplemental Figure s1. Higher nor lower dosages of NPY administered in the lateral ventricle 
affect hepatic VLDL production in anesthetized mice. After a 4 hour fast, mice were fully anesthetized 
and hepatic VLDL production was assessed using the tyloxapol method. Mice received an i.v. injection of 
Tran35S label,(t=-30 min), followed by an injection of tyloxapol (t=0 min), directly followed by an LV injection 
of NPY (0.0002, 0.002, 0.02, 0.2 or 2.0 mg/kg BW) or artificial cerebrospinal fluid (control; 0 mg/kg). Plasma 
triglycerides were determined at indicated time points (A). VLDL-TG production was calculated from the 
slopes of the individual TG-time graphs (B). Values are means ± SD (n =2-5).
Antagonizing central NPY signaling does not affect hepatic VLDL 
production
Since other modulators of NPY signaling have previously been shown to acutely 
interfere with VLDL-TG production in rats 12, we next assessed the effects of PYY3-36 and 
of GR231118, a synthetic Y1 receptor antagonist, on hepatic VLDL-TG and VLDL-apoB 
production. Central administration of GR231118 did not affect the hepatic production 
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of VLDL-TG (8.6±1.8 vs 8.7±1.4 μmol/h, n.s., Fig. 3A, B) or VLDL-apoB (55±11 vs 59±9 x103 
dpm/h, n.s., Fig. 3C). In line with this finding, intravenous administration of PYY3-36, the 
endogenous antagonist of NPY, was also ineffective in lowering the hepatic production 
of VLDL-TG (8.5±0.9 vs 7.5±0.9 μmol/h, n.s., Fig. 3D, E) and VLDL-apoB (73±18 vs 75± 
13 x103 dpm/h, n.s., Fig. 3F). 
Figure 3. Lateral ventricle nor peripheral administration of NPY antagonists affects hepatic VLDL 
production in anesthetized mice. After a 4 hour fast, mice were fully anesthetized and hepatic VLDL 
production was assessed. Mice received an i.v. injection of Tran35S label (t=-30 min), followed by an injection of 
tyloxapol (t=0 min), directly followed by an LV injection of GR231118 (0.5 mg/kg BW) or artificial cerebrospinal 
fluid (control; A-C), or by an i.v. injection of PYY3-36 (0.5 mg/kg BW) or PBS (control; D-F). Plasma triglyceride 
(TG) levels were determined at indicated time points (A+D). VLDL-TG production rate was calculated from the 
slopes of the individual TG-time graphs (B+E). At t=120 min, mice were exsanguinated and VLDL fractions were 
isolated from serum by ultracentrifugation. 35S-apoB production was determined by scintillation counting of 
the isolated VLDL fraction (C+F). Values are means ± SD (n = 7-11).
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Third ventricle NPY administration stimulates food intake in mice
In contrast to the LV, the third ventricle (3V) is located at the base of the hypothalamus, 
the brain area that mediates NPY-induced feeding. To exclude that the absence of 
effect of modulation of central NPY signaling was due to LV versus 3V injection, we next 
performed 3V cannulations in mice. We first assessed the effects of 3V NPY (0.2 mg/kg 
BW) on food intake. NPY significantly increased food intake not only during the first 
hour after injection by +367% (0.21±0.08 vs 0.98±0.44 g, p<0.001, Fig. 4), as observed 
with LV injection of NPY (Fig. 1), but also during the second hour after injection by 
+105% (0.22±0.11 vs 0.45±0.19, p<0.05, Fig. 4), suggesting that 3V NPY administration 
is more effective than LV NPY administration. However, the effect of NPY is both acute 
and transient irrespective of the specific location of i.c.v. injection.
Figure 4. NPY administration into the third ventricle acutely increases food intake. NPY (0.2 mg/kg) was 
administered in the third ventricle under light isoflurane anaesthesia, and food intake was measured for two 
hours, starting at 09:00 a.m. All animals served as their own controls (basal food intake). Values are means ± 
SD (n = 11), *p<0.05, ***p<0.001 compared to basal.
Third ventricle NPY administration does not affect hepatic VLDL-TG 
production 
Albeit that 3V injection of NPY increased food intake to a greater extent than LV injection, 
administration of NPY (0.2 mg/kg BW) in the 3V was still unable to increase hepatic VLDL 
production in conscious mice, as both the hepatic production rate of VLDL-TG (6.5±0.6 
vs 6.0±0.9 μmol/h, n.s., Fig. 5A, B) and VLDL-apoB (22±3 vs 22±2 x103 dpm/h, n.s., Fig. 5C) 
were unchanged. Collectively, these data thus show that acute modulation of central 
NPY signaling does not affect hepatic VLDL production in mice.
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Figure 5. NPY administration into the third 
ventricle does not affect hepatic VLDL production 
in awake mice. Hepatic VLDL production was 
assessed after a 4h-fast. Mice received an i.v. 
injection of Tran35S label (t=-30 min), followed by 
an injection of tyloxapol (t=0 min), directly followed 
by a 3V injection of NPY (0.2 mg/kg BW) or artificial 
cerebrospinal fluid (control). Plasma triglyceride (TG) 
levels were determined at indicated time points (A). 
VLDL-TG production rate was calculated from the 
slopes of the individual TG-time graphs (B). At t=120 
min, mice were exsanguinated and VLDL fractions 
were isolated from serum by ultracentrifugation. 
35S-apoB production was determined by scintillation 
counting of the isolated VLDL fraction (C). Values are 
means ± SD (n = 9-12).
 
DiscUssioN
Since modulation of central NPY signaling acutely increases VLDL-TG production in rats, 
we initially set out to investigate the acute effects of central NPY administration on VLDL-
TG production in mice, ultimately aimed at investigating the contribution of central NPY 
administration, by modulating VLDL production, to the development of atherosclerosis. 
We confirmed that central administration of NPY acutely increases food intake in mice, 
similarly as in rats. In contrast to the effects in rats, central administration of a wide dose 
range of NPY was unable to increase VLDL-TG production in mice. Moreover, inhibition 
of NPY signaling by PYY3-36 or Y1 receptor antagonism was ineffective. In contrast to 
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rats, in mice acute modulation of NPY signaling thus stimulates food intake but without 
affecting hepatic VLDL-TG production.
NPY is a well-known stimulant of food intake in both rats 18 and mice 19 and this 
feeding response is mediated via the hypothalamic NPY system (for review 20). The 
present study confirms this effect of NPY on food intake in mice, as administration of 
NPY in both the LV and 3V markedly increased food intake (Fig. 1 and 4, respectively). 
This effect was most pronounced in the first hour after injection, which is in line with 
previous observations 21. 3V injection was somewhat more effective than LV injection, 
which might be explained by a higher hypothalamic NPY concentration possibly 
reached by 3V NPY injection. Collectively, these data indicate that NPY acutely increases 
food intake irrespectively of the rodent species. 
Interestingly, neither LV nor 3V administration of NPY affected hepatic VLDL 
production in mice (Fig. 2 and 5, respectively). Furthermore, inhibition of central NPY 
signaling by PYY3-36 or the Y1 antagonist GR231118 also failed to affect VLDL production 
by the liver (Fig. 3). In contrast, in rats, central NPY administration was reported to acutely 
stimulate hepatic VLDL-TG production 12. Bruinstroop et al 22 recently confirmed that 
central NPY administration acutely increases VLDL-TG production in rats. In addition, 
they demonstrated that the regulation of hepatic lipid production by the central NPY 
system in rats is guided via the sympathetic nervous system, as selective sympathetic 
denervation of the liver abolished the effect of central NPY administration 22. 
We questioned whether differences in the experimental design between our VLDL 
production studies with those reported in rats 12 could have accounted for different 
outcomes. In mice, VLDL production experiments are commonly performed under 
anesthesia, whereas the studies by Stafford et al. 12 and Bruinstroop et al. 22 were 
performed in conscious rats. In theory, anesthesia could interfere with the effects of 
central NPY administration. For example, the μ-opioid receptor agonist fentanyl acts 
by inhibiting the release of multiple neurotransmitters, including the chief inhibitory 
transmitter gamma-aminobutyric acid (GABA) 23. A subpopulation of NPY neurons in the 
ARC co-produces GABA 24. Furthermore, NPY can act in concert with GABA to augment 
food intake mediated by the PVN 25. Hence, using an inhibitor of GABA release might 
interfere with the effects of the centrally administered NPY. However, in the current 
study we show that central NPY administration also failed to increase VLDL production 
by the liver in conscious mice (Fig. 5). Importantly, the VLDL-TG production rates were 
comparable in both anesthetized and conscious mice, indicating that anesthesia did 
not affect baseline hepatic VLDL-TG production. Hence, the divergent regulation of 
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A second difference in experimental design between the rat studies and our initial 
setup, was the site of i.c.v. administration of NPY. Initially, we cannulated the LV in 
mice for obvious practical reasons, whereas Stafford et al. 12 and Bruinstroop et al. 22 
cannulated the 3V which is more easily accessible in rats. As the third ventricle is located 
at the base of the hypothalamus, one could speculate that this difference in injection 
site might interfere with the results obtained. However, whereas 3V NPY administration 
induces a potent and longer-lasting effect on food intake (Fig. 4) as compared to LV 
administration, it still did not affect hepatic VLDL-TG nor VLDL-apoB production in our 
hands (Fig. 5). 
Interestingly, our group previously reported that LV administration of NPY was able 
to reverse the inhibition of hepatic VLDL-TG production in hyperinsulinemic euglycemic 
clamp conditions in mice 13.  This led us to conclude that insulin suppresses hepatic VLDL 
production at least in part by inhibiting central NPY signaling. Together with the present 
data, this suggests that in mice, NPY has no direct effect on hepatic VLDL production, 
whereas it is a downstream mediator in the suppression of hepatic lipid production by 
insulin.
In our study, as in previous studies 18, 19, the effects of NPY on food intake were 
measured in a satiated state. In contrast, hepatic VLDL production was assessed after a 
period of fasting, both in our study and in the previous rat studies 12, 22. Fasting induces 
hypothalamic NPY mRNA expression 26. Consequently, food intake and hepatic VLDL 
production were assessed during different states of endogenous NPY production, 
possibly leading to a different degree of sensitivity for exogenous NPY. However, the 
dose-finding study assessing the effects of both lower and higher dosages of NPY 
did not reveal any dose affecting hepatic VLDL production. Moreover, antagonizing 
central NPY signaling by PYY3-36 or an Y1 antagonist also did not affect VLDL production. 
Collectively, these data further support the notion that in mice, acute modulation of the 
central NPY system affects food intake but not hepatic VLDL production.
In addition to food intake, NPY also regulates hepatic glucose production in a 
similar fashion in mice and rats 13, 27. Hence, it is tempting to speculate why NPY exerts 
different effects in rats versus mice on hepatic VLDL production specifically. Based on 
the reports of Stafford et al. 12 and Bruinstroop et al. 22, rats display lower basal hepatic 
VLDL-TG production rates when compared to those currently reported in mice. Whereas 
in control rats, plasma TG levels increased by ~2 mM 12 and ~3.5 mM 22 within one hour 
after tyloxapol injection, we observed that in control mice plasma TG levels are increased 
by ~6 mM within the same period of time. This suggests that hepatic VLDL metabolism 
in itsel is differentially regulated in rats versus mic.  
However, the apparent species difference concerning the regulation of hepatic 
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VLDL-TG production by NPY might also be caused by a difference in the expression 
of its receptor. In mammals, NPY is one of the most abundant peptides found 
and its receptors are widely expressed in both the central nervous system and 
peripheral tissues 28, 29. Central expression of Y1-Y5 receptors is similar in rats and 
mice 28. Interestingly, in addition to the Y1-Y5 receptors, mice also express the Y6 
receptor. This receptor, which is a functional receptor in mice and is expressed 
in various brain sites including the hypothalamus 30, 31, is not expressed in rats 32. 
Even though a role for the Y6 receptor in appetite regulation has been doubted 30, 
the exact function of the Y6 receptor remains elusive. If activation of this receptor 
by NPY would exert an opposing effect specifically on hepatic VLDL production, this 
might explain our negative findings in mice. Obviously, further investigation is needed 
to confirm this hypothesis. Therefore, the Y6 receptor might be an interesting target 
for future research investigating the role of the central NPY system in the regulation of 
hepatic VLDL production in mice. 
Genetic association studies in humans have reported conflicting results on the role 
of NPY in serum TG metabolism. A polymorphism in the untranslated region between 
the Y1 and Y5 receptor genes was associated with lower serum TG levels in obese 
subjects 33. In addition, the Leu7Pro polymorphism in the signal peptide part of the NPY 
gene has been linked with higher serum TG levels in preschool-aged boys 34. However, 
this polymorphism was not associated with serum TG levels in female coronary heart 
disease patients 35. Furthermore, studies on a variation in the 5’-flanking region of the Y2 
receptor gene 36 and on the NPY signal peptide polymorphism T1128C 37 both report no 
association with serum TG levels. Collectively, these data emphasize the need of further 
research into the role of NPY in the regulation of peripheral TG metabolism. However, 
in light of the apparent species difference at least with respect to VLDL-TG production 
suggested from our study, caution should be taken when suggesting a common 
mechanism in humans based on findings resulting from animal studies. 
In conclusion, acute central administration of NPY increases food intake without 
affecting hepatic VLDL production in mice, whereas NPY increases both food intake and 
VLDL production in rats. This apparent species difference in the effects of NPY, specifically 
on hepatic VLDL-TG production, is of great significance for future animal studies on the 
central regulation of hepatic VLDL production and underscores a general concern in 
animal research in view of extrapolating findings from specific animal studies to explain 
observations done in humans.
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In addition to improve glucose intolerance, recent studies suggest that glucagon-like 
peptide-1 (GLP-1) receptor agonism also decreases triglyceride (TG) levels. The aim of 
this study was to evaluate the effect of GLP-1 receptor agonism on very-low-density 
lipoprotein (VLDL)-TG production and liver TG metabolism. The GLP-1 peptide analogues 
CNTO3649 and exendin-4 were continuously administered subcutaneously to high fat 
diet-fed APOE*3-Leiden transgenic mice. After 4 weeks, hepatic VLDL production, lipid 
content, and expression profiles of selected genes involved in lipid metabolism were 
determined. CNTO3649 and exendin-4 reduced fasting plasma glucose (up to -30% and 
-28% respectively) and insulin (-43% and -65% respectively). In addition, these agents 
reduced VLDL-TG production (-36% and -54% respectively) and VLDL-apoB production 
(-36% and -43% respectively), indicating reduced production of VLDL particles rather 
than reduced lipidation of apoB. Moreover, they markedly decreased hepatic content 
of TG (-39% and -55% respectively), cholesterol (-30% and -55% respectively), and 
phospholipids (-23% and -36% respectively), accompanied by down-regulation of 
expression of genes involved in hepatic lipogenesis (Srebp-1c, Fasn, Dgat1) and apoB 
synthesis (Apob). In conclusion, GLP-1 receptor agonism reduces VLDL production and 
hepatic steatosis in addition to an improvement of glycemic control. These data suggest 
that GLP-receptor agonists could reduce hepatic steatosis and ameliorate dyslipidemia 
in patients with type 2 diabetes mellitus. 
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iNTroDUcTioN
Type 2 diabetes mellitus (T2DM) has become a major metabolic disorder in both 
developed and developing countries, with impaired glucose tolerance and insulin 
resistance as hallmarks 1, 2. In addition to glucose metabolism, lipid metabolism is 
disturbed in T2DM patients, reflected by increased plasma levels of low-density 
lipoprotein, VLDL-TG, and decreased levels of high-density lipoprotein. Moreover, 
T2DM is strongly associated with fatty liver disease (i.e. hepatic steatosis) 3, for which no 
effective pharmacotherapeutic options are yet available.  
GLP-1 is an incretin hormone produced by intestinal L cells and the brain 4, 5. GLP-1 
is released in response to food intake to stimulate glucose-dependent insulin secretion 
by the pancreas 4, 6. Additionally, GLP-1 exerts multiple other effects, including inhibition 
of food intake 7, slowing gastric emptying 8, and inhibition of glucagon secretion 9. 
Thus, GLP-1 was considered as a good target for the treatment of T2DM. However, 
therapeutic application of GLP-1 is hampered due to its short circulating half-life (<2 
minutes), because it is rapidly degraded by dipeptidyl peptidase 4 (DPP-4) that is widely 
expressed in endothelium and intestinal mucosa 10. Therefore, pharmaceutical GLP-1 
analogues that are resistant to inactivation by DPP-4 have been developed with an 
improved pharmacokinetic profile related to a longer half-life, of which exenatide (a 
synthetic version of exendin-4) was approved in 2005 for the treatment of T2DM 11. We 
have previously described that CNTO736, a GLP-1 MimetibodyTM receptor agonist that 
incorporates a GLP-1 peptide analogue genetically fused by a unique linker to a domain 
that includes the Fc portion of an antibody, has an even longer circulating half-life than 
exendin-4 and retains the beneficial effects of GLP-1 on glucose metabolism 12. The 
long-acting GLP-1 analogue CNTO3649, a more recent version of CNTO736 with two 
point mutations introduced to improve protein solubility, retains this advantageous 
pharmacokinetic profile. 
In addition to improving glucose metabolism, preliminary studies suggested 
that GLP-1 receptor agonism decreases plasma TG levels in patients with T2DM 13, 14. 
However, the mechanism underlying these beneficial effects on TG metabolism remains 
unclear. Therefore, the objective of the present study was to evaluate the effects of 
GLP-1 receptor agonism via CNTO3649 and exendin-4 on VLDL-TG production and liver 
TG metabolism, and further to explore the underlying mechanisms, in APOE*3-Leiden 





For all experiments, 8-10 weeks old male E3L mice 16 were used, housed in a temperature 
and humidity-controlled environment with free access to food and water. Experiments 
were performed after 7 h of fasting at 14:00 pm with food withdrawn at 7:00 am. 
Body weight was measured weekly during experiments. All animal experiments were 
performed in accordance with the regulations of Dutch law on animal welfare, and 
the Institutional Ethics Committee for Animal Procedures from the Leiden University 
Medical Center, Leiden, The Netherlands, approved the protocol. All surgery was 
performed under isoflurane anesthesia 
Experiments 
Two experiments were conducted, each of which was designed to investigate a specific 
aspect of the overall hypothesis. 
In the first experiment, mice were fed a HFD (44 energy% fat, derived from bovine 
fat; Hope Farms, Woerden, The Netherlands) for 22 weeks. After 18 weeks of HFD 
feeding, mice were divided into 5 groups, matched for fasting body weight and plasma 
glucose levels. An osmotic minipump (model 1004, Alzet DURECT Corp., Cupertino, CA) 
was implanted subcutaneously in the left back region under light isoflurane anesthesia 
for the continuous delivery of CNTO3649 (1.0 or 3.0 mg/kg/day, dissolved in PBS), 
exendin-4 (15 or 50 µg/kg/day, dissolved in PBS) or PBS as a control for up to 4 weeks, 
while continuously feeding mice the HFD. Additionally, one group of mice received PBS 
while being fed a chow diet throughout the whole experiment as a control for HFD 
feeding. After 4 weeks of drug treatment, hepatic VLDL-TG and VLDL-apoB production 
were determined.
In the second experiment, mice were fed the HFD for 13 weeks. After 9 weeks of HFD 
feeding, mice were divided into 5 groups, matched for fasting body weight and plasma 
glucose levels. Osmotic minipumps were implanted subcutaneously for the continuous 
delivery of CNTO3649 (0.3 or 1.0 mg/kg/day, dissolved in PBS), exendin-4 (15 or 50 
µg/kg/day, dissolved in PBS) or PBS as a control for up to 4 weeks, while continuously 
feeding the mice the HFD. Additionally, one group of mice received PBS while being fed 
a chow diet as a control for HFD feeding. After 4 weeks of drug treatment, mice were 
perfused with ice-cold PBS via the heart, and livers were isolated to investigate hepatic 
lipid content and determine expression of selected genes involved in lipid metabolism. 
In addition, skeletal muscles from the hind leg were isolated to determine expression of 
selected genes involved in thermogenesis and fatty acid oxidation.
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Compounds
CNTO3649 (molecular weight = 68,000 g/mol) was constructed by fusing a GLP-1 
peptide analogue to a flexible Gly/Ser linker and a fragment of a V region heavy chain 
(VH) domain linked directly to the CH2 and CH3 domains of an Fc as described previously 
for CNTO736 17. Exendin-4 (molecular weight = 4186.6 g/mol) was purchased from 
Sigma (St. Louis, MO). 
Plasma glucose and insulin analysis
Blood was collected by tail bleeding into chilled capillary tubes. The tubes were placed 
on ice and centrifuged, and the obtained plasma was snap-frozen in liquid nitrogen 
and stored at -20 °C for further measurements. Plasma was assayed for glucose using 
a commercially available enzymatic kit according to the manufacturer’s protocol 
(Instruchemie, Delfzijl, The Netherlands), and insulin was measured by ELISA (Mercodia 
AB, Uppsala, Sweden). 
Hepatic VLDL-TG and VLDL-apoB production
Mice were fasted for 7 hours, with food withdrawn at 7.00 am and anesthetized 
by intraperitoneal injection of 6.25 mg/kg acepromazine (Alfasan, Woerden, The 
Netherlands), 6.25 mg/kg midazolam (Roche, Mijdrecht, The Netherlands), and 0.3125 
mg/kg fentanyl (Janssen-Cilag, Tilburg, The Netherlands). Mice received an intravenous 
(iv) injection of 100 µl PBS containing 100 µCi Tran35S label (MP Biomedicals, Eindhoven, 
the Netherlands) resulting in incorporation of 35S into newly produced apoB required 
for hepatic VLDL production. After 30 min, the animals received an iv injection of 
tyloxapol (500 mg/kg body weight; Triton WR-1339, Sigma), as a 10% (w/w) solution in 
sterile saline, to prevent systemic lipolysis of newly secreted hepatic VLDL-TG 18. Blood 
samples were drawn before (t=0) and at 15, 30, 60, and 90 min after tyloxapol injection. 
Plasma was assayed for TG concentration using the commercially available enzymatic 
kit 11488872 (Roche Molecular Biochemicals, Indianapolis, IN). At 120 min, mice were 
euthanized, and blood was collected by orbital puncture for isolation of VLDL by 
density gradient ultracentrifugation 19. 35S-apoB was measured in the VLDL fraction and 
VLDL-apoB production rate was calculated as dpm.h-1 20. TG and total cholesterol (TC) 
concentrations in the VLDL fractions were determined using the commercially available 
enzymatic kits 11488872 and 236691 (Roche) respectively, and phospholipid (PL) 





Liver lipids were extracted according to a modified protocol from Bligh and Dyer 21. 
Briefly, small liver pieces were homogenized in ice-cold methanol. After centrifugation, 
lipids were extracted by addition of 1800 µl CH3OH: CHCl3 (1:3 v/v) to 45 µl homogenate, 
followed by vigorous vortexing and phase separation by centrifugation (5 min at 
2,000 rpm). The CHCl3 phase was dried and dissolved in 2% Triton X-100. TG, TC, and PL 
concentrations were measured using commercial kits as described above. Liver lipids 
were expressed as nmol per mg protein, which was determined using the BCA protein 
assay kit.
Hepatic gene expression analysis
Total RNA was extracted from liver pieces using the Nucleospin RNA II kit (Macherey-
Nagel, Duren, Germany) or from muscle pieces using the RNeasy Fibrous Tissue Mini kit 
(Qiagen, Valencia, CA, USA) according to manufacturer’s instructions. RNA quality of each 
sample was examined by the lab-on-a-chip method using Experion Std Sens analysis 
kit (Biorad, Hercules, CA) and RNA concentration of each sample was determined by 
Nanodrop technology (Thermo Scientific, Wilmington, USA). Then, total RNA was reverse-
transcribed with iScript cDNA synthesis kit (1708891, Bio-Rad), subsequently, obtained 
cDNA was purified with Nucleospin Extract II kit (636973, Macherey-Nagel, Bioké). 
Real-time PCR was performed on a CFX96 machine (Bio-Rad), the reaction mixture 
consisting of SYBR-Green Sensimix (QT615, GC Biotech), cDNA, primers (Biolegio, 
Nijmegen, The Netherlands), and nuclease-free water in a total reaction volume of 10 µl. 
mRNA values of each gene were normalized to mRNA levels of cyclophilin (Cyclo) and 
hypoxanthine ribosyltransferase (Hprt). Primer sequences are listed in supplementary 
table 1.
Statistical analysis
Differences between groups were determined with the Kruskal-Wallis non-parametric 
test for k independent samples. When significant differences were found, the Mann-
Whitney non-parametric test was used as a post-hoc test to determine differences 
between two independent groups. A P-value of less than 0.05 was considered statistically 
significant. Data are presented as means ± SEM.
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supplemental Table 1. Primer sequences used for rT-qPcr 
Gene Forward primer Reverse Primer 
Abcg5 TGTCCTACAGCGTCAGCAACC GGCCACTCTCGATGTACAAGG
Acox1 TATGGGATCAGCCAGAAAGG ACAGAGCCAAGGGTCACATC












Abcg5, ATP-binding cassette sub-family G member 5; Acox1, acyl-CoA oxidase 1; Apob, apolipoprotein B; Cpt1, 
carnitine palmitoyltransferase 1; Cyclo, cyclophilin; Dgat1, acyl:diacylglycerol transferase 1; Fasn, fatty acid 
synthase; Hmgcoar, HMG-CoA reductase; Hprt, hypoxanthine ribosyltransferase; Mttp, microsomal TG transfer 
protein; Pgc1α, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; Pgc1β, peroxisome 
proliferator-activated receptor gamma coactivator 1-beta; Srebp-1c, sterol regulatory element binding protein 




GLP-1 receptor agonism reduces body weight and fasting plasma 
glucose and insulin levels in high fat diet-fed E3L mice
E3L mice were fed a HFD for 18 weeks and thereafter were treated with the GLP-1 
receptor agonists CNTO3649 or exendin-4 via subcutaneous osmotic minipumps for 4 
weeks while continuing the HFD. Body weight and fasting plasma glucose and insulin 
levels before and after treatment are shown in Figure 1. Eighteen weeks of HFD feeding 
increased body weight (+24%, P<0.05) (Fig. 1A), tended to increase fasting plasma 
glucose (+36%, P=0.055) (Fig. 1B) and increased fasting insulin levels (13-fold, P<0.05) 
(Fig. 1C) compared to chow diet feeding. CNTO3649 (1.0 and 3.0 mg/kg/day) and the low 
dose of exendin-4 (15 µg/kg/day) did not affect body weight, whereas the high dose of 
exendin-4 (50 µg/kg/day) decreased body weight (-16%, P<0.01) (Fig. 1A) as compared 
to HFD control mice. Both doses of CNTO3649 and exendin-4 decreased fasting plasma 
glucose levels (up to -30%, P<0.05 and -28%, P<0.01, respectively) compared to HFD 
control mice (Fig. 1B). Additionally, the high dose of both CNTO3649 and exendin-4 
decreased plasma insulin (-43% and -65%, respectively, P<0.05 for exendin-4 only) 
compared to HFD control mice (Fig. 1C). Collectively, these data confirm that GLP-1 
receptor agonism by either CNTO3649 or exendin-4 improved glycemic control in the 
HFD-fed E3L mouse model. 
GLP-1 receptor agonism reduces hepatic secretion of VLDL particles 
without affecting particle composition
To evaluate the effect of GLP-1 receptor agonism on hepatic VLDL production, mice 
received an intravenous injection of Tran35S to label newly formed apoB, and tyloxapol to 
block LPL-mediated lipolysis of newly synthesized VLDL. HFD feeding increased the hepatic 
production rate of both VLDL-TG (Fig. 2A-C) and VLDL-apoB (Fig. 2D) compared to chow 
diet, which is in line with a previous study 22. Interestingly, the VLDL-TG production rate 
induced by HFD was reduced by both doses of CNTO3649 (up to -36%, P<0.01) (Fig. 2A, C) 
and exendin-4 (up to -54%, P<0.001) (Fig. 2B, C), as determined from the slope of the 
curve from the individual mice. Likewise, the VLDL-apoB production rate as induced 
by HFD was decreased by the high dose of both CNTO3649 and exendin-4 (-36% and 
-43%, P<0.01, respectively) (Fig. 2D). HFD feeding increased the TG/apoB ratio within 
VLDL as compared to chow feeding by +68% (P<0.001) (Fig. 2E), indicating that HFD 
induces the formation of larger lipid-enriched VLDL particles. However, both CNTO3649 
and exendin-4 did not affect the VLDL-TG/apoB ratio compared with HFD control group. 
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Since each VLDL particle contains a single apoB molecule, GLP-1 receptor agonism 
apparently decreases the production rate of VLDL particles rather than decreasing the 
lipidation of VLDL particles. Accordingly, CNTO3649 and exendin-4 did not affect the 
composition of VLDL with respect to TG, TC, PL, and protein content as compared with 
HFD control group (Fig. 2F).
Figure 1. GLP-1 receptor agonism reduces body weight and fasting plasma glucose and insulin levels. 
APOE*3-Leiden (E3L) mice were fed a high fat diet (HFD) for 22 weeks. The last 4 weeks, mice were treated 
with either vehicle (HFD control), CNTO3649 (1.0 or 3.0 mg/kg/day) or exendin-4 (15 or 50 μg/kg/day). As a 
control for HFD feeding, an additional group of mice was included fed a chow diet that received vehicle (chow 
control). Blood was collected by tail bleeding after 7 h of fasting. Just before drug treatment (week 18) and 
after treatment (week 22), body weight (A), plasma glucose (B) and plasma insulin (C) levels were determined. 




Figure 2. GLP-1 receptor agonism reduces hepatic VLDL-TG and VLDL-apoB production without 
affecting VLDL particle composition. E3L mice were fed a HFD for 22 weeks. The last 4 weeks, mice were 
treated with either vehicle (HFD control), CNTO3649 (1.0 or 3.0 mg/kg/day) or exendin-4 (15 or 50 μg/kg/
day). As a control for HFD feeding, an additional group of mice fed a chow diet was included that received 
vehicle (chow control). After 7 h fasting, mice were injected with Tran35S label (t=-30 min) and Triton WR-1339 
(t=0 min). Blood was drawn at the indicated time points and plasma TG concentrations were determined 
(A, B). VLDL-TG production rate was calculated as µmol/h from the slopes of the TG-time curves of the 
individual mice (C). At t=120 min, mice were exsanguinated, and VLDL was isolated by density gradient 
ultracentrifugation. 35S-activity was determined, and VLDL-apoB production rate was calculated as dpm.h-1 
(D). The VLDL-TG production rate to VLDL-apoB production rate ratio was calculated as nmol/dpm (E). The 
content of triglycerides, cholesterol, phospholipids and protein in VLDL was determined and calculated 
as % of total mass (F). Values are means ± SEM for at least 6 mice per group. *P<0.05, **P<0.01, ***P<0.001 
compared to HFD controls. TG: triglycerides; TC: total cholesterol; PL: phospholipids; Pro: protein. 
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GLP-1 receptor agonism reverses high fat diet-induced hepatic steatosis 
To obtain insight into the mechanism underlying the reduction in hepatic VLDL 
production induced by GLP-1 agonism, we next determined the effect of the GLP-1 
receptor agonists on hepatic lipid content in a second set of mice. Consistent with the 
first experiment, CNTO3649 and exendin-4 decreased body weight and fasting plasma 
glucose and insulin levels compared to the HFD control group (Supplemental Fig. 1) to a 
similar extent as in the first study. HFD feeding induced a marked increase in hepatic TG, 
TC, and PL content compared to chow diet (Fig. 3), indicating that HFD leads to hepatic 
steatosis. The high dose of both CNTO3649 and exendin-4 largely reduced hepatic TG 
(-39%, P<0.05 and -55%, P<0.01, respectively). Hepatic TC was reduced by both doses 
of CNTO3649 and exendin-4, (up to -32%, P<0.05 and -55%, P<0.01, respectively). Also, 
both doses of CNTO3649 and exendin-4 reduced hepatic PL (up to -23%, P<0.01 and 
-36%, P<0.01, respectively). Importantly, hepatic lipid content observed after treatment 
with the high dosages of CNTO3649 and exendin-4 group did not differ from that of 
the chow control group (P>0.05), suggesting that GLP-1 receptor agonism completely 
reversed HFD-induced hepatic steatosis.
Figure 3. GLP-1 receptor agonism reverses high fat diet-induced hepatic steatosis. E3L mice were fed 
HFD for 13 weeks. The last 4 weeks, mice were treated with either vehicle (HFD control), CNTO3649 (0.3 or 1.0 
mg/kg/day) or exendin-4 (15 or 50 μg/kg/day). As a control for HFD feeding, an additional group of mice was 
included fed a chow diet that received vehicle (chow control). Livers were isolated from 7 h fasted mice, liver 
pieces were homogenized, and triglycerides, cholesterol and phospholipids were determined as nmol per 
mg protein. Values are means ± SEM for at least 6 mice per group. *P<0.05, **P<0.01, ***P<0.001 compared 
to HFD controls. 
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supplemental Figure s1. GLP-1 receptor 
agonism reduces fasting glucose and 
insulin levels. E3L mice were fed a high fat 
diet (HFD) for 13 weeks. The last 4 weeks, 
mice were treated with either vehicle (HFD 
control), CNTO3649 (0.3 or 1.0 mg/kg/day) or 
exendin-4 (15 or 50 μg/kg/day). As a control 
for HFD feeding, an additional group of mice 
fed a chow diet was included that received 
vehicle (chow control). Just before drug 
treatment (week 13) and after treatment 
(week 17), body weight (A), plasma glucose 
(B) and plasma insulin (C) levels were 
determined. Values are means ± SEM for at 
least 6 mice. *P<0.05, **P<0.01, ***P<0.001 
compared to HFD controls.
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GLP-1 receptor agonism affects hepatic expression of genes involved in 
VLDL production, lipogenesis and lipid homeostasis
To elucidate the mechanism how GLP-1 receptor agonism reduces liver lipids and VLDL 
secretion, we investigated the hepatic expression of genes involved in lipid metabolism 
(i.e. lipogenesis, VLDL secretion, cholesterol metabolism, and FA oxidation) (Fig. 4). HFD 
feeding strongly tended to increase the expression of peroxisome proliferator-activated 
receptor gamma coactivator 1-beta (Pgc1β), whereas the high dose of CNTO3649 and 
both doses of exendin-4 tended to reduce this HFD-induced increase in Pgc1β. Next, 
HFD feeding increased the expression of the lipogenic transcription factor sterol 
regulatory element binding protein 1c (Srebp-1c) (3.7-fold, P<0.05) (Fig. 4A) and its 
target gene FA synthase (Fasn) (6.7-fold, P<0.01) (Fig. 4B), which plays a role in de novo 
lipogenesis, contributing to HFD-induced hepatic steatosis. The high dose of CNTO3649 
and both doses of exendin-4 decreased the expression of Srebp-1c (-53%, P<0.05, and 
up to -75%, P<0.05, respectively) (Fig. 4A) and the low dose of CNTO3649 and the high 
dose of exendin-4 decreased Fasn (-40%, P<0.05 and -53%, P<0.01, respectively) (Fig. 4B) 
compared with the HFD group. Acyl:diacylglycerol transferase 1 (Dgat1), which catalyzes 
the final step in hepatic TG synthesis, was significantly decreased by exendin-4 only (up 
to -71%, P<0.05) (Fig. 4C). In addition, the high dose of CNTO3649 and both doses of 
exendin-4 suppressed expression of apoB (Apob) (-62%, P<0.05 and up to -72%, P<0.01, 
respectively) (Fig. 4D), without affecting expression of microsomal TG transfer protein 
(Mttp) (Fig. 4E) that mediates apoB lipidation. In addition, the high dose of CNTO3649 
and both doses of exendin-4 suppressed the expression of the FA oxidation gene 
acyl-CoA oxidase 1 (Acox1) (-56% and up to -75%, P<0.01, respectively) (Fig. 4F). 
Moreover, both doses of CNTO3649 and exendin-4 increased the expression of HMG-
CoA reductase (Hmgcoar) (up to 2.1-fold and 3.4-fold, P<0.05, respectively) involved in 
de novo cholesterol synthesis (Fig. 4G). Finally, the expression of ATP-binding cassette 
sub-family G member 5 (Abcg5), involved in bile acid secretion, was significantly 
decreased for both doses of exendin-4 only (up -58%, P<0.01) (Fig. 4H).
Collectively, these data indicate that GLP-1 receptor agonism decreases lipogenesis 
and apoB synthesis, consequently resulting in suppression of VLDL particle production 
and a compensatory decrease in hepatic FA oxidation. In addition, the reduction in 
hepatic cholesterol content results in compensatory mechanisms to increase hepatic 
cholesterol synthesis and decrease secretion of hepatic cholesterol as bile acids. 
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Figure 4. GLP-1 receptor agonism affects hepatic expression of genes involved in VLDL production, 
lipogenesis, and lipid homeostasis. E3L mice were fed HFD for 13 weeks. The last 4 weeks, mice were treated 
with either vehicle (HFD control), CNTO3649 (0.3 or 1.0 mg/kg/day) or exendin-4 (15 or 50 μg/kg/day). As a 
control for HFD feeding, an additional group of mice was included fed a chow diet that received vehicle (chow 
control). Livers were isolated from 7 h fasted mice, and mRNA was extracted from liver pieces. mRNA values 
of indicated genes were normalized to Cyclo and Hprt mRNA levels. Data were calculated as fold difference 
as compared with the HFD control group. Values are means ± SEM for at least 6 mice per group. *P<0.05, 
**P<0.01, ***P<0.001 compared to HFD controls.
GLP-1 receptor agonism affects muscle expression of genes involved in 
fatty acid oxidation
To gain insight into the fate of the FA from the diet we also measured muscle expression 
of genes involved in thermogenesis and FA oxidation (Supplemental Fig. 2). No 
differences between groups were found for the thermogenic markers uncoupling 
protein 1 (Ucp1) and peroxisome proliferator-activated receptor gamma coactivator 
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1-alpha (Pgc1α), suggesting that both compounds did not affect energy expenditure by 
the muscle. However, the expression of Acox1 was significantly increased for the high 
dose of CNTO3649 and exendin-4 (+33% and +56%, P<0.05, respectively) as compared 
to HFD controls. Also, the high dose of exendin-4 increased the expression of carnitine 
palmitoyltransferase 1 (Cpt1) (+73%, P<0.05). These data indicate an increased FA 
oxidation in muscle. 
supplemental Figure s2. GLP-1 receptor agonism affects muscle expression of genes involved in 
fatty acid oxidation. E3L mice were fed HFD for 13 weeks. The last 4 weeks, mice were treated with either 
vehicle (HFD control), CNTO3649 (0.3 or 1.0 mg/kg/day) or exendin-4 (15 or 50 μg/kg/day). As a control for 
HFD feeding, an additional group of mice was included fed a chow diet that received vehicle (chow control). 
Skeletal muscles were isolated from 7 h fasted mice, and mRNA was extracted from muscle pieces. mRNA 
values of indicated genes were normalized to Cyclo and Hprt mRNA levels. Data were calculated as fold 
difference as compared with the HFD control group. Values are means ± SEM for at least 6 mice per group. 




In the present study, we show that GLP-1 receptor agonism both by CNTO3649 and 
exendin-4 decreases fasting plasma glucose and insulin levels in HFD-fed E3L mice. This 
is in line with earlier reports that GLP-1 and its analogs ameliorate whole-body glucose 
intolerance in obese animal models 23, 24 and in T2DM patients 25. More importantly, to 
our knowledge, this study is the first to demonstrate that CNTO3649 and exendin-4 
reduce hepatic VLDL particle production, evidenced by similarly reduced VLDL-TG and 
VLDL-apoB production rates. In addition, both GLP-1 receptor agonists largely decrease 
the hepatic lipid content thereby reversing HFD-induced hepatic steatosis.
Increased plasma VLDL-TG levels are a central feature of T2DM, and are mainly 
caused by increased hepatic VLDL-TG and VLDL-apoB production 26. We observed that 
HFD feeding increased VLDL-TG and VLDL-apoB production, and in addition increased 
the VLDL-TG/apoB ratio. As each VLDL particle contains a single molecule of apoB, VLDL-
apoB reflects particle number, whereas VLDL-TG reflects the major lipid constituent of 
the particle. An increased VLDL-apoB production rate with a concomitantly increased 
VLDL-TG/apoB ratio thus indicates that HFD feeding not only results in overproduction 
of VLDL particles but also in the formation of larger lipid-enriched VLDL particles. 
Both CNTO3649 and exendin-4 reduced the VLDL-TG and VLDL-apoB production rates 
without affecting the VLDL-TG/apoB ratio, suggesting that GLP-1 agonism reduces the 
VLDL particle production without affecting the lipidation of VLDL-apoB. This was indeed 
confirmed by VLDL composition analysis. Notably, we have observed the same effects 
in WT mice treated with exendin-4 (data not shown), ruling out a possible impact of the 
genetic background of the E3L mice on the treatment outcome.
We also observed that both CNTO3649 and exendin-4 completely reversed HFD-
induced hepatic steatosis reflected by largely decreased hepatic TG and TC contents 
to the low levels observed in chow-fed control mice. This corroborates recent studies 
showing that prolonged infusion of exendin-4 in ob/ob mice reduced hepatic TG 
accumulation 27. Hepatic gene expression analysis revealed that the GLP-1 receptor 
agonists decreased the expression of the nuclear transcription factor Srebp-1c and its 
targets Fasn and Dgat1, which are involved in de novo FA and TG synthesis, respectively. 
At the same time, the GLP-1 receptor agonists decreased ApoB expression without 
affecting the expression of Mttp, of which the gene product MTP is involved in the 
transfer of TG onto apoB. On the other hand, they decreased the expression of Acox1 
and Cpt1a (not shown), both of which are involved in FA oxidation.
Collectively, these data strongly suggest that GLP-1 receptor agonism primarily 
reduces hepatic lipogenesis, thereby causing a reduction in hepatic TG content, with a 
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compensatory reduction in FA oxidation. Taken together with the concomitantly reduced 
apoB production, lower hepatic availability of TG results in a reduced production of 
VLDL particles. It is known that the contribution of de novo lipogenesis to total hepatic 
VLDL secretion strongly increases from 2-5% under healthy conditions up to 25-30% 
in T2DM patients with hepatic steatosis 28, 29. Since HFD feeding of E3L mice similarly 
induced hepatic steatosis, the contribution of de novo lipogenesis to the increased VLDL 
production was likely also augmented by HFD feeding, and reversed by GLP-1 receptor 
agonism concomitant with attenuating hepatic steatosis. Interestingly, the increased 
expression of Acox and Cpt1 in the muscle suggests an increase in FA oxidation. In 
addition, by indirect calorimetry (Supplemental Fig. S3) we observed that exendin-4 
treatment reduces the respiratory exchange rate, indicating an increased oxidation of 
fat. Although this effect was transient, it might have contributed to differences in the 
observed phenotypes after prolonged treatment. Collectively, these data suggest that 
GLP-1 receptor agonism not only decreases the production of FA, but also upregulates 
an oxidative pathway in the muscle to deal with the elevated uptake of FA present in 
the diet. 
supplemental Figure s3. exendin-4 treatment reduces respiratory exchange ratio. C57Bl/6 mice were fed 
a HFD for 3 weeks before they were treated with either vehicle (control) or exendin-4 (50 μg/kg/day). Directly 
after the initiation of the treatment, indirect calorimetry measurements were started. Individual energy intake 
(A), activity (B), O2 consumption, and CO2 production rates were monitored. Respiratory exchange rate (C) 
and total energy expenditure (D) were calculated from the O2 consumption and CO2 production rates. Lines 
represent the mean values of 8 mice treated with vehicle (solid lines) or exendin-4 (dotted lines). Black areas 




The mechanism underlying the reduced hepatic cholesterol content is less clear, 
although it may be expected from the reduced TG content given the tight relationship 
between hepatic TG and cholesterol levels. The reduction in hepatic cholesterol 
content evidently results in a compensatory induction of Hmgcoar, involved in de novo 
cholesterol synthesis, and downregulation of Abcg5, involved in the elimination of 
hepatic cholesterol as bile acids into the bile.
It is interesting to speculate on the molecular mechanisms that underlie the 
reduction in hepatic lipogenesis as induced by GLP-1 receptor agonism. Since Srebp-1c 
plays a crucial role in insulin-mediated de novo lipogenesis in the liver 30, it is well possible 
that the improved HFD-induced glucose intolerance accompanied by reduced insulin 
levels resulted in downregulation of hepatic Srebp-1c expression, thereby attenuating 
the HFD-induced increase in de novo lipogenesis. Beside insulin levels, Pgc1β could 
also be involved as it impacts on Srebp-1c expression 31. Therefore, the observed trend 
towards a reduction in Pgc1β expression might also have contributed to a decreased 
Srebp-1c and consequently a decrease in de novo lipogenesis. Interestingly, it has 
recently been established that human hepatocytes 32, 33 as well as rodent hepatocytes 34 
express GLP-1 receptors. In fact, incubation of hepatocytes with GLP-1 and exendin-4 in 
the absence of insulin directly reduces Srebp-1c 34, and reduces hepatocyte steatosis 32. 
This indicates that GLP-1 receptor agonism may directly downregulate Srebp-1c and 
lipogenesis through binding of hepatocytic receptors. Third, GLP-1 receptor agonism 
by exendin-4 or the DPP-4 inhibitor sitagliptin reduces the intestinal production of 
chylomicron-TG and apoB in hamsters 35, and the DPP-4 inhibitor vildagliptin reduces 
postprandial chylomicron-TG and apoB in T2DM patients 36. Indeed, pilot data from our 
lab confirmed that exendin-4 reduces postprandial TG excursion in mice (unpublished). 
Since uptake of TG from the diet eventually contributes to VLDL-TG production 37, 38, 
reduced chylomicron production may contribute to the observed effect of GLP-1 receptor 
agonism on hepatic VLDL production. Finally, circulating GLP-1 can cross the blood-
brain barrier 39 and GLP-1 receptors are abundantly expressed in many brain areas 40. 
Several studies have shown that central GLP-1 receptor signaling mediates the effect 
of GLP-1 on hepatic glucose output 41 and lipid deposition in white adipose tissue 42. It 
is therefore reasonable to postulate that the brain-nerve-liver axis might contribute to 
the beneficial effects of GLP-1 agonism on hepatic lipid metabolism and VLDL secretion. 
In our previous study, in which we administered exendin-4 by daily intraperitoneal 
injections, we were unable to detect any effect of exendin-4 on VLDL production, 
albeit that exendin-4 did improve glucose tolerance 12. In that study, daily injections 
of CNTO736, a previous version of CNTO3649, with a considerably longer half-life than 
exendin-4, did reduce VLDL production. Since we now demonstrate that continuous 
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delivery of exendin-4 inhibits VLDL production, it is likely that the ability of GLP-1 
agonists to reduce hepatic steatosis and VLDL production is mainly determined by their 
pharmacokinetic profile. Whereas pulsated exposure of GLP-1 (analogues) is sufficient 
to improve glucose intolerance, more chronic exposure is required for additional 
beneficial effects on TG metabolism.
How do the present data obtained in E3L mice translate to clinical practice? 
Recently, it has been reported that treatment of T2DM patients with exenatide on top 
of pioglitazone resulted in a greater decrease in both hepatic TG and plasma TG levels 
compared to treatment with pioglitazone only 43. Based on our present data, it is likely 
that these observations can be explained by a reduction in Srebp-1c- induced lipogenesis, 
resulting in attenuation of the hepatic TG content, reduction of VLDL-TG production 
and thus plasma VLDL-TG levels. Therefore, it would be interesting to determine the 
effect of GLP-1 analogues and DPP-4 inhibitors on VLDL production in future human 
intervention studies. In addition, we anticipate that the effects of long-circulating GLP-1 
receptor agonists such as liraglutide (duration of action ≥ 24 hours) on lipid metabolism 
will prove to be superior to those of exenatide (duration of action < 24 hours) and in 
addition will lead to better tolerability due to the necessity of injecting once daily only as 
compared to twice daily for exenatide 44. In addition to the beneficial effects on glucose 
metabolism, VLDL secretion and hepatic lipid content, GLP-1 receptor agonism also 
reduces blood pressure and the severity of myocardial infarction, while it concomitantly 
improves left ventricular ejection fraction after infarction 45, enforcing GLP-1 receptor 
agonism as a valuable therapy to combat T2DM and associated cardiovascular diseases.
In conclusion, our results show that GLP-1 agonism not only decreases bodyweight 
and improves glycemic control, but also reduces HFD-induced hepatic steatosis, thereby 
reducing hepatic VLDL biosynthesis and secretion. Therefore, we anticipate that GLP-1 
receptor agonism is a valuable strategy to treat T2DM patients, especially those with 
disturbed lipid metabolism related to hepatic steatosis. 
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The etiology of inflammation in the liver and vessel wall, leading to non-alcoholic 
steatohepatitis (NASH) and atherosclerosis respectively, share common mechanisms 
including macrophage infiltration. To test both disorders simultaneously, it is highly 
important to tackle the inflammatory status. Exendin-4, a glucagon-like peptide-1 
receptor agonist, reduces hepatic steatosis and has been suggested to reduce 
atherosclerosis; however its effects on liver inflammation are underexplored. Here, we 
tested the hypothesis that exendin-4 reduces inflammation in both the liver and vessel 
wall, and investigated the common underlying mechanism. Female APOE*3-Leiden.
CETP mice, a model with human-like lipoprotein metabolism that develops human-like 
atherosclerosis, were fed a cholesterol-containing Western-type diet for 5 weeks and 
were subsequently treated for 4 weeks with exendin-4 or vehicle. Exendin-4 slightly 
improved dyslipidemia, but markedly decreased atherosclerotic lesion severity and area 
(-33%), accompanied with a reduction in monocyte adhesion to the vessel wall (-42%) 
and macrophage content in the plaque (-44%). Furthermore, exendin-4 reduced hepatic 
lipid content and inflammation as well as hepatic CD68+ (-18%) and F4/80+ (-25%) 
macrophage content. This was accompanied by less monocyte recruitment from the 
circulation as the Mac-1+ macrophage content was decreased (-36%). Finally, exendin-4 
reduced chemokine expression in vivo and suppressed oxidized LDL accumulation 
in peritoneal macrophages in vitro, dependent on the GLP-1 receptor. In conclusion, 
exendin-4 reduces inflammation in both the liver and the vessel wall by reducing 
macrophage recruitment and activation. These data suggest that exendin-4 could be a 




EXENDIN-4 REDUCES ATHEROSCLEROSIS AND NASH
iNTroDUcTioN
Cardiovascular disease (CVD) due to atherosclerosis is the leading cause of morbidity 
and mortality in the Western world. There is a strong association between atherosclerosis 
and non-alcoholic fatty liver disease (NAFLD), which raised the interest of the role 
of the liver in the development of atherosclerosis. NAFLD embraces a pathological 
spectrum of liver diseases, from steatosis with virtually no evidence of hepatocellular 
injury or liver inflammation to non-alcoholic steatohepatitis (NASH) and cirrhosis 1. 
NASH is characterized by accumulation of fat in the liver in combination with hepatic 
inflammation 2. This inflammatory response was assumed to be the consequence rather 
than the cause of the disease. However, compelling data point to a central initiating 
role of monocyte recruitment and macrophage activation in the progression of hepatic 
inflammation in a similar way as in the development of atherosclerosis as we recently 
reviewed 3.  The potential of a shared etiology between inflammation in the liver and 
vessel wall leads to putative intervention therapies to tackle both disorders at the 
same time by targeting macrophage infiltration. This is particularly interesting, since 
the current standard therapies to reduce inflammation in NASH have only limited 
effectiveness. Lifestyle intervention, including exercise, is recommended in patients 
with NASH. However, it appears to be difficult to achieve improvements in NASH in the 
long run and pharmacological intervention is ultimately required 4.
Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as exendin-4, are currently 
being validated for the treatment of type 2 diabetes mellitus and have been shown 
to increase glucose-dependent insulin secretion, to regulate gastric emptying, and 
to reduce food intake and body weight 5. In addition to improving glycemic control, 
GLP-1R activation improves lipid metabolism. We 6 and others 7-9 have shown that 
GLP-1R activation reduces hepatic steatosis, increases hepatic lipid oxidation, decreases 
lipogenesis, and attenuates hepatic VLDL production.Collectively, these data indicate 
the potential of GLP-1R activation to treat NAFLD, but the impact on liver inflammation 
and atherosclerosis is still uncertain. Moreover, contrasting results have been reported 
regarding the effects on atherosclerosis in ApoE-/- mice. While Gaspari et al. 10 showed 
clear inhibiting effects on the progression of atherosclerosis, Panjwahi et al. 11 did not 
observe any effects on atherosclerosis development. It should be noted that these mice 
do not respond to lipid-lowering therapy and lack apoE, a crucial factor for cholesterol 
efflux from macrophages. Given this controversy, combined with the reduction in 
hepatic steatosis, it is of significant importance to further explore the therapeutic 




The aim of the current study was to evaluate the effect of exendin-4 treatment on 
hepatic inflammation in addition to its effect on the development of atherosclerosis, and 
to elucidate the underlying mechanisms, in APOE*3-Leiden.CETP (E3L.CETP) mice fed a 
Western-type diet. We show that exendin-4 reduces the influx of macrophages into both 




Twelve week old, female E3L.CETP transgenic mice expressing human CETP under 
the control of its natural flanking regions were used 12 and housed under standard 
conditions in conventional cages with free access to food and water unless indicated 
otherwise. The animals were fed a semi-synthetic Western-type diet, containing 
0.4% (w/w) cholesterol, 1% (w/w) corn oil, and 15% (w/w) cacao butter (Hope Farms, 
Woerden, The Netherlands) for 5 weeks. After randomization according to body weight, 
plasma total cholesterol (TC), and triglyceride (TG) levels, an osmotic minipump (model 
1004, Alzet DURECT Corp., Cupertino, CA) was implanted subcutaneously in the left 
back region under light isoflurane anesthesia for the continuous delivery of exendin-4 
(50 µg/kg/day, Bachem AG, Bubendorf, Switzerland; dissolved in PBS) or PBS as a control 
for 4 weeks while the Western-type diet was continued. Experiments were performed 
after 4 h of fasting at 12:00 pm with food withdrawn at 8:00 am. The Institutional Ethics 
Committee for Animal Care and Experiments from the Leiden University Medical Center, 
Leiden, the Netherlands approved all experiments.
Blood sampling, plasma metabolites, and lipoprotein profiles
Blood was obtained via tail vein bleeding into heparin-coated capillary tubes. The tubes 
were placed on ice and centrifuged, and the obtained plasma was snap-frozen in liquid 
nitrogen and stored at -20°C until further measurements. Plasma was assayed for glucose 
(Instruchemie, Delfzijl, The Netherlands) as well as TC, and TG using the commercially 
available enzymatic kits 236691, 11488872 (Roche Molecular Biochemicals, Indianapolis, 
IN, USA), respectively. Plasma insulin was measured by ELISA (Mercodia AB, Uppsala, 
Sweden). The distribution of lipids over plasma lipoproteins was determined using fast 
protein liquid chromatography. Plasma was pooled per group, and 50 µL of each pool 
was injected onto a Superose 6 PC 3.2/30 column (Äkta System, Amersham Pharmacia 
Biotech, Piscataway, NJ, USA) and eluted at a constant flow rate of 50 µL/min in PBS, 
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Plasma CETP concentration 
Plasma CETP concentration was measured using the DAIICHI CETP ELISA kit according 
to manufacturer’s instructions (Daiichi, Tokyo, Japan).
Atherosclerosis quantification and monocyte adhesion to the 
endothelium wall
After 4 weeks of treatment, mice were sacrificed and perfused with ice-cold PBS via 
the heart. Hearts were isolated and fixed in phosphate-buffered 4% formaldehyde, 
dehydrated, embedded in paraffin and cross-sectioned (5 µm) through the aortic root 
area. Cross-sections were stained with hematoxylin-phloxine-saffron to determine 
lesion area and lesion severity as described before 13, 14. Briefly, various types of lesions 
were discerned: no lesions, mild lesions with fatty streak-like lesions containing foam 
cells, and severe lesions referred to advanced lesions containing foam cells in the media, 
presence of fibrosis, cholesterol clefts, mineralization and/or necrosis. Additionally, 
cross-sections were stained with AIA 31420 antiserum (1:3000, Accurate Chemical and 
Scientific, Westbury, NY, USA) to determine macrophage area and monocyte adhesion 
to the endothelium wall as described 15. Lesion area and macrophage area were 
determined using Leica Qwin-software. 
Hepatic lipid content
After 4 weeks of treatment, mice were sacrificed and perfused with ice-cold PBS via 
the heart, and livers were isolated. Lipids were extracted according to a modified 
protocol from Bligh and Dyer 16. Briefly, small liver pieces were homogenized in ice-cold 
methanol. After centrifugation, lipids were extracted by addition of 1800 µl CH3OH: CHCl3 
(1:3 v/v) to 45 µL homogenate, followed by vigorous vortexing and phase separation by 
centrifugation (5 min at 2,000 rpm). The CHCl3 phase was dried and dissolved in 2% Triton 
X-100. TG and TC concentrations were measured as described above. Phospholipids (PL) 
concentration was measured using a commercial kit (phospholipids B, Wako Chemicals, 
Neuss, Germany). Liver lipids were expressed as nmol per mg protein, which was 
determined using the BCA protein assay kit (Pierce, Rockford, IL, USA).
Hepatic gene expression analysis
Total RNA was extracted from liver pieces using the Nucleospin RNAII kit (Macherey-
Nagel, Duren, Germany) according to manufacturer’s instructions. RNA quality was 
examined by the lab-on-a-chip method using Experion Std Sens analysis kit (Biorad, 
Hercules, CA) and RNA concentration was determined by Nanodrop technology (Thermo 
9
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Scientific, Wilmington, USA). Total RNA was reverse-transcribed with iScript cDNA 
synthesis kit (1708891, Bio-Rad), and the obtained cDNA was purified with Nucleospin 
Extract II kit (636973, Macherey-Nagel, Bioké). Real-time PCR was performed on a CFX96 
machine (Bio-Rad), the reaction mixture consisting of SYBR-Green Sensimix (QT615, 
GC Biotech), cDNA, primers (Biolegio, Nijmegen, The Netherlands; see Supplemental 
Table 1 for primer sequences), and nuclease-free water in a total reaction volume of 10 
µL. mRNA values of each gene were normalized to mRNA levels of cyclophilin (Cyclo) 
and hypoxanthine ribosyltransferase (Hprt). Data were calculated as fold difference as 
compared with the PBS control group.
supplemental Table 1. Primer sequences used for rT-qPcr 











Apoa1, apolipoprotein A1; Cd68, cluster of differentiation 68; CETP, cholesteryl ester transfer protein; Cyclo, 
cyclophilin; Il-1ß, interleukin-1ß; Il-6, interleukin-6; Hprt, hypoxanthine ribosyltransferase; Mcp-1, monocyte 
chemotactic protein-1; Tnfα, tumor necrosis factor α. 
Liver histology 
Paraffin-embedded liver sections were stained for F4/80+ macrophages (1/600; Serotec, 
Oxford, UK) as described 17. Frozen liver sections (7 µm) were stained for CD68+ resident 
macrophages (CD68 marker, FA11) and infiltrated macrophages (macrophage marker, 
Mac-1) as described previously 15. 
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LDL isolation, radiolabeling, and oxidation
LDL was isolated from human serum by density-gradient ultracentrifugation as 
described.17 LDL was labeled with [3H]cholesteryl oleoyl ether (COEth) by incubation 
with donor [3H]COEth-containing liposomes in the presence of human lipoprotein-
deficient serum. In short, liposomes were created by sonication of 1 mg of egg yolk 
phosphatidylcholine and 200 µCi of [3H]COEth using a Soniprep 150 (MSE Scientific 
Instruments, Crawley, UK). Subsequently, LDL was incubated with the liposomes 
(protein: liposomal phospholipid = 1:8, w/w) for 24 h at 37°C under argon. [3H]COEth-
labeled LDL was purified by density gradient ultracentrifugation and dialyzed overnight 
at 4°C against PBS, pH 7.4. Both LDL and [3H]COEth-LDL were oxidized with 5 µM CuSO4 
at 37°C for 20 h. Oxidation was terminated by adding 200 μM EDTA. EDTA and CuSO4 
were removed by overnight dialysis at 4°C against PBS, pH 7.4. Proper oxidation of LDL 
was confirmed by a 2.5-fold increased electrophoretic mobility of oxidized LDL (oxLDL) 
and [3H]COEth-oxLDL compared to LDL on agarose gel. Protein concentration was 
determined by the BCA protein assay kit.
 
Plasma anti-oxLDL antibodies 
An EIA/RIA high binding 96-well Costar plate (Corning Inc., Corning, NY, USA) was coated 
with oxLDL (7.5 µg/mL) in PBS. IgM, IgG1, and IgG2a antibodies against oxLDL in serum 
were measured using an ELISA Ig detection kit (Zymed Laboratories, San Francisco, CA, 
USA) according to the manufacturer’s protocol.
OxLDL uptake by peritoneal macrophages and Oil-red O staining for 
foam cells
Three days after intraperitoneal injection of 1 mL 4% thioglycollate, peritoneal 
macrophages from E3L.CETP mice were harvested into 10 mL PBS. Subsequently, 
cells were resuspended in DMEM supplemented with 10% fetal bovine serum, 1% 
L-glutamine, 100 units/mL penicillin and 100 mg/mL streptomycin, and incubated at 
37°C in a humidified 5% CO2 incubator. Three hours post-plating, cells were washed 
twice with warm PBS to remove non-adherent cells. Cells were counted and seeded into 
24-well plates at a density of 5 x 105 cells per well for three days before the experiment. 
On the experimental day, peritoneal macrophages were washed three times with PBS 
and incubated in DMEM supplemented with 1% BSA, 100 units/mL penicillin and 100 
mg/mL streptomycin for 1 h, followed by DMEM supplemented with 1% BSA, 100 units/
mL penicillin, 100 mg/mL streptomycin), 10 µg/mL [3H]COEth-oxLDL, and exendin-4 
(0.05 or 0.5 nM) for 48 h at 37°C in a humidified 5% CO2 incubator. When indicated, 
exendin-9 (50 nM; Bachem AG, Bubendorf, Switzerland) was added 1 h before addition 
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of exendin-4. After incubation, macrophages were washed twice with 500 μL PBS and 
cell lysates were obtained by adding 500 µL of 0.1 M NaOH. 250 µL of cell lysates was 
used for quantification of 3H-radioactivity. Dpm values were normalized to the total 
amount of protein (mg) present in 250 μL of cell lysates. Protein concentration in cell 
lysates was quantified with BCA protein assay kit.
For Oil-red O staining, after incubation, cells were washed twice with PBS and fixed 
for 30 min in 4% formaldehyde in PBS. Cell were incubated in 60% 2-propanol for 2 min, 
immediately placed in 60% Oil-red O for 30 min, followed by washing with dH2O. Cell 
nuclei were counterstained with hematoxylin for 1 min.
 
Statistical analysis
All data are presented as means ± SEM. Statistical differences between groups were 
assessed with the Mann-Whitney U test for two independent groups. A P-value of less 
than 0.05 was considered statistically significant.
supplemental Figure s1. exendin-4 decreases 
plasma glucose and insulin levels. After 5 weeks 
of feeding a Western-type diet containing 0.4% 
cholesterol, mice were treated with exendin-4 
(50 µg/kg/day) or vehicle (PBS) subcutaneously for 
4 weeks. Blood was collected by tail bleeding after 
4h of fasting before treatment (T=0) and after 2 
(T=2) and 4 (T=4) weeks of treatment (A). Plasma 
glucose (B) and insulin (C) levels were determined. 
Values are means ± SEM (n=17 mice per group). 
*P<0.05, **P<0.01, ***P<0.001 compared to vehicle.
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resULTs
Exendin-4 reduces plasma glucose and insulin levels 
E3L.CETP mice were fed a Western-type diet containing 0.4% cholesterol for 5 weeks and 
thereafter were treated with exendin-4 or PBS via subcutaneous osmotic minipumps 
for 4 weeks while continuing the diet (Supplemental Fig. S1A). After 2 and 4 weeks of 
treatment, exendin-4 significantly decreased plasma glucose levels (-21%, P<0.001 and 
-24%, P<0.001, respectively, Supplemental Fig. S1B) and insulin levels (-30%, P<0.05 and 
-34%, P<0.01, respectively, Supplemental Fig. S1C), which is in line with our previous 
observations in high-fat diet fed E3L mice 6. 
Figure 1. exendin-4 decreases (V)LDL and slightly increases HDL. After 5 weeks of feeding Western-
type diet containing 0.4% cholesterol, mice were treated with exendin-4 (50 µg/kg/day) or vehicle (PBS) 
subcutaneously for 4 weeks. Blood was collected by tail bleeding after 4 h of fasting before treatment 
(T=0) and after 2 (T=2) and 4 (T=4) weeks of treatment. Plasma cholesterol (A) and triglyceride (B) levels 
were determined. After 4 weeks of treatment, group-wise pooled plasma was fractionated using FPLC on a 
Superose 6 column and the individual fractions were assayed for cholesterol (C). Livers were isolated, mRNA 
was extracted and Apoa1 mRNA was determined as normalized to Cyclo and Hprt mRNA levels. Data were 
calculated as fold difference compared to vehicle (D). Values are means ± SEM (n=17 mice per group). *P<0.05 
compared to vehicle. 
9
170
Exendin-4 decreases plasma VLDL and slightly increases HDL 
Despite clear beneficial effects on glucose metabolism, exendin-4 only tended to 
decrease plasma cholesterol levels (-14%, P=0.05, Fig. 1A) and TG levels (-22%, P=0.07, 
Fig. 1B) after 4 weeks of treatment. Lipoprotein profiling revealed that exendin-4 
decreased VLDL-cholesterol and slightly increased HDL-cholesterol levels (Fig. 1C). The 
latter effect was accompanied by a 26% increased hepatic expression of apolipoprotein 
A1 (Apoa1), encoding the major lipoprotein of HDL (Fig. 1D).
Figure 2. exendin-4 reduces aortic atherosclerosis development and monocyte recruitment to the 
endothelium wall. After 5 weeks of feeding a Western-type diet containing 0.4% cholesterol, mice were 
treated with exendin-4 (50 µg/kg/day) or vehicle (PBS) subcutaneously for 4 weeks. Subsequently, hearts were 
isolated, fixed, dehydrated and embedded in paraffin. Cross-sections of the aortic root were stained with 
hematoxylin-phoxin-saffron (HPS) (A, B) or anti-AIA serum (C, D). Total lesion area (A), lesion severity (B), the 
number of adhering monocytes to the endothelium wall (C), and macrophage area (D) were quantified. Values 
are means ± SEM (n=17 mice per group). *P<0.05, ***P<0.001 compared to vehicle. 
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Exendin-4 largely suppresses atherosclerosis development and 
monocyte recruitment in the aortic root
Despite slightly attenuating dyslipidemia, exendin-4 treatment markedly reduced total 
atherosclerotic lesion area as compared to controls (-33%; P<0.05) (Fig. 2A). Additionally, 
mice treated with exendin-4 showed more lesion-free sections (+63%; P=0.07) and less severe 
lesions (-42%; P<0.05) as compared to PBS controls (Fig. 2B). Moreover, exendin-4 significantly 
reduced the number of monocytes adhering to the endothelium wall in the aortic root (-42%, 
P<0.001, Fig. 2C) as well as the macrophage area in the plaque (-44%, P<0.05, Fig. 2D).
Figure 3. exendin-4 reduces liver inflammation and macrophage content. After 5 weeks of feeding 
a Western-type diet containing 0.4% cholesterol, mice were treated with exendin-4 (50 µg/kg/day) or 
vehicle (PBS) subcutaneously for 4 weeks.  mRNA was extracted from liver pieces, and mRNA expression of 
inflammatory markers Tnfα, Il-1β, and Il-6 (A), Cd68 (B) and F4/80 (C) was determined as normalized to Cyclo 
and Hprt mRNA levels. Data were calculated as fold difference as compared to vehicle (A, B, C). Liver sections 
were immunostained for CD68 and F4/80, and CD68+ (D) F4/80+ (E) macrophages were quantified. Values are 
means ± SEM (n=17 mice per group). *P<0.05, **P<0.01, ***P<0.001 compared to vehicle. 
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Exendin-4 reduces hepatic lipids, inflammation and macrophage 
content 
Four weeks of exendin-4 treatment decreased hepatic TG (-11%; P=0.057) and TC content 
(-19%, P<0.05), without affecting hepatic phospholipid content. In addition, exendin-4 
largely reduced the hepatic expression of the inflammatory markers Tnfα, Il-1β, and Il-6 
(-45%; P<0.01; -47%; P<0.001; -40%; P<0.05, respectively; Fig. 3A). Moreover, exendin-4 
reduced hepatic mRNA expression of the macrophage markers Cd68 (-30%; P<0.01; 
Fig. 3B) and F4/80 (-28%; P<0.05; Fig. 3C). In line with these data, exendin-4 decreased 
hepatic CD68+ macrophages (-18%, P<0.05; Fig. 3D) and F4/80+ macrophages (-25%, 
P<0.001; Fig. 3E).
Figure 4. exendin-4 reduces macrophage infiltration into the liver. After 5 weeks of feeding a Western-
type diet containing 0.4% cholesterol, mice were treated with exendin-4 (50 µg/kg/day) or vehicle (PBS) 
subcutaneously for 4 weeks. In the livers, mRNA expression of Mcp-1 (A) were determined as normalized to 
Cyclo and Hprt mRNA levels. Data were calculated as fold difference as compared to vehicle (A). Liver sections 
were immunostained for Mac-1 and Mac-1+ macrophages were quantified (B). Values are means ± SEM (n=17 
mice per group). *P<0.05, **P<0.01 compared to vehicle.
Exendin-4 reduces macrophage infiltration into the liver
To elucidate the mechanism underlying the reduction of liver macrophage content by 
exendin-4, we first determined the hepatic gene expression of monocyte chemotactic 
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protein-1 (Mcp-1), which mediates monocyte recruitment from the circulation to sites of 
infection and inflammation. As shown in Fig. 4A, exendin-4 reduced Mcp-1 expression 
(-34%; P<0.05). This was accompanied by a reduction of macrophages positive for 
Mac-1, an infiltrating macrophage marker (-36%, P<0.01; Fig. 4B). 
Figure 5. exendin-4 has no effect on plasma antibodies against oxLDL, but reduces oxLDL-induced 
foam cell formation by using peritoneal macrophages. After 5 weeks of feeding a Western-type diet 
containing 0.4% cholesterol, mice were treated with exendin-4 (50 µg/kg/day) or vehicle (PBS) subcutaneously 
for 4 weeks. Plasma anti-oxidized LDL (oxLDL) antibodies were determined (A). Peritoneal macrophages were 
incubated with exendin-4 and/or exendin-9 for 48 h. The uptake of [3H]COEth-labeled oxLDL was quantified 
(B). After fixation, lipid accumulation into the cells was visualized by staining with Oil red O (C). Values are 
means ± SEM (n=17 mice per group). *P<0.05, **P<0.01 compared to vehicle.
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Exendin-4 does not affect circulating antibodies against oxLDL, but 
reduces oxLDL uptake by macrophages
Since the uptake of oxLDL by macrophages can drive both atherosclerosis and NASH, 
we first measured specific antibodies against oxLDL in the circulation. Exendin-4 did not 
affect oxLDL-specific IgG1, IgG2a, and IgM levels in plasma (Fig. 5A). Next, to determine 
if exendin-4 can impact on oxLDL uptake by macrophages, we incubated peritoneal 
macrophages with [3H]COEth-oxLDL (10 µg/ml) for 48 h with or without exendin-4 (0.05 
and 0.5 nM). Exendin-4 decreased the uptake of [3H]COEth-oxLDL (up to -33%, P<0.01) 
compared to controls (Fig. 5B). This effect was completely abolished by pre-treatment 
of the cells with exendin-9 (Fig. 5B), which demonstrates that exendin-4 reduces oxLDL 
uptake by activating the GLP-1R. Oil-red O staining confirmed that exendin-4 reduced 
foam cell formation, which was blocked by exendin-9 (Fig. 5C). 
DiscUssioN 
In this study, we investigated the effect of exendin-4 treatment on liver inflammation 
in addition to the development of atherosclerosis in E3L.CETP mice fed a Western-
type diet. Our data show that 4 weeks of exendin-4 infusion markedly decreases total 
atherosclerotic lesion area, accompanied by a reduction in plaque macrophages. In 
parallel, exendin-4 caused a marked reduction in hepatic lipids and macrophages as 
well as hepatic inflammation, hallmarks of NASH.
It is interesting to note that short-term treatment with exendin-4, as compared 
with vehicle, caused a substantial reduction in atherosclerosis albeit that exendin-4 
only slightly affected cholesterol levels and the lipoprotein profile. Therefore, the 
anti-atherogenic effect of exendin-4 is likely largely independent of modulation of 
plasma lipid levels. This observation contrasts the effects of classic lipid-lowering 
compounds including atorvastatin, which reduce atherosclerosis in E3L.CETP mice 
mainly by reducing apoB-containing lipoproteins 14. We found that exendin-4 inhibited 
the adherence of monocytes to the vessel wall and decreased the macrophage area 
of the plaque, suggesting that exendin-4 decreases the recruitment of monocytes into 
the vessel wall. Our finding add to previous findings demonstrating that 4 weeks of 
GLP-1 receptor activation decreases atherosclerotic development without reducing 
plasma lipids in ApoE-/- mice 10, 18, 19. Although a recent study did not find a reduction in 
atherosclerosis in ApoE-/- mice 11, this might be related to potential tissue heterogeneity 
in GLP-1 receptor expression in the ApoE-/- mice as well as variations in the experimental 
set-up (e.g. animal age, treatment regimen).
Second, we observed that exendin-4 reduced the lipid content of the liver, which 
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was accompanied by a reduction in inflammatory markers and macrophage content of 
the liver as judged from hepatic gene and protein expression. It is known that feeding 
hyperlipidemic mice a diet containing cholesterol increases the hepatic macrophage 
content already within a few days 20. Since in our study mice were fed the Western-type 
diet for 5 weeks before starting treatment, exendin-4 may thus have reduced the hepatic 
macrophage content either by reducing the infiltration of activated macrophages 
from the circulation or by inducing the elimination of macrophages from the liver. The 
current study design does not allow us to discriminate between these possibilities. 
However, we did observe a decrease in hepatic MCP-1 expression along with a 
reduction in Mac-1+ infiltrating macrophages, suggesting that reduced recruitment of 
monocytes/macrophages from the circulation to the liver contributes to the reduction 
in total macrophages. Collectively, we show that exendin-4 treatment affects important 
features of NASH, including reduction of liver macrophages as well as lipid content. 
Historically, NASH was thought to be a causal risk factor for cardiovascular 
disease (CVD) as patients with NASH have a higher mortality risk than the general 
population, mainly due to CVD 2. However, the biological mechanisms linking NASH 
and accelerated atherosclerosis are still poorly understood. Recently, Bieghs et al. put 
forward the hypothesis that there is a central role for inflammation in the development 
of NASH and atherosclerosis with common etiologies involving monocyte recruitment 
and macrophage foam cell formation 3. From this perspective, we hypothesized that 
exendin-4 reduces atherosclerosis as well as hepatic inflammation by acting directly on 
monocyte/macrophage recruitment into both the vessel wall and liver. 
So what mechanisms may then be involved? In addition to reducing hepatic MCP-1 
as observed in our study, exendin-4 reduces the expression of E-selectin, intercellular 
adhesion molecule-1, and vascular cell adhesion molecule-1 in the aorta of ApoE-/- mice 18. 
These are all processes which likely lead to inhibition of monocyte/macrophage 
adhesion to the vessel wall and the liver. The importance of blood monocytes in the 
development of atherosclerosis has been firmly established 21, and accumulating 
evidence demonstrates the role of hepatic infiltration of blood-borne monocytes in 
liver inflammation 22, 23. In fact, the migration of immune cells into the liver appears to 
be one of the first critical steps in both acute and chronic liver inflammation, mediating 
innate and adaptive inflammatory responses, which result in ongoing immune cell 
recruitment, tissue damage, and fibrosis 23. 
As a second mechanism explaining the reduction of macrophage recruitment, we 
showed that exendin-4, via the GLP-1R, reduces the uptake of oxLDL by peritoneal 
macrophages and, as a consequence, reduced foam cell formation in vitro. These 
data are in full accordance with previous observations showing that native GLP-1 also 
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reduces oxLDL uptake by peritoneal macrophages thereby reducing atherosclerosis 
development from ApoE-/- mice 19. We did not observe any changes in plasma anti-oxLDL 
antibodies after exendin-4 treatment, indicating that exendin-4 probably does not 
affect the oxLDL levels in plasma. Since native GLP-1 decreased the macrophage protein 
levels of CD36 19, involved in the uptake of modified LDL, it is likely that in our study 
exendin-4 exerts its protective effects on macrophage foam cell formation by a similar 
mechanism. The relevance for oxLDL uptake via scavenger receptors by macrophages 
in atherosclerosis development has been confirmed by many studies 24. Recent 
studies have shown that oxLDL uptake via scavenger receptors is also an important 
risk factor for the progression to hepatic inflammation 15. In fact, inhibition of oxLDL 
uptake and thus foam cell formation by deficiency of the scavenger receptors CD36 
and scavenger receptor class A in hematopoietic cells reduces hepatic macrophage 
infiltration 25, confirming that oxLDL uptake by macrophages not only plays a vital role 
in atherosclerosis development but also regulates hepatic inflammation.
Figure 6. Proposed mechanism underlying the beneficial effects of exendin-4 on atherosclerosis 
development and NAsH. Exendin-4 attenuates the development of atherosclerosis and NASH by 1) 
reducing the expression of chemokines and adhesion molecules, which leads to less recruitment of 
circulating monocytes/macrophages, and 2) inhibiting the uptake of oxLDL by macrophages and the 
subsequent formation of foam cells in the vessel wall and liver, respectively. For further explanation see text. 
CR, chemokine receptor(s); ICAM, intercellular adhesion molecule-1; mФ, macrophage; MCP-1, monocyte 
chemotactic protein-1; oxLDL, oxidized LDL; SR, scavenger receptor; VCAM, vascular cell adhesion molecule-1.
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Collectively, we hypothesize that the protective effect of exendin-4 against 
inflammation in both the vessel wall and liver can be explained by (1) reducing 
monocyte/macrophage recruitment from the circulation and by (2) inhibiting the 
uptake of oxLDL by macrophages and the subsequent activation and formation of foam 
cells at these locations (see Fig. 6).
Interestingly, we also observed that exendin-4 decreased hepatic CETP gene 
expression (-34%, P<0.05) and plasma CETP concentration (-15%, P<0.01) (Supplemental 
Fig. S2). Recently, we demonstrated similar effects for niacin, which were explained 
by a reduction in macrophages that largely contribute to hepatic CETP expression 26. 
In our present study, hepatic CETP expression positively correlated with the hepatic 
expression of the macrophage markers CD68 (R2=0.332; P<0.001) and F4/80 (R2=0.607; 
P<0.001) (Supplemental Fig. S3), indicating that exendin-4 also reduces CETP expression 
by reducing the hepatic macrophage content. Since CETP is involved in the transfer of 
cholesteryl esters from HDL to (V)LDL, the reduction in CETP may have contributed 
to the slight decrease in (V)LDL/HDL ratio, and thereby to reduced atherosclerosis 
development. Taken together, these data suggest that reducing NASH in general, by 
reducing the macrophage content, may reduce CETP expression, thereby improving the 
lipoprotein profile and therefore decrease the risk of developing atherosclerosis.
Thus far, there is no established pharmacological compound to treat NASH. Lifestyle 
modifications, such as weight loss, exercise, and restriction of nutrition intake are still the 
mainstays for the treatment of NASH 27. Although lipid-lowering agents (e.g. statins and 
fibrates) and anti-oxidants (e.g. vitamins C, E) have beneficial effects on atherosclerosis 
development, none of them have shown adequate and convincing benefits in the 
treatment of NASH 28, 29. Exendin-4 has been approved for the treatment of T2DM 5 
and has also been shown to possess cardioprotective actions that include, in addition 
to reducing atherogenesis, suppression of arrhythmias, heart failure, myocardial 
infarction, and death 30. Based on our collective findings that exendin-4 reduces high fat 
diet-induced hepatic steatosis by decreasing lipogenesis 6 and suppresses macrophage 
content in both vessel wall and liver (in the current study), we propose that exendin-4 is 
a suitable candidate to concomitantly treat atherosclerosis and NASH. 
In conclusion, our findings show that exendin-4 treatment reduces inflammation 
in both the liver and vessel wall in E3L.CETP mice fed a Western-type diet, by 
reducing monocyte/macrophage recruitment and inhibiting the uptake of oxLDL by 
macrophages. We anticipate that exendin-4 can be used as a valuable strategy to treat 
NASH and atherosclerosis in addition to T2DM, especially in patients who display a 
combination of these diseases.
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supplemental Figure s2. exendin-4 decreases 
hepatic expression and plasma level of ceTP. 
After 5 weeks of feeding a Western-type diet 
containing 0.4% cholesterol, mice were treated 
with exendin-4 (50 µg/kg/day) or vehicle (PBS) 
subcutaneously for 4 weeks. mRNA was extracted 
from liver pieces, and mRNA expression of CETP (A) 
was determined as normalized to Cyclo and Hprt 
mRNA levels. Data were calculated as fold difference 
as compared to vehicle. Plasma CETP levels were 
determined (B). Values are means ± SEM (n=17 mice 
per group). *P<0.05, **P<0.01 compared to vehicle. 
supplemental Figure s3. Hepatic ceTP 
expression is positively correlated with hepatic 
cD68 and F4/80 expression. After 5 weeks of 
feeding a Western-type diet containing 0.4% 
cholesterol, E3L.CETP mice were treated with 
exendin-4 (50 µg/kg/day) or vehicle (Control) 
subcutaneously for 4 weeks. Subsequently, livers 
were isolated and mRNA was extracted from liver 
pieces. mRNA expression of Cd68, F4/80, and CETP 
was determined as normalized to Cyclo and Hprt 
mRNA levels. Data were calculated as fold difference 
as compared to vehicle and the correlation between 
hepatic CETP expression and hepatic CD68 (A) or 
F4/80 (B) expression was linearly plotted.
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The role of glucocorticoids in atherosclerosis development is not clearly established. 
Human studies show a clear association between glucocorticoid excess and 
cardiovascular disease, whereas most animal models indicate an inhibitory effect of 
glucocorticoids on atherosclerosis development. These animal models, however, neither 
reflect long-term glucocorticoid overexposure nor display human-like lipoprotein 
metabolism. To investigate the effects of transient and continuous glucocorticoid 
excess on atherosclerosis development in a mouse model with human-like lipoprotein 
metabolism upon feeding a Western-type diet. Pair-housed female APOE*3-Leiden.CETP 
(E3L.CETP) mice fed a Western-type containing 0.1% cholesterol for 20 weeks were given 
corticosterone (50 µg/ml) for either 5 (transient group) or 17 weeks (continuous group), 
or vehicle (control group) in the drinking water. At the end of the study, atherosclerosis 
severity, lesion area in the aortic root, the number of monocytes adhering to the 
endothelial wall and macrophage content of the plaque were measured. Corticosterone 
treatment increased body weight and food intake for the duration of the treatment and 
increased gonadal and subcutaneous white adipose tissue weight in transient group 
by +35% and +31%, and in the continuous group by +140% and 110%. Strikingly, both 
transient and continuous corticosterone treatment decreased total atherosclerotic 
lesion area by -39% without lowering plasma cholesterol levels. In addition, there was a 
decrease of -56% in macrophage content of the plaque with continuous corticosterone 
treatment, and a similar trend was present with the transient treatment. In conclusion, 
increased corticosterone exposure in mice with human-like lipoprotein metabolism 
has beneficial, long-lasting effects on atherosclerosis, but negatively affects body fat 
distribution by promoting fat accumulation in the long-term. This indicates that the 
increased atherosclerosis observed in humans in states of glucocorticoid excess may 




CORT INHIBITS ATHEROSCLEROSIS IN MICE
iNTroDUcTioN
Atherosclerosis develops as a result of a chronic inflammatory response in an injured 
vessel wall 1, which is preceded by accumulation of leukocytes and fat deposition, 
leading to plaque formation 2. The initial mechanisms in atherogenesis, however, are 
still incompletely understood. 
The role of glucocorticoids (GC) in the development of atherosclerosis is not yet 
clearly established in humans or in animals and is, at least, dependent on individual’s 3, 4 
or animal’s 5 exposure to appropriate levels of adrenal steroids. Human data show an 
association between increased GC secretion and cardiovascular disease even after 
long-term successful correction of GC excess 6, whereas previous studies in animals, e.g. 
rabbits 7-11 and dogs 12  using either natural or synthetic GC, suggest an atheroprotective 
role of GC. On the other hand, 11β-dehydrogenase type 2 (11βHSD2) deficient mice, 
in which the activation of the mineralocorticoid receptor (MR) by GCs cannot be 
prevented, have an increased atherosclerotic plaque development 13, suggesting that 
increased activation of the MR promotes atherosclerotic plaque formation. However, 
a recent study demonstrated that adrenalectomy, which removes endogenous GC, 
stimulated the formation of initial atherosclerotic lesions in low-density-lipoprotein 
receptor knockout mice 5.
Only a limited number of studies have evaluated the effect of endogenous GC 
excess on atherosclerosis development in mice. These studies, that used chronic 
stress to increase endogenous GC, reported either an increase 14, 15 or no effect 16 on 
atherosclerosis development in ApoE-deficient mice. However, chronic stress, in addition 
to increasing GC, induces other complex endocrine and metabolic changes, for instance 
increased sympathetic outflow 17 that may affect atherosclerosis development. These 
mouse models therefore do not reflect long-term endogenous GC overexposure, like 
in Cushing’s syndrome (CS) in humans. Furthermore, ApoE-deficient mice do not reflect 
human-like lipoprotein metabolism and have a deviant immune status compared to 
wild-type mice 18.
In the present study, our aim was to investigate the effects of GC excess on 
atherosclerosis development in the APOE*3-Leiden.CETP (E3L.CETP) mouse, a well-
established model for human-like lipoprotein metabolism that is prone to develop 
atherosclerosis upon feeding a cholesterol-containing Western-type diet 19 and is 
responsive to the hypolipidemic drugs used in the clinic similar to humans 20-23. The 
latter is in sheer contrast to other mouse models for hyperlipidemia and atherosclerosis 
including apoE-knockout and LDL receptor-knockout mice. We administered 
corticosterone (CORT) non-invasively via the drinking water, and based on the clinical 
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observation in CS patients, we investigated both transient and chronic effects of CORT 
on atherosclerosis development. 
mATeriALs AND meTHoDs
Ethics statement
This study was carried out in strict accordance with the regulations of Dutch law on 
animal welfare, and the institutional ethics committee for animal procedures of Leiden 
University. The protocol was approved by the institutional ethics committee for animal 
procedures of Leiden University (Permit Number: 10132 and for the pilot experiment: 
08221) and all efforts were made to minimize suffering.
Mice, housing, corticosterone supplementation, and diets
Human CETP expressing transgenic mice, which express CETP under control of its 
natural flanking regions, were crossbred in our own animal facility with E3L mice 
to obtain the heterozygous E3L.CETP mice on a C57Bl/6 background 24. Female mice 
(10-16 weeks of age) were pair housed and maintained on a 12 h:12 h light-dark cycle 
(lights on 7 a.m.) in a climate controlled environment, with ad libitum access to food and 
drinking water. Mice were fed a Western-type diet containing 0.1% cholesterol (Diet T 
+ 0.1% cholesterol, Arie Blok Diervoeding, Woerden, the Netherlands) for a period of 
three weeks after which they were matched for age, plasma cholesterol, triglycerides, 
phospholipids, age and bodyweight and then randomized to receive CORT (Sigma-
Aldrich, Manchester, UK) at a concentration of 50 μg/ml in the drinking water with 
0.25% ethanol as vehicle for five weeks (transient group, n=17), continuously for the 
entire duration of the experiment (seventeen weeks) (continuous group, n=21), or 
vehicle (control group, n=19). Food and bodyweight were recorded weekly. At the end 
of the experiment mice were decapitated within 90 seconds from disturbing the cage 
and trunk blood was collected. Gonadal and subcutaneous fat pads were removed from 
each mouse by the same person to reduce inter-observer variation. The same area of 
subcutaneous fat was removed from each mouse excluding the inguinal lymph node. 
Fat pads and adrenals were weighed using a micro scale, and frozen in liquid nitrogen.
Pilot experiment for the determination of optimal CORT dose
Prior to experiment, we performed a dose finding study in male C57Bl/6J mice fed HFD 
with 12.5 µg/ml (n=2), 25 µg/ml (n=4) and 50 µg/ml (n=2) of CORT, and control receiving 
0.25% ethanol (n=2) as vehicle for four weeks to determine the optimal CORT dose. 
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These dosages were chosen based upon a previous study 25 that documented profound 
metabolic effects with CORT 100 µg/ml and less pronounced effects with 25 µg/ml. 
Based upon our dose finding study, we chose 50 µg/ml CORT in the drinking water 
for our subsequent experiments as this dose led to the largest increases in food intake 
and body weight as well as in plasma cholesterol. Because male mice do not readily 
develop atherosclerosis and the known models are in majority female models, we used 
female mice for the purpose to study the atherosclerosis development. In males and 
females, this CORT dose was sufficient to increase food intake and to maintain a higher 
bodyweight throughout the experiment. In addition, circulating circadian CORT levels 
at week 5 were 5-8 fold increased in the morning and 3-4 fold in the evening (data not 
shown).
Sampling of circadian corticosterone, hormone, and lipid measurements
Plasma CORT was sampled before CORT administration (baseline), and after CORT 
administration at week 5 during the first light hour at 07.00 h, at 12.00 h, during the 
last light hour at 18.00 h, and three hours after the onset of the dark phase at 22.00 h. 
During the dark phase samples were collected in red light conditions. All CORT samples 
were obtained within 90 seconds from disturbing the cage, via tail incision, allowing the 
mouse to move freely on top of the home cage 26. Trunk blood was used to determine 
plasma CORT at the end of the experiment after CORT administration at week 17 at 
09.00 h and 18.00 h. Total plasma cholesterol, triglycerides, phospholipids, insulin and 
glucose were sampled after 4 hour-fast at baseline, week 5, 8 and 17 of the intervention. 
Body weight and food intake were measured weekly.
Plasma CORT levels were determined by radioimmunoassay (MP Biomedicals LCC, 
Orangeburg, NY). Plasma levels of total cholesterol, triglycerides and non-esterified 
free fatty acids were measured with enzymatic colorimetric reaction (Roche diagnostics 
GmbH, Mannheim; and Wako Pure Chemical Industries, respectively), plasma insulin was 
measured with an ELISA (Crystal Chem Inc., Downers Grove, IL, USA) and plasma glucose 
with a hexokinase method (Instruchemie, Delfzijl, The Netherlands). Homeostasis model 
index of insulin (HOMA-IR) was calculated by multiplying fasting insulin concentration 
(µU/ml) with fasting glucose (mmol/l), and dividing with 22.5 27. 
Lipoprotein profiling
Distribution of cholesterol over plasma lipoproteins was determined using fast protein 
liquid chromatography. Pooled plasma from each group were used and 50 μl of each 
pool was injected onto a Superpose 6 PC 3.2/30 column (Äkta System, Amersham 
Pharmacia Biotech, Piscataway, NJ) and eluted at a constant rate of 50 μl/min in PBS, 
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1 mM EDTA, pH 7.4. Fraction were collected and assayed for cholesterol as described 
above. 
Gene expression analysis in adipose tissue  
Total RNA was extracted from gonadal fat pads using the Nucleospin RNA II kit 
(Macherey-Nagel, Duren, Germany) according to manufacturer’s instructions. RNA 
quality of each sample was examined by the lab-on-a-chip method using Experion 
Std Sens analysis kit (Biorad, Hercules, CA) and RNA concentration of each sample was 
determined by Nanodrop technology (Thermo Scientific, Wilmington, USA). Then, total 
RNA was reverse-transcribed with iScript cDNA synthesis kit (1708891, Bio-Rad), and 
obtained cDNA was purified with Nucleospin Extract II kit (636973, Macherey-Nagel, 
Bioké). Real-time qPCR was performed on a CFX96 machine (Bio-Rad), the reaction 
mixture consisting of SYBR-Green Sensimix (QT615, GC Biotech), cDNA, primers 
(Biolegio, Nijmegen, The Netherlands), and nuclease-free water in a total reaction 
volume of 10 µl. mRNA values of each gene were normalized to mRNA levels of 
ß2-microglobulin (ß2m) and hypoxanthine ribosyltransferase (Hprt). Primer sequences 
are listed in supplementary table 1.
supplemental Table 1. Primer sequences used for rT-qPcr 
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Quantification of atherosclerosis
After 17 weeks of intervention, mice were killed by decapitation and the hearts were 
isolated. Hearts were fixed in phosphate-buffered 4% formaldehyde, dehydrated and 
embedded in paraffin. Cross-sections (5 μm) throughout the aortic root area were 
cut. 12 sections per mouse, stained with hematoxylin-phloxin-saffron for histological 
analysis, with 50 μm-intervals were used for atherosclerosis measurements. Lesions were 
categorized for severity according to the guidelines of the American Heart Association, 
adapted for mice 28, 29, as follows:  type 0 (no lesions), types 1 through 3 (early fatty 
streak-like lesions containing foam cells), and type 4 to 5 (advanced lesions containing 
foam cells in the media, presence of fibrosis, cholesterol clefts, mineralization, and/or 
necrosis). AIA 31240 antiserum (1:3000, Accurate Chemical and Scientific, Westbury, NY) 
was used to quantify macrophage content of the plaque as well as monocytes adhering 
to the endothelium. Lesion area, the macrophage area and the number of monocytes 
adhering to the endothelium were quantified using Image J software (National Institutes 
of Health).
Serum macrophage colony-stimulating factor (M-CSF) and anti-oxidized 
low-density lipoprotein (ox-LDL) antibodies measurements
Macrophage colony-stimulating factor (M-CSF) was measured using a mouse M-CSF 
Quantikine ELISA kit according to the manufacturer’s instructions (MMC00, R&D Systems 
Inc, Germany). An EIA/RIA high binding 96-well Costar plate (Corning Inc., Corning, NY, 
USA) was coated with ox-LDL (7.5 µg/mL) in PBS. IgM and IgG2a antibodies against 
oxLDL in serum were measured using an ELISA Ig detection kit (Zymed Laboratories, 
San Francisco, CA, USA) according to the manufacturer’s protocol.
Statistical analysis
Data are presented as means ±  SEM. Statistical differences were calculated using 
Anova with Tukey’s post-hoc test, for multiple comparisons, except for plasma CORT 
measurements transient and continuous groups were compared with the control group 
individually per time point using an unpaired two tailed t-test, with GraphPad Prism, 




CORT treatment increases plasma CORT concentrations and affects 
circadian rhythm 
Chronic administration of high doses of CORT in the drinking water (50 µg/ml) resulted 
in significant increases in plasma CORT levels at week 5 (Fig. 1B) in both groups, 
compared to controls (transient group: 07.00 h 8-fold, 12.00 h 3-fold, 18.00 h 1-fold 
and 22.00 h 4-fold; continuous group: 07.00 h 5-fold, 12.00 h 4-fold, 18.00 h 1-fold and 
22.00 h 3-fold). At week 17 (Fig. 1C) there were no differences between groups at 09.00 
h and 18.00 h. At the end of the experiment, thymus weight (Fig. 1D) was not different 
between the three groups but adrenal weight (Fig. 1E) was significantly reduced in the 
continuously exposed group by -50%, in agreement with adrenal atrophy secondary to 
long-term exogenous GC exposure.
Figure 1. effect of transient and continuous corT treatment on circadian plasma corT levels in 
female E3L.CETP mice at baseline (A), week 5 (B) and week 17 (c), as well as on thymus weight (D) and 
adrenal weight (e) at week 17 (Control group: white bars, transient group: grey bars and continuous group: 
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CORT treatment affects food intake and bodyweight and induces long-
lasting changes in body composition and inflammation in adipose 
tissue 
As expected, CORT treatment increased food intake of the transient and the continuous 
group during the first three weeks of the experiment after which the transient group 
returned to the level of the controls and food intake with continuous treatment 
remained elevated (Fig. 2A). This increase was accompanied by an increase in body 
weight (Fig. 2B) in both groups. After the discontinuation of CORT treatment, body 
weight decreased to the level of the controls. The continuously exposed group showed 
a continuous increase in body weight and maintained a higher body weight to the end 
of the experiment (Fig. 2B) compared to the other two groups. After 17 weeks, gonadal 
and subcutaneous fat pad weights (Fig. 2C and D), when compared to controls, were 
significantly increased by +35% and +31%, respectively, in the transient group, and by 
+140% and +110% in the continuous group. To evaluate whether the increased fat mass 
resulted in changes of inflammation in the fat pad, the mRNA expression of markers of 
the macrophage content (i.e. F4/80 and Cd68) and proinflammatory cytokines [Tumor 
necrosis factor α (Tnfα) and Interleukin-6 (Il-6)] in the gonadal fat pad were determined. 
As compared to control group, transient administration of CORT did not affect the 
expression of F4/80 (Fig. 2E) and CD68 (Fig. 2F), but decreased the expression levels of 
Tnfα (Fig. 2G) and Il-6 (Fig. 2H) in the long-term by -32% and -47%, respectively; while 
continuous administration of CORT increased the expression of F4/80 (Fig. 2E) and CD68 
(Fig. 2F) by +58% and +70%, respectively, decreased the expression of Tnfα (Fig. 2G) by 
-26% and did not affect the expression of Il-6 (Fig. 2H). These data indicate although 
excess GC exposure increased fat mass which was accompanied with an increase in 
macrophage content, expression of proinflammatory cytokines in the adipose tissue 
was generally reduced. 
CORT treatment does not affect plasma lipids, cholesterol lipoprotein 
profile, but increases plasma insulin and HOMA-IR
Although both transient and continuous administration of CORT increased food intake 
to a certain extent, CORT treatment did not increase plasma levels of total cholesterol, 
triglycerides or phospholipids during the experimental period of 17 weeks (Table 1). 
Moreover, there were no differences between groups in the distribution of cholesterol 
over lipoproteins (Fig. 3A-C). Plasma levels of insulin and HOMA-IR, but not plasma 
glucose levels, were increased (Fig. 3 D-F) in the continuous group at week 17, reflecting 
GC-induced insulin resistance. 
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Figure 2. effect of transient and continuous corT treatment on food intake (A), body weight (B) (Control 
group: white circles, transient group: grey squares and continuous group: black triangles), gonadal fat (c) 
and subcutaneous fat (D) as % of the body weight, mrNA expression of F4/80 (e), CD68 (F), Tnfα (G) and 
Il-6 (H) in the gonadal fat (Control group: white bars, transient group: grey bars and continuous group: black 
bars). Data are means ±SEM (n=17-21), Anova with Tukey’s post-hoc test, *, #P<0.05, **, ##P<0.01, ***, ###P<0.001, 
*versus control group and #versus transient group.
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Table 1. effect of corT treatment on fasting plasma lipids.
Total cholesterol (mmol/l) Triglycerides (mmol/l) Phospholipids (mmol/l)
week Control Transient Continuous Control Transient Continuous Control Transient Continuous
0 10.0±1.5 10.2±2.3 10.2±2.1 3.9±1.1 4.3±1.1 4.1±1.4 3.6±0.4 3.7±0.6 3.5±0.6
5 13.2±1.8 14.0±5.2 14.8±4.2 4.6±1.6 4.8±2.3 4.5±1.6 4.5±0.6 4.5±1.1 4.6±1.0
8 13.4±2.0 13.7±3.9 12.4±4.3 3.8±1.5 4.0±1.7 4.2±0.9 4.5±0.5 4.6±0.8 4.2±0.9
17 12.4±2.8 10.2±3.2 10.0±3.0 3.2±1.4 3.3±1.0 2.9±0.5 3.8±0.9 3.4±0.9 3.4±0.7
Data are means ± SEM (n=17-21), Anova with Tukey’s post-hoc test. 
Figure 3. effect of transient and continuous corT treatment on cholesterol distribution over 
lipoproteins fractioned by FPLc at baseline (A), week 5 (B) and 17 (c) (Control group: white circles, 
transient group: grey squares and continuous group: black triangles) and on plasma insulin (D), plasma 
glucose (e), HomA-ir (F) on week 17 (Control group: white bars, transient group: grey bars and continuous 
group: black bars). Data are means ± SEM (n=17-21), Anova with Tukey’s post-hoc test, **, ###P<0.001, *versus 
control group and #versus transient group.
Transient and continuous CORT treatment decrease atherosclerosis 
lesion area to a similar extent 
Remarkably, CORT treatment decreased total atherosclerotic lesion area equivalently 
in both transiently (-39%) and continuously (-39%) treated groups (Fig. 4A and B). 
Moreover, both transient and continuous groups showed similar trends towards a less 
severe lesion phenotype as compared to the control group (Fig. 4C), suggesting that 
CORT treatment reduces atherosclerosis development in a long-lasting manner. CORT 
treatment, neither transiently nor continuously, affected the number of monocytes 
adhering to endothelium wall (Fig. 4D and E), yet continuous administration of CORT 
did reduce the macrophage content (-56%) of the plaque (Fig. 4D and F) as well as the 
macrophage content as percentage of the total plaque area (-52%) (Fig. 4G). 
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Figure 4. effect of transient and continuous corT treatment on atherosclerosis development: 
representative HPs-stained pictures of lesions (A), lesion area (B), lesion type as % of the total lesion 
(c), representative pictures of monocyte/macrophage staining (adhering monocytes shown by arrows) 
(D), adhering monocytes per segment (e), macrophage content of the plaque (F) and macrophages 
as % of the lesion area (G). Serum anti-ox-LDL specific antibodies (H) and serum M-CSF (I) were measured 
on week 17.  (Control group: white bars, transient group: grey bars and continuous group: black bars). Data 
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A reduction of the macrophage content of the plaque (-27%, P=0.125) and percentage 
macrophages in total plaque area (-27%, P=0.145) was observed in the transient 
group and but these reductions failed to reach statistical significance (Fig. 4F and G). 
Since uptake of oxidized LDL (ox-LDL) by macrophages to become foam cell plays an 
important role in the development and progression of atherosclerosis, we measured 
specific antibodies against ox-LDL in the circulation. As compared to control group, 
CORT treatment, neither transiently nor continuously, influenced the ox-LDL specific 
IgG2a and IgM level, indicating that CORT probably does not affect the ox-LDL level in 
circulation (Fig. 4H). Because macrophage proliferation and differentiation was shown 
to be linked to the atherosclerotic process 1, an essential factor regulating macrophage 
growth, macrophage colony stimulation factor (M-CSF) 30 was measured at the end of 
this experiment. However, no differences in the serum levels of M-CSF were detected 
among groups (Fig. 4I)    
DiscUssioN
This study demonstrates for the first time that CORT treatment resulting in increased 
plasma CORT concentrations decreases atherosclerotic plaque formation in mice 
with human-like lipoprotein metabolism, without affecting either plasma lipid levels 
or lipoprotein profiles. Interestingly, inhibition of atherogenesis was found both in 
transiently and continuously exposed animals, whereas continuous treatment with 
CORT also decreased macrophage content of the plaque despite the normalization 
of the body weight. In addition, CORT treatment resulted in long-lasting changes in 
body fat content, which were still present even 12 weeks after abrogation of CORT. This 
indicates that increased CORT exposure per se has beneficial, long-lasting effects on 
atherosclerosis, but negatively affects body fat distribution and insulin sensitivity, by 
promoting fat accumulation in the long-term.  
The concentration of glucocorticoids (GCs) attained in our experiments is higher 
than under stress state but well comparable to patients with severe Cushing’s syndrome, 
where cortisol secretion was 7 times higher that in healthy controls and circulation 
cortisol concentrations was 3-5 times higher 31. 
Increased plasma CORT levels were easily induced non-invasively using CORT in the 
drinking water. CORT affected circadian GC rhythm by reducing the degree of variation 
in plasma concentrations. The human clinical equivalent of chronic hypercortisolemia, 
Cushing’s syndrome (CS), is characterized by a blunted or even complete loss of diurnal 
rhythm 3. In our model we re-capitulate some of these key temporal aspects of CS: 
although a chronic high circulating cortisol levels is a key aspect of CS, the most reliable 
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measure for diagnosis is very high late night (i.e. 22:00 –24:00 h) plasma cortisol 3. 
Our high- CORT animals parallel these aspects of the syndrome, with both high 
baseline levels of CORT (200 ng/ml), as well as a peak in CORT at the end of the night 
(rather than at the beginning). Moreover, the continuously exposed group displayed 
reduced adrenal sizes, in agreement with adrenal atrophy, secondary to the long-term 
exogenous CORT administration despite normal plasma CORT levels found at the end of 
the experiment. This might be explained by increased metabolism of CORT as well as by 
other pharmacokinetic adaptations like increased clearance and increased distribution 
volume as a result of increased adipose tissue. 
Plasma lipid levels were not affected by transient nor continuous CORT treatment. 
This is interesting particularly in the case of plasma values of total cholesterol, VLDL-
cholesterol and VLDL-triglycerides since these are well known risk factors for the 
development of atherosclerosis. In fact, cholesterol exposure generally is a good 
predictor of atherosclerosis development in E3L.CETP mice (Princen and Rensen, 
unpublished observations). Moreover, CORT exposure did not affect lipoprotein 
profiles. In previous studies, mice were subjected to chronic stress, which causes a 
complex of endocrine changes, including high CORT levels. These studies have reported 
inconsistent effects on plasma cholesterol levels, which were increased 15, decreased 16, 
or not reported 14. These studies used ApoE-deficient mice in which the ApoE- deficiency 
causes severe accumulation of cholesterol in macrophages resulting in a high pro-
inflammatory state, which could explain the differences observed in atherosclerosis 
development between our low grade inflammation model of E3L.CETP mice fed a low 
amount of dietary cholesterol (twice human daily intake) 32, 33. In addition, the use of 
chronic stress to increase endogenous GCs in previous models will also induce other 
complex endocrine and metabolic changes 17 that may also affect atherosclerosis 
development. Humans with high GCs also have inconsistent cholesterol levels. In the 
literature, the prevalence of hyperlipidemia in patients with CS varies from 38% to 71% 34. 
A study by Mancini et al. (2004) has shown that hyperlipidemia occurs less frequently 
than the other metabolic complications of CS and that it was not correlated to the 
degree of hypercortisolism or duration of the disease 35. However, the causative role of 
cortisol excess for hyperlipidemia has not been extensively described in the literature 
and the findings are, like the animal data, controversial. In some study populations, the 
prevalence of hypertriglyceridemia was even lower than in BMI-matched controls 36. 
Intriguingly, CORT treatment reduced atherosclerotic lesion area, and tended to 
decrease lesion severity, to a similar extent in transiently vs continuously exposed mice. 
This suggests that GCs are able to induce long-term effects in the preliminary processes 
of atherosclerotic plaque formation. It is tempting to speculate on possible underlying 
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mechanistic explanations for this phenomenon. One possibility is the induction by 
increased GC exposure of epigenetic mechanisms, like chromatin remodeling and 
histone modifications 37. These alterations have been demonstrated in the context of 
chronic CORT 38, and may lead to long lasting suppression of or changes in macrophage 
function. Extensive documentation supports a crucial role for macrophages in the 
initiation of atherosclerosis by entering the vessel wall, taking up oxidized LDL 
(ox-LDL) 1, 2 and transforming into foam cells that produce a variety of cytokines further 
driving the process of the plaque formation, as well as macrophage proliferation and 
differentiation 39, 40. In the present study, transient and continuous CORT treatment did 
not affect the plasma ox-LDL level, albeit that continuous CORT treatment significantly 
reduced the macrophage content of the plaque, and a similar trend was also observed 
in the transiently exposed group. GCs were shown to decrease the development of 
atherosclerosis by reducing the monocyte recruitment 41-43, macrophage foam cell 
formation 44, macrophage growth, as well as macrophage inflammatory action to 
produce pro-inflammatory cytokines 45.  In this study, no differences were observed in the 
number of monocytes adhering to endothelium between the groups. It is plausible that 
GCs excess inhibits macrophage growth instead of monocyte recruitment as GCs inhibit 
macrophage colony stimulating factor (M-CSF)-induced macrophage differentiation 
in vitro 45. Although, we did not detect any differences in serum M-CSF level between 
groups, it should be realized that M-CSF is a general marker for macrophage growth, 
and the systemic concentration in plasma may not reflect the local macrophage growth 
in the vessel. Additionally, GCs can also inhibit macrophage growth by suppressing the 
granulocyte/macrophage colony-stimulating factor (GM-CSF) production in isolated 
macrophages 46, confirming that GCs might target the macrophage, the major cellular 
CORT target, thereby attenuating macrophage proliferation and differentiation, and 
thus inhibiting atherosclerotic plaque formation. 
In humans, increased GC exposure, like in patients with CS, is associated with the 
metabolic syndrome and cardiovascular disease, even after long-term successful 
correction of GC excess 6, 47, 48. Carotid intima media thickness (IMT) is increased and 
vessel wall plaques are more common in patients with CS 36, 49, 50. Indeed, CS patients 
have abnormal fat distribution and suffer from disturbed coagulation and osteoporosis. 
Although, it is documented that bone mineral density fully recovers after normalization of 
cortisol levels, other features, like the adverse metabolic profile and the hypercoagulable 
state, do not completely resolve 51, 52. The causal relation, however, between the episode 
of cortisol overexposure and long-term changes in the development of cardiovascular 
diseases is not established and is difficult to assess in humans because of the rarity 
and heterogeneity of CS. In agreement, in our mouse model CORT also stimulated 
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the development of other components of the metabolic syndrome. We observed 
that CORT increased food intake, body weight, insulin concentrations, and altered 
body composition. High CORT levels are known to stimulate voluntary food intake 
dose-dependently 53-55. GCs are also known to induce insulin resistance 48. Moreover, 
insulin and CORT synergistically promote redistribution of energy storage in favor of 
increased fat tissue 56. The changes in body weight were accompanied by a significant 
increase in both gonadal and subcutaneous fat mass in continuous group and, 
remarkably after 12 weeks of wash out, in transiently exposed group as well. Chronically 
administered GC facilitates an increase of fat mass in mice 25, 57. In humans, increased 
exposure to cortisol (being either endogenous CS or exogenous corticosteroids) 
induces increased total body fat 58, and is specifically characterized by a redistribution 
of adipose tissue from peripheral to central sites of the body, mainly in the truncal 
region and visceral depots 59. This is accompanied by a greater than two-fold increased 
risk in insulin resistance/diabetes, hypertension, and hyperlipidemia 39. In the human 
equivalent of severe chronic stress, CS, the prevalence of the metabolic syndrome is 
increased 47, 48, and intriguingly, after remission, these patients still have increased waist 
circumference 36, 60 and higher visceral fat mass without an effect on the body mass 
index 61, and their cardiovascular risk remains increased. 
Adipose tissue macrophages are the primary source of the proinflammatory 
cytokines, and the macrophage content of adipose tissue has been shown to correlate 
positively with adiposity 62. In the present study, although excess GC exposure increased 
fat mass and induced obesity which was accompanied with an increase in macrophage 
content, inflammation in the adipose tissue was not elevated. Moreover, after abrogation 
of CORT treatment, the macrophage content in the adipose tissue was normalized and 
the reduction of inflammation was persisted in the long-term despite of the presence of 
a persistent increase in fat mass. CORT treatment induces prolonged, complex changes 
in the adipose tissue that reflect both the adverse metabolic effects of glucocorticoids by 
increasing the adiposity, and the anti-inflammatory capacity by reducing the expression 
of the proinflammatory molecules in the macrophages. Therefore, we cannot exclude 
that the protective effects of CORT treatment on atherosclerosis development can, at 
least partly, be explained by decreased release of cytokines from adipose tissue. It is well 
possible that at high dose, the anti-inflammatory effects of GCs attenuate potentially 
adverse metabolic influences. In clinical practice, this means that GC schemes as used 
for anti-inflammatory indications might benefit from adjustments towards a higher 
dose for a shorter period of time (or even as a few ‘high dose ‘pulses’ as is used in clinical 
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In conclusion, increased CORT exposure in mice with a human like lipoprotein 
metabolism has beneficial, long-lasting effects on atherosclerosis, despite negatively 
affecting body fat distribution and insulin sensitivity by promoting fat accumulation in 
the long term. This indicates that the increased atherosclerosis observed in the human 
in states of GC excess may not be related to cortisol per se, but may be the result of 
complex effects of cortisol on the endothelium and/or coagulation. The effects of GC 
excess, therefore, are multiple, and dependent on many factors, but above all, may 
irreversibly affect many pathophysiological processes, thereby influencing long-term 
cardiovascular risk.
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Cardiovascular disease (CVD), which is mainly due to atherosclerosis, is currently the 
leading cause of death in the Western world 1. One of the most important risk factors 
for atherosclerosis is dyslipidemia, hallmarked by increased plasma levels of (V)LDL-
cholesterol (C) and triglycerides (TG), and decreased plasma levels of HDL-C. Lipid-
lowering agents (especially statins) improve dyslipidemia and have proven to reduce 
major cardiovascular events 2, 3. However, since these drugs only partially improve 
the mortality and morbidity due to CVD, other drug targets to combat CVD are being 
explored. Since HDL-C is inversely correlated with cardiovascular risk 4, novel strategies 
to raise HDL-C levels are currently under development, aiming at further reduction of 
atherosclerosis. Because the cholesteryl ester transfer protein (CETP) plays a pivotal 
role in HDL-C metabolism 5, CETP has become one of the most important targets for 
development of HDL-raising strategies.
Another risk factor for CVD is non-alcoholic steatohepatitis (NASH), characterized by 
accumulation of triglycerides and immune cells including macrophages in the liver. The 
prevalence of NASH is increasing steadily 6. In contrast to atherosclerosis, no established 
pharmacological agents have been identified thus far to treat NASH. Lifestyle 
modifications, such as weight loss, exercise, and restriction of nutrient intake, are still 
the mainstays for the treatment of NASH 7. Additionally, the non-invasive diagnosis for 
NASH is cumbersome in routine clinical practice, and no easily accessible biomarker with 
sufficient sensitivity and specificity is available to detect increased hepatic macrophage 
content, a hallmark of NASH. 
The studies described in this thesis 1) demonstrated the cellular origin of CETP 
expression and its implications for NASH and CVD, 2) elucidated the effects of 
pharmacological and dietary lipid-lowering interventions on plasma CETP levels, 3) 
investigated a novel target for treatment of atherosclerosis and NASH, and 4) evaluated 
the role of the brain in peripheral TG metabolism. 
The cellular origin of CETP, and its implications for NASH and CVD
Previous studies have demonstrated that CETP mRNA is abundantly expressed in adipose 
tissue and liver of several mammalian species, including human, monkey, rabbit, pig 
and hamster 8. In addition, CETP is expressed to a lower extent in the spleen, heart, small 
intestine, adrenal gland, and skeletal muscle 9-12. A small human cohort study suggested 
that CETP expression in adipose tissue correlates with plasma CETP concentration 13. 
In chapter 6, our data showed much more prominent CETP expression in the liver as 
compared to adipose tissue. In addition, we observed no association between central 
obesity measured as waist circumference and plasma CETP level in a large cohort of the 
general population (n~1,500), implying that central adipose tissue does not correlate 
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with plasma CETP concentration. Rather, by analyzing liver biopsies from obese patients 
undergoing bariatric surgery, we found that plasma CETP concentration was strongly 
correlated with CETP expression in the liver but not with that in the adipose tissue, 
indicating that liver is the main site of CETP expression and is a determinant of the total 
plasma CETP pool in humans. Few studies suggested that changes in the degree of 
adiposity induced by body weight reduction reduced CETP expression and improved 
lipoprotein metabolism 14, 15. However, we (chapter 4) and others 16 showed that body 
weight reduction, in addition to reducing adiposity, significantly reduced hepatic lipid 
content and attenuated hepatosteatosis. Moreover, we also showed in this thesis that 
a decrease in hepatic lipid content was accompanied by a decrease in plasma CETP 
level (chapter 3 and 4). It is thus tempting to speculate that bodyweight reduction via 
attenuation of hepatosteatosis reduces the production of CETP by the liver, and via this 
mechanism reduces plasma CETP concentration. 
The liver consists of multiple cell types including hepatocytes and non-parenchymal 
cells such as endothelial cells and macrophages (i.e. Kupffer cells). Therefore, we set out 
to evaluate the cell type responsible for the hepatic expression of CETP. In this thesis, we 
demonstrated that the expression of established macrophage markers (e.g. Cd68, Abcg1 
and Marco) in the liver strongly correlated with the hepatic expression of CETP both in 
human CETP transgenic (Tg) mice (chapter 5) and in humans (chapter 6). Moreover, 
CETP appeared to be specifically co-localized with F480+ macrophages in the mouse 
liver and with CD68+ macrophages in the human liver (chapter 6). Mechanistic studies 
in APOE*3-Leiden.CETP (E3L.CETP) mice showed that depletion of macrophages from 
liver following administration of clodronate liposomes virtually abolished hepatic CETP 
expression and largely reduced plasma CETP level, fully corroborating our findings in 
humans that hepatic macrophages, rather than hepatocytes, are the main cellular origin 
of hepatic CETP expression and the plasma CETP pool.
Previously, hepatic expression of CETP has been attributed to both macrophages 
and hepatocytes. This dogma was mainly derived from studies assessing hepatic CETP 
expression 8 weeks after transplantation of bone marrow from wild-type (WT) 
littermates into human CETP Tg mice and vice versa, suggesting that hepatic 
macrophages contribute ~50% to total hepatic CETP expression 17. However, it should 
be realized that the turnover of liver macrophages after bone marrow transplantation 
occurs slowly. In the same study, it was found that only 50% of Kupffer cells were 
replaced by the donor cells 8 weeks after bone marrow transplantation, accompanied 
by 50% reduction in plasma CETP as well as 2-fold lower hepatic CETP expression in 
WT   CETP Tg mice as compared to control transplanted CETP Tg   CETP Tg mice 17. 
Interestingly, we found hepatic CETP expression to be decreased by approximately 
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-90% at 12 weeks after transplantation when more Kupffer cells had been replaced 
(Berbée et al. unpublished), again confirming that hepatic macrophages are the main 
predominant source of CETP expression. 
 In contrast to the liver (i.e. Kupffer cells), we could hardly detect CETP expression 
in extrahepatic macrophage-rich organs, including adipose tissue and spleen, or in 
isolated peritoneal macrophages. It has been reported that that CETP gene promoter 
contains a liver X receptor α (LXRα) responsive element 10, and CETP expression is 
regulated by the activation of LXRα 18, which is highly expressed in multiple organs. 
Recently, Gautier et al. 19 reported that hepatic CETP expression is also upregulated by 
activation of the farnesoid X receptor (FXR), for which bile acids are the natural ligands. 
In addition to an LXRα responsive element in the CETP gene promoter, the CETP gene 
was shown to contain an ER8 FXR response element in its first intron. Since FXR is highly 
expressed in the liver and its natural ligand bile acids are produced by hepatocytes, the 
specific liver environment may be essential for maintaining high expression of CETP in 
hepatic versus extrahepatic macrophages. Although treatment of CETP Tg mice with 
both LXR agonists 18 and FXR agonists 19 induces CETP expression in the liver, the leading 
regulator for CETP expression in hepatic macrophages in vivo is still unknown yet, which 
should be investigated by future studies. 
Our findings that whole body CETP expression is predominantly derived from hepatic 
macrophages reveal that plasma CETP may be a biomarker for hepatic macrophage 
content, a hallmark of NASH. NASH is characterized by accumulation of fat (steatosis) in 
combination with inflammation (e.g. infiltrated macrophages) in the liver 20. Although 
several imaging modalities have been advocated as non-invasive diagnostic method for 
liver steatosis, they are insufficient to distinguish NASH from simple non-inflammatory 
fatty liver disease (NAFLD). Liver biopsies are currently the golden standard methods for 
the diagnosis of NASH. However, there are several severe limitations to liver biopsies, 
such as sampling error, differences in histopathologic interpretation, as well as patient 
stress and discomfort, risk of bleeding and long hospitalizations. In this thesis, we 
showed that hepatic macrophages are the main cellular origin of the plasma CETP 
pool (chapter 6), and that the plasma CETP level significantly correlates with hepatic 
macrophage content in CETP Tg mice (chapter 5). More importantly, treatment of 
E3L.CETP mice with niacin (chapter 5) and exendin-4 (chapter 10) reduces hepatic 
macrophage content accompanied with the reduction in plasma CETP level. Taken 
together, these data suggest that measurement of the plasma CETP concentration can 
be developed as a diagnostic and predictive test for the hepatic macrophage content in 
clinical practice, which should be tested in large population cohorts. 
In addition, our findings that CETP expression in the hepatic macrophages 
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determines the plasma CETP level as well as the metabolism of plasma lipoproteins 
sheds new light on the development of new strategies involving CETP inhibition for the 
treatment of dyslipidemia and CVD. Although a past CETP inhibitor (i.e. torceptrapib) 
and current CETP inhibitors (e.g. dalcetrapib, anacetrapib, evacetrapib) convincingly 
demonstrate HDL-raising effects, they show uncertain results for the treatment of CVD. 
For example, although torcetrapib 21 and dalcetrapib 22 increase the plasma HDL-C level 
effectively, both of them failed to reduce CVD outcome in trials. Torcetrapib even caused 
a marked increase in deaths 21, and dalcetrapib had no beneficial effects on carotid 
artery wall index, endothelial function or CVD outcomes 23-25. Although the precise 
mechanism(s) by which torcetrapib and dalcetrapib inhibit CETP activity is not known, 
these CETP inhibitors directly act on the plasma CETP protein and induce tight binding 
of CETP to HDL particles 26. However, the tight binding of CETP with HDL particles might 
compromise the function of HDL to generate large CE-rich HDL particles instead of 
small HDL particles and nascent discoidal HDL, as observed with torcetrapib 27.
The development of CETP inhibitors to raise HDL-C is based on epidemiological 
studies showing a strong inverse correlation of HDL-C level with CVD risk 4. The classical 
“HDL cholesterol hypothesis” predicted that interventions to raise the HDL-C level will 
result in reduction of CVD risk. However, recent studies showed that HDL functionality 
perhaps is a more important consideration than the circulating HDL-C level for the 
treatment of CVD. Indeed, the reverse cholesterol transport capacity of HDL has been 
shown a much better predictor of CVD than the concentration of HDL-C 28, 29. Therefore, 
within the field of HDL-targeting therapeutics a gradual transition takes places from 
the simple “HDL cholesterol hypothesis” to the “HDL functionality hypothesis” aimed at 
increasing the HDL particle number and improving HDL functionality for the treatment 
of CVD 28-30. Based on this perspective, to avoid potentially adverse effects of the current 
CETP inhibitors on the function of HDL, strategies focusing on inhibiting CETP synthesis 
at its cellular origin may be a promising alternative. 
Regulation of plasma CETP by pharmacological and dietary lipid-
lowering interventions
Previously, we have shown that several classical lipid-lowering drugs including statins 31, 
fibrates 32 and niacin 33, increase the plasma level of HDL-C in addition to decreasing the 
plasma level of (V)LDL-C and TG by reducing hepatic CETP expression and decreasing 
plasma CETP activity in preclinical studies using E3L.CETP transgenic mice. In this thesis, 
we again demonstrated in chapter 6 that fenofibrate and niacin raise the HDL-C level 
accompanied by reduced hepatic CETP expression and plasma CETP level in E3L.CETP 
mice. In line with those classical lipid lowering drugs, in chapter 10 we observed that 
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exendin-4, a glucagon like peptide-1 (GLP-1) receptor agonist that was approved in 
2005 for the treatment of T2DM, decreased plasma VLDL-C and increased HDL-C also 
accompanied with decreased hepatic CETP expression as well as plasma CETP level 
in E3L.CETP mice. Moreover, in chapter 3, we found that although both pioglitazone 
(PPARγ agonists) and metformin decreased plasma TG and apoB level equivalently, only 
pioglitazone significantly increased the plasma HDL-C level associated with a reduction 
in hepatic triglyceride and plasma CETP level in patients with type 2 diabetes mellitus 
(T2DM). In addition to pharmacological interventions, in chapter 4, prolonged caloric 
restriction markedly decreased the plasma CETP level and increased the plasma apoAI 
level in obese patients with T2DM. These collective results from human studies are in 
full accordance with the findings in E3L.CETP mice, suggesting that reduction of (liver-
derived) CETP plays an important role in the HDL-raising effects of both pharmacological 
and dietary lipid-lowering interventions.
Although accumulating evidence indicates that lipid-lowering interventions exert 
HDL-raising capacity by reducing the plasma CETP level, the mechanisms underlying 
the CETP-reducing effects of those lipid-lowering interventions has thus far not been 
delineated. In chapter 6, we demonstrated that hepatic macrophages are the main 
cellular origin of CETP expression, and that CETP expression in hepatic macrophages 
determines the plasma CETP level and modulates plasma lipoprotein metabolism. Thus, 
in chapter 5, we set out to investigate the role of hepatic macrophages in the CETP-
lowering effect of niacin. Interestingly, our observations in vitro showed that niacin at 
various concentrations did not reduce CETP expression in cultured macrophages derived 
from CETP Tg mice, indicating that niacin does not directly regulate the CETP expression 
per se in macrophages. Rather, we observed that niacin reduced the hepatic cholesterol 
content in vivo. More importantly, in line with attenuated liver cholesterol accumulation, 
we observed that niacin decreased hepatic mRNA expression of macrophage markers 
(e.g. Cd68 and Abcg1) and the number of F4/80+ macrophages, as well as the hepatic 
expression of CETP. In fact, hepatic macrophage markers showed a high correlation 
and association with hepatic CETP expression. These data suggest that the reduction of 
hepatic CETP expression induced by niacin treatment is a direct consequence of reduced 
macrophage content in the liver. In addition to niacin, we demonstrated in E3L.CETP 
mice that fenofibrate (chapter 6) and exendin-4 (chapter 10) also reduce the hepatic 
lipid content and decreased the hepatic macrophage content thereby decreasing the 
hepatic expression and plasma level of CETP. 
In humans, we are able to measure hepatic TG content by proton (1H) magnetic 
resonance spectroscopy, although it is currently impossible to assess the hepatic 
macrophage content noninvasively. We observed that both pioglitazone (chapter 3) 
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and prolonged caloric restriction (chapter 4) decreased the plasma CETP level 
accompanied with a decrease in hepatic TG content in patients with T2DM. It has 
been reported that the reduction of hepatic TG content induced by e.g. weight loss is 
associated with a decrease in hepatic inflammation 34, and that the histological severity 
of inflammation is correlated with the number of CD68+ macrophages in patients 
with NASH 35. It is thus tempting to speculate that both pioglitazone (chapter 3) and 
prolonged caloric restriction (chapter 4) decrease not only the hepatic lipid content 
but also hepatic macrophage content in humans, thereby reducing hepatic expression 
and plasma level of CETP. This hypothesis needs to be evaluated in future studies, for 
which the assessment of macrophage number in the liver will ultimately be required. 
As summarized in Figure 1, we propose the current mechanism how lipid-lowering 
interventions reduce hepatic CETP expression and plasma CETP level. Albeit through 
different actions, they all reduce hepatic lipid content (i.e. TG and cholesterol). This 
reduction in hepatic lipid content subsequently attenuates hepatic inflammation, 
which leads to less macrophage infiltration into and/or increased macrophage efflux/
emigration out of the liver. Since liver macrophages are the main cellular origin of CETP 
expression, the decreased number of hepatic macrophages leads to an overall reduction 
in hepatic CETP expression, and, consequently, the plasma CETP level. Therefore, these 
lipid-lowering interventions induce a less atherogenic lipid phenotype, e.g. decreasing 
(V)LDL-C and TG, and increasing HDL-C.  
Novel strategies for treatment of atherosclerosis and NASH
Given the fact that current strategies are insufficient to reduce CVD and no established 
pharmacological agents have shown adequate and convincing benefits in NASH 
outcomes, novel strategies for the treatment of those two diseases are eagerly warranted 
and under development. Emerging evidence indicates that gut hormones regulating 
energy homeostasis and food intake, could also beneficially affect lipid metabolism, 
thus have the potential to treat atherosclerosis and fatty liver disease. Glucagon like 
peptide-1 (GLP-1) is one of those incretin hormones produced by intestinal L-cells and 
the brain 36, 37, and released in response to food intake to stimulate glucose-dependent 
insulin production 38. In addition, GLP-1 exerts multiple other functions, including 
inhibition of food intake 39, slowing the gastric emptying 40, inhibition of glucagon 
secretion 41, and improving glucose metabolism 41, 42. In addition, we (Chapter 10) and 
others 43, 44 observed that GLP-1 receptor agonists decrease plasma TG and VLDL-C level, 
and increase HDL-C level. Thus, GLP-1 receptor agonism may be a valuable target for 
both atherosclerosis and NASH. 
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Figure 1. Proposed mechanism underlying the ceTP-lowering effects of lipid-lowering interventions. 
(A) Under diseased conditions (e.g. NASH and atherosclerosis), macrophages infiltrate into both the vessel wall 
and the liver. In the liver, increased hepatic macrophages result in an overproduction of CETP, and consequently 
to an elevated plasma CETP pool. (B)  Lipid-lowering interventions, including both pharmacological (e.g. 
fenofibrate, niacin, pioglitazone and exendin-4) and dietary (e.g. caloric restriction) interventions, reduce 
the hepatic lipid content and concomitantly attenuate macrophage infiltration into the liver. The decreased 
number of hepatic macrophages leads to a reduction in hepatic CETP expression and plasma CETP level, as a 
result, generating a less atherogenic lipid phenotype. See text for further explanation.
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In chapter 8, we first investigated the mechanisms underlying the beneficial effects 
of GLP-1 receptor agonism on liver TG metabolism in E3L mice fed a high fat diet (HFD). 
We found that GLP-1 receptor agonists decreased hepatic VLDL particle production 
and completely reversed HFD-induced hepatic steatosis reflected by largely decreasing 
the hepatic lipid content to the low levels observed in chow-fed control mice. GLP-1 
receptor agonists decreased the expression of the nuclear transcription factor Srebp-1c 
and its targets Fasn and Dgat1, implying that GLP-1 receptor agonism primarily reduces 
hepatic lipogenesis, thereby causing a reduction in hepatic lipid content. Taken together 
with the concomitantly reduced Apob expression, GLP-1 receptor agonism lowers the 
hepatic availability of TG, thereby reducing the production of VLDL particles. In addition 
to decreasing hepatic lipogenesis and increasing fatty acid oxidation, GLP-1 receptor 
agonists activate AMP-activated protein kinase (AMPK) and SIRT (sirtuin) dependent on 
GLP-1 receptor expressed in hepatocytes 45, thereby improving hepatic glucose and lipid 
metabolism and relieving NAFLD. Recently, several clinical trials have confirmed that 
GLP-1 receptor agonists largely reduce the hepatic TG content in obese patients with 
T2DM 45, 46, indicating that the GLP-1 receptor is a promising novel target for treatment 
of NAFLD.
Moreover, in chapter 10, we observe that only 4 weeks of exendin-4 infusion 
markedly decreases total atherosclerotic lesion area, accompanied by a reduction in 
plaque macrophage content. Notably, in contrast to classical lipid-lowering compounds 
that reduce atherosclerosis mainly by improving dyslipidemia, exendin-4 only slightly 
decreased (V)LDL-C and TG, and increased HDL-C. Furthermore, exendin-4 also 
decreased hepatic inflammation reflected by reduced expression of inflammatory 
markers (e.g. TNFα, IL-1β and Il-6), as well as hepatic macrophage content. The GLP-1 
receptor is thus not only a promising target for NAFLD, but also NASH and atherosclerosis. 
It is interesting to note that atherosclerosis and NASH are strongly associated and 
share common etiologies, involving monocyte recruitment and macrophage foam 
cell formation 47. We demonstrated a reduced number of both adhering monocytes 
to the vessel wall and infiltrated macrophages into the liver after the treatment of 
exendin-4. In addition, exendin-4, via the GLP-1 receptor, reduced the uptake of oxLDL 
by macrophages, which may implicate reduced foam cell formation in the vessel wall 
and in the liver. Taken together, these data corroborate the hypothesis that exendin-4 
reduces the development of atherosclerosis and NASH simultaneously by acting directly 
on monocyte/macrophage recruitment/maturation into both the vessel wall and liver. 
So far, exendin-4 has been approved for the treatment of T2DM in the clinical practice. 
We show that GLP-1 receptor agonism not only suppresses diet-induced NAFLD, but 
also reduces the development of NASH and atherosclerosis, at least when administered 
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chronically by using an osmotic minipump. Therefore, we propose that GLP-1 receptor 
agonism is a novel strategy for treatment of atherosclerosis and NASH in addition to 
T2DM, in particular in patients who display a combination of these diseases. 
The role of brain in triglyceride metabolism  
The brain plays an important role in maintaining energy homeostasis, with the 
hypothalamus being its key regulator 48. Two major neuronal populations within 
the hypothalamic arcuate nucleus are involved in the regulation of energy intake, 
including pro-opiomelanocortin/cocaine and amphetamine-regulated transcript-
expressing neurons and neuropeptide Y (NPY)/agouti-related protein-expressing 
neurons. Although the role of brain in the regulation of glucose metabolism has been 
firmly established 49, only a few studies have focused on its function in maintaining TG 
homeostasis. Recently, accumulating evidence have suggested that various neuronal 
populations, such as NPY expressing neurons and the melanocortin (MC) expressing 
neurons, modulate sympathetic outflow from the hypothalamus towards target organs 
involved in TG metabolism, such as liver, white adipose tissue (WAT) and brown adipose 
tissue (BAT), and thereby modulate peripheral TG metabolism. For example, a recent 
study in rats showed that central administration of NPY acutely increases hepatic 
VLDL-TG production 50. Also, Bruinstroop et al. 51 further confirmed that hypothalamic 
NPY regulates hepatic VLDL secretion in rats via the sympathetic outflow, as selective 
sympathetic denervation of the liver abolished the effect of central NPY administration. 
In contrast to NPY signaling, central administration of melanocortin receptor (MC) 
receptor agonists decrease hepatic lipogenic gene expression in diabetic mice 52 and 
decrease hepatic TG content in rats 53. 
Hypertriglyceridemia, associated with increased hepatic VLDL-TG production 
and/or decreased VLDL-TG clearance, is an important risk factor for CVD 54, 55. Since 
atherosclerosis is generally studied in hyperlipidemic mice rather than in rats, in 
chapter 7, we set out to validate the effect of central NPY signaling on hepatic VLDL-
TG production in mice, with the ultimate goal to investigate whether NPY, by affecting 
VLDL-TG synthesis, contributes to the development of atherosclerosis. Although we 
confirmed that central administration of NPY acutely increases food intake in mice, 
similarly as in rats 56, surprisingly we were unable to detect any increase in hepatic VLDL-
TG production in mice after central NPY infusion. Likewise, antagonizing central NPY 
signaling by either PYY3-36 or Y1 receptor antagonism did not affect VLDL production in 
mice. Apparently, central NPY signaling exerts different effects on TG metabolism in rats 
versus mice. One potential explanation is that the hepatic VLDL metabolism in itself is 
differentially regulated in rats versus mice, as rats display lower basal hepatic VLDL-TG 
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production rates 50, 51 when compared to that in mice. Secondly, the expression of the 
several NPY receptors in rats versus mice is different. Both rats and mice express similar 
Y1-Y5 receptors 57, while only mice express the Y6 receptor 58. Although the exact function 
of Y6 receptor in appetite regulation remains elusive, if activation of this receptor by 
NPY would exert an opposing effect on hepatic VLDL production, this might explain our 
negative findings in mice. Notably, genetic association studies in humans have reported 
conflicting results on the association of polymorphisms in the NPY gene with plasma 
TG levels 59, 60. Collectively, these data emphasize the requirement of further research, 
particularly in humans, on the role of hypothalamic NPY in peripheral TG metabolism. 
In addition to hypothalamic NPY, gut hormones regulate energy homeostasis via 
activation of their receptors expressed in the brain. The GLP-1 receptor is abundantly 
expressed in various tissues 61, not only in the gastrointestinal tract, pancreatic islands, 
kidneys, and heart, but also in the central nervous system 62. After showing that GLP-1 
receptor agonism decreased hepatic VLDL-TG production and hepatic lipid content in 
mice (chapter 8), we next investigated whether the effects of GLP-1 receptor agonism 
on lipid metabolism would be dependent on central GLP-1 receptor signaling. We found 
that chronic central administration of the GLP-1 receptor antagonist exendin-9 did not 
counteract the peripherally administered exendin-4-induced decrease in hepatic VLDL-
TG production, suggesting that the beneficial effects of exendin-4 on hepatic lipid 
metabolism is not mediated by the central GLP-1 receptor signaling (unpublished). 
In contrast to our findings, Panjwani et al. 63 recently showed that acute central 
administration of exendin-4 rapidly decreased hepatic VLDL-TG production, indicating 
that central GLP-1 signaling might regulate hepatic lipid metabolism. There are several 
possible explanations for the distinct results obtained from our study and Panjwani’s 
study: (1) the dosage of exendin-9 used in our study is insufficient to block the effects of 
central GLP-1 receptor activation on hepatic lipid production, and (2) acute activation 
of the central GLP-1 signaling plays a more important role in hepatic VLDL production 
than chronic activation. Experiments combining central and/or peripheral GLP-1 
administration with hepatic denervations might prove an effective strategy to elucidate 
the exact role of central GLP-1 signaling in the regulation of hepatic TG metabolism. 
The hypothalamus not only regulates, via the modulation of sympathetic outflow, 
TG metabolism in the liver but also in white adipose tissue (WAT). For example, chronic 
central NPY infusion promoted lipogenesis in WAT, independent of its effects on food 
intake 64. Likewise, inhibition of central MC signaling induced the expression of lipogenic 
genes in WAT 65. In contrast, activation of central MC signaling by chronic infusion of 
an MC3/4 receptor agonist, increased the expression of lipolytic genes in WAT of rats. 
Additionally, central GLP-1 was implicated to regulate TG metabolism in WAT, as a mouse 
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study showed that central infusion of GLP-1 decreased TG content in WAT 66.
Unlike WAT, BAT combusts TG in the process of thermogenesis. Recently, evidence has 
accumulated to suggest that hypothalamic signaling also influence BAT thermogenesis. 
We and others showed that central infusion of NPY decreased BAT activity and 
thermogenesis, both in mice (unpublished) and in rats 67. Also, central infusion of MC4R 
antagonist resulted in decreased BAT thermogenesis in rats 68. Since those studies 
investigating the effect of neuroendocrine factors on BAT thermogenesis have neither 
focused on lipid metabolism nor performed TG clearance experiments, future studies 
should therefore emphasize the effect of central signaling on TG clearance by BAT.
Taken together, the brain, in particular the hypothalamus is an important regulator 
of peripheral TG metabolism. However, the exact role of specific neuroendocrine factors 
that mediate TG metabolism in liver and BAT needs to be determined by future research. 
Concluding remarks
The current strategies for the treatment of atherosclerosis, i.e. lipid-lowering strategies, 
are insufficient, and at the start of the studies described in this thesis no pharmacological 
agents had been identified thus far to treat NASH. Therefore, novel strategies for 
the treatment of those two diseases were eagerly warranted and currently under 
investigation. In addition to classical lipid-lowering agents, HDL-raising strategies, e.g. 
CETP inhibitors, are currently still considered as promising methods to treat dyslipidemia 
and ultimately CVD. However, current CETP inhibitors may affect the functionality of 
HDL. Therefore, other ways to reduce CETP levels may be advantageous. 
In this thesis, we demonstrated CETP to be involved in the HDL-raising effects 
of both lipid-lowering agents (i.e. fenofibrate, niacin, pioglitazone and the GLP-1 
receptor agonist exendin-4), as well as dietary lipid-lowering interventions (i.e. caloric 
restriction). In fact, we found that all of these interventions reduced plasma CETP level 
accompanied by reduction in hepatic lipid content. More mechanistic studies revealed 
that CETP is predominantly expressed by hepatic macrophages, and that reducing the 
hepatic macrophage content by lipid-lowering strategies reduces the hepatic CETP 
expression and plasma CETP level. Therefore, targeting the hepatic macrophage may be 
a promising alternative for CETP inhibitors to reduce the plasma CETP level and increase 
the HDL level. In addition, the fact that plasma CETP is mainly derived from hepatic 
macrophages, a hallmark of NASH, implies that measuring plasma CETP concentration 
may provide a useful relatively non-invasive biomarker for the hepatic macrophage 
content in NASH in clinical practice. In addition, we identified, by using E3L.CETP mice, 
the GLP-1 receptor as a novel target for the treatment of atherosclerosis and NASH in 
addition to T2DM, which need to be confirmed in future human studies.  
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Atherosclerosis and non-alcoholic steatohepatitis (NASH) are the leading causes of 
cardiovascular disease (CVD) and chronic liver disease, respectively, both of which remain 
common reasons of morbidity and mortality in the Western world. Atherosclerosis and 
NASH share the same etiologies, of which disturbed lipid metabolism manifested by 
dyslipidemia is the most important one, hallmarked by increased plasma levels of 
(V)LDL-cholesterol (C) and triglycerides (TG), and decreased plasma levels of HDL-C. 
Pharmacological lipid-lowering agents improving dyslipidemia are effective tools 
to prevent and treat atherosclerosis. However, since mortality and morbidity due to 
cardiovascular disease are only partially improved by current lipid-lowering strategies, 
novel strategies are currently under development aimed at further reduction of 
atherosclerosis. Since HDL-C levels are inversely associated with cardiovascular risk, 
one of these strategies is to raise HDL levels. As no pharmacological agents have been 
identified thus far to treat NASH, and no biomarkers are available to detect NASH, the 
search for both treatment modalities and biomarkers for NASH is also warranted.
Among HDL-raising strategies, infusion of reconstituted HDL (rHDL) seems to be 
a promising one for the treatment of CVD, as rHDL has been shown to induce 
atherosclerosis regression in human studies. Studies in mice indicated that rHDL 
infusion adversely affects VLDL levels, but this effect is less apparent in humans. This 
discrepancy may be explained by the fact that humans, in contrast to mice, express 
CETP. CETP plays a vital role in lipid metabolism by mediating the transfer of TG and CE 
between (V)LDL and HDL. In chapter 2, we investigated the role of CETP in the effects 
of rHDL on VLDL metabolism by using APOE*3-Leiden (E3L) mice, a well-established 
model for human-like lipoprotein metabolism, which had been crossbred with mice 
expressing human CETP under control of its natural flanking regions (E3L.CETP mice). 
At 1 hour after injection, rHDL increased plasma VLDL-C and TG in E3L mice, but not in 
E3L.CETP mice. This initial raise in VLDL was caused by competition between rHDL and 
VLDL for lipoprotein lipase (LPL)-mediated TG hydrolysis, and was thus prevented by 
the expression of CETP. At 24 hours after injection, rHDL caused a second increase in 
VLDL-C and TG in E3L mice, whereas rHDL even decreased VLDL in E3L.CETP mice. This 
secondary raise in VLDL was due to increased hepatic VLDL-TG production. Collectively, 
we concluded that CETP protects against the rHDL-induced increase in VLDL, and that 
treatment of atherogenic dyslipidemia by rHDL should thus not be combined with 
agents that aggressively reduce CETP activity.
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Thiazolidinediones (PPARγ agonists) decrease plasma TG, increase HDL-C and reduce 
hepatic steatosis. Since previous studies in mice have shown that reduction of hepatic 
steatosis by lipid-lowering agents is accompanied by reduced hepatic CETP expression 
and plasma CETP levels, which may explain a secondary increase in HDL-C, we assessed 
in chapter 3 the effects of pioglitazone on plasma CETP levels in patients with type 
2 diabetes mellitus (T2DM). Patients with T2DM were randomized to treatment with 
pioglitazone or metformin and matching placebos, in addition to glimepiride. At 
baseline and after 24 weeks of treatment, plasma HDL-C and CETP levels were measured, 
and hepatic TG content was assessed by proton magnetic resonance spectroscopy. 
Pioglitazone decreased the hepatic TG content, which was indeed associated with 
decreased plasma CETP levels and increased plasma HDL-C levels, whereas metformin 
did not significantly change any of these parameters. We concluded that the decrease 
in hepatic TG content by pioglitazone was accompanied by a decrease in plasma CETP 
concentration and, therefore, associated with an increase in HDL-C levels. 
In contrast to pharmacological interventions, lifestyle interventions such as diet-
induced weight loss and exercise are still the mainstays for the treatment of NASH. We 
recently reported that a 16-week very low calorie diet (VLCD) significantly decreased 
plasma total cholesterol (TC) and TG levels and markedly reduced the hepatic TG 
content in obese patients with T2DM and hepatic steatosis, but the potential beneficial 
effect of a VLCD on plasma CETP and  HDL levels had not been studied. In chapter 4, we 
investigated the effects of VLCD, resulting in a major reduction in hepatic TG content, 
on plasma CETP and HDL levels in obese patients with T2DM and hepatic steatosis. 
VLCD markedly decreased plasma CETP concentration and increased plasma apoAI 
levels, without significantly affecting plasma HDL-C and HDL-phospholipids levels. 
Although VLCD resulted in HDL that was less lipidated, the functionality of HDL with 
respect to inducing cholesterol efflux in vitro was unchanged. Therefore, we concluded 
that the marked decrease in hepatic TG content induced by VLCD was accompanied 
by a decrease in plasma CETP concentration and an increase in apoAI levels, without 
improving the cholesterol efflux properties of HDL in vitro. 
Niacin (nicotinic acid) is the most potent HDL-raising drug used in the clinic practice. 
In addition to raising the level of anti-atherogenic HDL-C, niacin also decreases plasma 
levels of pro-atherogenic lipoproteins and lipids including VLDL, LDL and TG. Therefore, 
niacin is regarded as a candidate for the treatment of atherosclerosis. Niacin has recently 
been shown in E3L.CETP mice to decrease the hepatic lipid content, accompanied with 




HDL-C. In chapter 5, we investigated the mechanisms underlying the CETP-lowering 
effect of niacin by using human CETP transgenic mice. In vitro studies demonstrated 
that niacin did not directly attenuate CETP expression in macrophages. In vivo studies 
showed that niacin reduced the hepatic cholesterol content and attenuated Western 
type diet-induced hepatic inflammation. Furthermore, niacin reduced the hepatic 
gene expression and plasma level of CETP. Concomitantly, niacin decreased the hepatic 
expression of CD68 and ABCG1, both of which are specific markers for the hepatic 
macrophage content, as well as the actual hepatic macrophage content. In fact, the 
hepatic CETP expression was significantly correlated with the hepatic macrophage 
markers. We concluded that niacin decreases hepatic CETP expression and plasma 
CETP mass by attenuating liver inflammation and macrophage content in response to 
its primary lipid-lowering effect, rather than by attenuating the CETP expression level 
within macrophages.
Since CETP is a current target for treating dyslipidemia, it is crucial to understand the 
true origin of CETP in humans. Previous studies indicated that adipose tissue and liver 
are the two major sources of plasma CETP. However, the relative contribution of tissue-
specific CETP expression to plasma CETP levels is unknown. Therefore, in chapter 6, 
we aimed to elucidate the cellular origin of CETP using human cohorts and E3L.CETP 
mice. In a general population study, plasma CETP levels did not correlate with waist 
circumference, suggesting that central adipose tissue does not contribute to plasma 
CETP. Microarray analysis of liver and adipose tissue biopsies from bariatric surgery 
patients showed that CETP expression was highest in the liver, and correlated with 
inflammatory pathways. Immunohistochemistry revealed that CETP was primarily 
expressed by hepatic macrophages. CETP expression in liver, but not adipose tissue, 
positively correlated with plasma CETP levels, and inversely correlated with plasma 
HDL-C. Selective elimination of macrophages from liver versus adipose tissue in 
E3L.CETP mice virtually abolished hepatic CETP expression, but not adipose tissue CETP 
expression, accompanied by largely reduced plasma CETP concentration and increased 
plasma HDL-C. Treatment of E3L.CETP mice with lipid-lowering drugs that are known to 
reduce the plasma CETP concentration and to increase HDL-C in humans, reduced the 
hepatic macrophage content, thereby reducing plasma CETP and increasing HDL-C. We 
concluded that plasma CETP is primarily derived from liver macrophages and plasma 
CETP is a biomarker for the hepatic macrophage content, a hallmark of NASH for which 
no non-invasive diagnostic tool is currently available.
Accumulating evidence indicates that strategies targeting regulation of energy 
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homeostasis and food intake also beneficially affect lipid metabolism, and have 
the potential to treat atherosclerosis and NASH. The brain plays an important role in 
mediating energy homeostasis, with the hypothalamus being its key regulator. Two 
major neuronal populations within the hypothalamic arcuate nucleus are involved in the 
regulation of food intake, including pro-opiomelanocortin/cocaine- and amphetamine-
regulated transcript-expressing neurons and neuropeptide Y (NPY)/agouti-related 
protein-expressing neurons. Previous studies suggested that central NPY administration 
increases hepatic production of VLDL-TG in rats. In chapter 7, we set out to validate 
the effects of central NPY on hepatic VLDL production in mice, to ultimately investigate 
whether NPY, by inducing dyslipidemia, affects the development of atherosclerosis. 
Administration of NPY into both the lateral and third ventricle of the brain of mice 
increased food intake within one hour after injection, but had no effects on hepatic 
VLDL-TG or VLDL-apoB production. Likewise, antagonizing central NPY signaling did not 
affect hepatic VLDL production. We concluded that in mice, as opposed to rats, acute 
central administration of NPY increases food intake without affecting hepatic VLDL 
production. This apparent species difference in the effect of NPY on hepatic VLDL-TG 
production is of great significance for future animal studies on the central regulation of 
hepatic VLDL metabolism. 
Human studies suggested that glucagon-like peptide-1 (GLP-1) receptor agonism 
not only modulates energy homeostasis and improves glucose metabolism, but also 
decreases the plasma TG level. However, the mechanism underlying the reduction in 
plasma TG remained unclear. In chapter 8, we evaluated the effects of GLP-1 receptor 
agonism on TG metabolism in high fat diet (HFD)-fed E3L mice. Four weeks of treatment 
with GLP-1 receptor agonists (i.e. CNTO3649 and exendin-4) by using subcutaneous 
osmotic minipumps improved glycemic control by reducing fasting plasma glucose and 
insulin levels. In addition, both GLP-1 receptor agonists reduced hepatic VLDL-TG and 
VLDL-apoB production, indicating reduced production of VLDL particles rather than 
reduced lipidation of apoB. Moreover, GLP-1 receptor agonism markedly decreased the 
hepatic content of TG, cholesterol and phospholipids, accompanied by down-regulation 
of expression of genes involved in hepatic lipogenesis (Srebp-1c, Fasn, Dgat1) and apoB 
synthesis (Apob). We concluded that GLP-1 receptor agonism, in addition to improving 
glycemic control, ameliorates dyslipidemia and reduces hepatic steatosis. 
Since our studies showed that exendin-4 improves glycemic control and lipid 
metabolism, and reverses HFD-induced hepatic steatosis (chapter 8), we anticipated that 




However, the impact of GLP-1 receptor agonism on NASH, especially with respect to 
hepatic inflammation, was still uncertain. Since the development of atherosclerosis and 
NASH share common etiologies, in chapter 9 we evaluated the effects of exendin-4 on 
the development of atherosclerosis and NASH simultaneously by using E3L.CETP mice 
fed a Western-type diet. Although four weeks of treatment with exendin-4 only slightly 
reduced plasma lipid and lipoprotein levels, it markedly decreased atherosclerotic 
lesion severity and area, accompanied with a reduction in monocyte adhesion to the 
vessel wall and macrophage content in the plaque. Furthermore, exendin-4 reduced 
the hepatic cholesterol content as well as the hepatic CD68+ and F4/80+ macrophage 
content indicating that exendin-4 attenuated diet-induced NASH. This was accompanied 
by less monocyte recruitment from the circulation as the hepatic Mac-1+ macrophage 
content was decreased. Finally, exendin-4 reduced chemokine expression in vivo and 
suppressed oxLDL accumulation in peritoneal macrophages in vitro, dependent on the 
GLP-1 receptor, suggesting that exendin-4 reduces both atherosclerosis and NASH by 
reducing macrophage recruitment and activation. We concluded that exendin-4 could 
be a valuable strategy to treat atherosclerosis and NASH in addition to T2DM, especially 
in patients who display a combination of these diseases.
In addition to lipid-lowering strategies, anti-inflammatory agents that are aimed at 
reducing the risk of CVD are now under development. Glucocorticoids are one of the 
strongest anti-inflammatory drugs widely used as immunosuppressive agents in the 
clinical practice. However, glucocorticoids excess can also induce adverse metabolic 
effects in adipose tissue, such as central obesity and insulin resistance, which may 
attenuate the potentially protective effects of glucocorticoids on CVD. In chapter 10, 
we investigated the effects of both transient and continuous glucocorticoid treatment 
on atherosclerosis development by using E3L.CETP mice, which display human-like 
lipoprotein metabolism upon feeding a Western-type diet. Although both 5 weeks 
(transient) and 17 weeks (continuous) of corticosterone (CORT) treatment increased 
body weight and food intake for the duration of the treatment, only continuous CORT 
treatment induced changes in body composition with lower adrenal weight and 
higher gonadal and subcutaneous fat pad weights at 17 weeks. Moreover, the group 
that continuously received CORT displayed increased plasma insulin levels and HOMA-
IR index, indicating that long-term administration of glucocorticoids induces insulin 
resistance. Strikingly, both transient and continuous CORT treatment decreased total 
atherosclerotic lesion area after 17 weeks to a similar extent, without affecting either 
plasma lipid levels or lipoprotein profiles, accompanied by decreased macrophage 
content in the atherosclerotic plaque. We concluded that CORT treatment per se has 
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long-lasting beneficial effects on atherosclerosis development. Therefore, in clinical 
practice, glucocorticoids schemes as used for anti-inflammatory indications might 
benefit from adjustments towards higher doses for a shorter period of time instead of 
lower dosages for a prolonged period of time.  
Taken together, the studies described in this thesis have contributed to the discovery 
of CETP as a biomarker for the hepatic macrophage content, a hallmark of NASH for 
which no non-invasive diagnostic method is currently available, and discovery of novel 
therapeutic modalities for atherosclerosis and NASH. First of all, we gained more insight 
into the true cellular origin of CETP (i.e. the liver macrophage), and the mechanisms 
underlying the CETP-lowering effects of HDL-raising agents (i.e. by reducing the hepatic 
macrophage content). We extrapolated the association between the reduction of 
hepatic lipid content and plasma CETP concentration upon lipid-lowering interventions 
from mice to humans. Furthermore, we demonstrated the role of CETP in discrepant 
effects of rHDL on VLDL metabolism between mice and humans, and reported a species 
difference in the central regulation of hepatic VLDL metabolism by NPY between 
mice and rats, which underscores a general concern in animal research in view of 
extrapolating findings from specific animal studies to explain observations done in 
humans. Additionally, we demonstrated that CORT has long-lasting beneficial effects 
on atherosclerosis development suggesting a possibility for therapeutic application of 
anti-inflammatory agents in CVD. Finally, we described GLP-1 receptor agonism as a 
novel strategy to improve lipid metabolism and hepatic inflammation, which may result 





Atherosclerose en non-alcoholische steatohepatitis (NASH) zijn de voornaamste oorzaken 
van respectievelijk hart- en vaatziekten (HVZ) en chronische leverziekte. Dit zijn beide 
belangrijke factoren voor morbiditeit en mortaliteit in de westerse wereld. Atherosclerose 
en NASH delen een vergelijkbare etiologie, waarbij een verstoord vetmetabolisme 
de belangrijkste factor is. Dit komt tot uiting door dyslipidemie, gekenmerkt door 
verhoogde plasmaniveaus van (V)LDL-cholesterol (C) en van triglyceriden (TG), en een 
verlaagd plasmaniveau van HDL-C. Lipidenverlagende geneesmiddelen die dyslipidemie 
verbeteren zijn effectieve middelen om atherosclerose te voorkomen en behandelen. 
Echter, omdat de mortaliteit en morbiditeit geassocieerd met HVZ slechts gedeeltelijk 
worden verbeterd door de huidige lipidenverlagende strategieën zijn momenteel 
nieuwe strategieën in ontwikkeling met als doel atherosclerose verder te reduceren. 
Aangezien het HDL-C niveau omgekeerd gecorreleerd is met het cardiovasculair risico, 
behoort het verhogen van HDL-C tot deze nieuwe strategieën. Omdat er nog geen 
farmacologische middelen zijn geïdentificeerd voor het behandelen van NASH en er 
nog geen biomarkers beschikbaar zijn om NASH te detecteren, is het ook noodzakelijk 
te zoeken naar behandelingsstrategieën en biomarkers voor NASH.
Omdat gereconstitueerd HDL (rHDL) een regressie van atherosclerose teweeg bracht in 
humane studies, lijkt infusie van rHDL, als onderdeel van HDL-verhogende strategieën, 
veelbelovend voor de behandeling van HVZ. Studies in muizen lieten zien dat rHDL het 
plasmaniveau  van VLDL verhoogde, een effect dat minder duidelijk was in mensen. Dit 
verschil kan mogelijk verklaard worden door het feit dat de mens, in tegenstelling tot de 
muis, het cholesteryl ester transfer proteïne (CETP) tot expressie brengt. CETP speelt een 
belangrijke rol in het lipidenmetabolisme door het faciliteren van de overdracht van de 
neutrale lipiden triglyceriden (TG) en cholesteryl esters (CE) tussen (V)LDL en HDL. In 
hoofdstuk 2 hebben we de rol van CETP in de effecten van rHDL op het VLDL metabolisme 
onderzocht in APOE*3-Leiden (E3L) en APOE*3-Leiden.CETP (E3L.CETP) transgene muizen 
die uitstekende modellen vormen voor het lipoproteïnenmetabolisme in de mens. Eén 
uur na injectie verhoogde rHDL de niveaus van VLDL-C en TG in E3L muizen, maar niet 
in E3L.CETP muizen. Deze initiële toename in VLDL werd veroorzaakt door competitie 
tussen rHDL en VLDL voor de lipoproteïne lipase (LPL)-gemedieerde hydrolyse van TG, 
en werd dus voorkomen door de expressie van CETP. Vierentwintig uur na injectie van 
rHDL werd een tweede toename in VLDL-C en TG in E3L muizen waargenomen, terwijl 
het VLDL zelfs was verlaagd in E3L.CETP muizen. Deze secundaire stijging in VLDL werd 
veroorzaakt door een verhoogde VLDL-TG productie. Uit deze studie concludeerden wij 
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dat CETP beschermt tegen de rHDL-geïnduceerde stijging van VLDL en dat behandeling 
van atherogene dyslipidemie met rHDL niet gecombineerd zou moeten worden met 
middelen die CETP activiteit op een agressieve manier verlagen.
Thiazolidinediones (PPARγ agonisten) verlagen het plasma TG niveau, verhogen het 
plasma HDL-C niveau, en reduceren hepatische steatose. Eerdere studies in muizen 
hebben aangetoond dat reductie van hepatische steatose door lipidenverlagende 
middelen samengaat met verlaagde hepatische CETP expressie en een verlaagd 
plasmaniveau van CETP, wat vervolgens kan leiden tot een verhoging van het HDL-C 
gehalte. Daarom hebben we in hoofdstuk 3 het effect van de thiazolidinedione 
pioglitazon op het CETP niveau in patiënten met type 2 diabetes mellitus (T2DM) 
onderzocht. Patiënten met T2DM werden gerandomiseerd tot behandeling met 
pioglitazon of metformine, bovenop behandeling met glimepiride. Aan het begin 
van de behandeling en na 24 weken behandeling werden de plasmaniveaus van 
HDL-C en CETP gemeten en werd de hepatische TG inhoud bepaald door middel van 
proton magnetische resonantie spectroscopie. Pioglitazon verlaagde het hepatische 
TG gehalte, wat inderdaad geassocieerd was met een verlaagd plasma CETP niveau 
en een verhoogd plasma HDL-C gehalte, terwijl metformine geen effect had op deze 
parameters. Wij concludeerden dan ook dat de verlaging van de hepatische TG inhoud 
door pioglitazon vergezeld ging van een verlaging in plasma CETP concentratie, en 
daarom geassocieerd was met een verhoging in HDL-C. 
Bij gebrek aan farmacologische geneesmiddelen, wordt NASH momenteel nog 
voornamelijk behandeld door aanpassing van gedrag, d.w.z. afvallen en meer bewegen. 
Recent toonden wij aan dat een zeer laag calorisch dieet (VLCD) gedurende 16 weken 
het plasma totaal cholesterol (TC) en TG niveau significant verlaagde, en daarbij het 
hepatisch TG gehalte verlaagde in obese patiënten met T2DM en hepatische steatose. 
Een mogelijk gunstig effect van een dergelijk VLCD op plasma CETP en HDL niveaus 
was echter nog niet onderzocht. In hoofdstuk 4 onderzochten wij de effecten van 
een VLCD dat resulteerde in een forse verlaging van het hepatische TG gehalte op het 
plasma CETP en HDL niveau in obese patiënten met T2DM en hepatische steatose. 
Het VLCD verlaagde de plasma CETP concentratie en verhoogde het plasma apoAI 
niveau, zonder een effect te hebben op het plasma HDL-C en HDL-fosfolipidengehalte. 
Hoewel het VLCD resulteerde in minder gelipideerd HDL was de functionaliteit van 
het HDL met betrekking tot het induceren van cholesterolefflux vanuit macrofagen 
in vitro onveranderd. Wij concludeerden daarom dat de aanzienlijke verlaging van het 




concentratie en een stijging in apoAI niveau, zonder de eigenschappen van het HDL 
m.b.t. cholesterolefflux te verbeteren.
Niacine (nicotinezuur) is het meest potente HDL-verhogende middel dat in de kliniek 
wordt toegepast. Naast het verhogen van het HDL-C niveau verlaagt niacine ook het 
plasmaniveau van proatherogene lipoproteïnen en lipiden waaronder VLDL, LDL en 
TG. Daarom wordt niacine gezien als een goede kandidaat voor het behandelen van 
atherosclerose. In E3L.CETP muizen verlaagde niacine het hepatische TG gehalte, wat 
samenging met een verlaging van de hepatische genexpressie en het plasmaniveau 
van CETP en een verhoging van het HDL-C. In hoofdstuk 5 hebben we het mechanisme 
onderzocht waardoor niacine CETP verlaagt door gebruik te maken van transgene 
muizen die humaan CETP tot expressie brengen. In vitro studies toonden aan dat 
niacine niet direct de CETP expressie in macrofagen verlaagde. In vivo studies lieten 
zien dat niacine in CETP transgene muizen op een westers dieet het hepatische 
cholesterolgehalte en de ontsteking in de lever verlaagde. Niacine reduceerde ook 
de hepatische genexpressie van CETP en het plasmaniveau van CETP. Tegelijkertijd 
verlaagde niacine de hepatische expressie van CD68 en ABCG1 (beide specifieke markers 
voor de macrofaaginhoud van de lever) als ook het gehalte aan macrofagen in de lever. 
De hepatische CETP expressie was zelfs significant gecorreleerd met de hepatische 
macrofaagmarkers. Wij concludeerden dat niacine de hepatische CETP expressie en 
de plasma CETP concentratie verlaagt door het reduceren van leverontsteking en de 
macrofaaginhoud van de lever ten gevolge van zijn primaire lipidenverlagende effect, 
en niet door de expressie van CETP in de macrofaag te verlagen.
Omdat CETP een huidig doel is voor de behandeling van dyslipidemie is het cruciaal 
om de bron van het CETP in de mens te identificeren. Eerdere studies toonden aan dat 
CETP vooral gesynthetiseerd wordt in vetweefsel en in de lever. Echter, de relatieve 
bijdrage van de weefselspecifieke CETP expressie aan het plasma CETP niveau was 
nog onbekend. Daarom was het doel van hoofdstuk 6 om de cellulaire bron van CETP 
op te helderen door gebruik te maken van humane cohorten en E3L.CETP muizen. 
In een algemene populatie, de Rijswijk studie, bleek het plasma CETP niveau niet te 
correleren met de buikomvang, wat suggereert dat centraal vetweefsel niet bijdraagt 
aan de plasma CETP pool. Microarray analyse van lever- en vetweefselbiopten van 
patiënten die bariatrische chirurgie hadden ondergaan, toonden aan dat de CETP 
expressie in de lever het hoogst was en correleerde met inflammatoire reactiepaden. 
Via immunohistochemische technieken werd duidelijk dat CETP vooral tot expressie 
kwam in hepatische macrofagen. De expressie van CETP in de lever, maar niet in 
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vetweefsel, correleerde positief met het plasma CETP niveau en omgekeerd met het 
plasma HDL-C niveau. Selectieve eliminatie van macrofagen uit de lever ten opzichte 
van vetweefsel in E3L.CETP muizen deed de CETP expressie nagenoeg teniet in de lever, 
maar niet in vetweefsel, en leidde tot een sterk verlaagde plasma CETP concentratie 
en een verhoging van het plasma HDL-C. Behandeling van E3L.CETP muizen met 
lipidenverlagende middelen waarvan bekend is dat zij in de mens de plasma CETP 
concentratie verlagen en de HDL-C concentratie verhogen, reduceerde de hoeveelheid 
macrofagen in de lever, verlaagde het plasma CETP niveau en verhoogde het HDL-C. 
Wij concludeerden dat plasma CETP primair wordt gesynthetiseerd door macrofagen 
in de lever en dat plasma CETP een biomarker is voor de hoeveelheid macrofagen in de 
lever, een belangrijke factor van NASH waarvoor nog geen non-invasieve diagnostische 
middelen voorhanden zijn.
Toenemend bewijs toont aan dat strategieën gericht op het reguleren van de 
energiehomeostase en voedselopname ook het vetmetabolisme gunstig beïnvloeden 
en mogelijk zowel atherosclerose als NASH kunnen behandelen. De hersenen spelen 
een belangrijke rol bij de energiehomeostase, waarbij de belangrijkste rol is weggelegd 
voor de hypothalamus. Twee belangrijke neuronale populaties in de arcuate nucleus 
van de hypothalamus zijn betrokken in de regulatie van de voedselinname: de neuronen 
die het pro-opiomelanocortine/cocaine- and amphetamine-gereguleerde transcript 
tot expressie brengen, en de neuronen die neuropeptide Y (NPY)/agouti-gerelateerde 
proteïne tot expressie brengen. Eerdere studies lieten zien dat centrale toediening van 
NPY de productie van VLDL-TG door de lever verhoogde. In hoofdstuk 7 wilden we het 
effect van centraal NPY op de hepatische VLDL-TG productie in muizen valideren om 
uiteindelijk te onderzoeken of NPY bijdraagt aan de ontwikkeling van atherosclerose 
door dyslipidemie te induceren. Toediening van NPY in zowel de laterale als derde 
ventrikel in de hersenen van muizen verhoogde de voedselinname binnen een uur 
na injectie, maar had geen effect op de hepatische productie van VLDL-TG of VLDL-
apoB. Eveneens had het blokkeren van de centrale NPY signalering geen effect op de 
hepatische VLDL productie. We concludeerden dat acute centrale toediening van NPY 
in muizen de voedselinname verhoogt net zoals in ratten, maar dat het in tegenstelling 
tot in ratten de VLDL productie in muizen niet beïnvloedt. Dit diersoortafhankelijke 
effect met betrekking tot het effect van NPY op de hepatische VLDL-TG productie is van 
groot belang voor toekomstige studies naar de centrale regulatie van het hepatische 
VLDL metabolisme. 




1) receptor niet alleen het energiemetabolisme en het glucosemetabolisme verbetert, 
maar ook het plasma VLDL niveau verlaagt. Het achterliggende mechanisme van 
de reductie in het plasma TG was echter nog onbekend. In hoofdstuk 8 hebben we 
daarom de effecten onderzocht van GLP-1 receptor agonisme op het TG metabolisme 
door gebruik te maken van E3L muizen die een vetrijk dieet gevoerd werden. 
Behandeling met de GLP-1 receptor agonisten CNTO3649 en exendin-4 gedurende 4 
weken d.m.v. subcutane osmotische minipompjes verbeterde de glucosehuishouding 
door het plasmaniveau van glucose en insuline in gevaste dieren te verlagen. Daarnaast 
reduceerden de GLP-1 receptor agonisten ook de hepatische productie van VLDL-TG en 
VLDL-apoB door een verlaagde productie van VLDL deeltjes en niet door minder lipidatie 
van apoB. Tegelijkertijd bleek GLP-1 receptor agonisme het hepatische lipidengehalte 
aanmerkelijk te verlagen. Deze verlaging ging samen met een downregulatie van de 
expressie van genen die betrokken zijn bij de hepatische lipogenese (Srebp-1c, Fasn, 
Dgat1) en de apoB synthese (Apob). We concludeerden dat GLP-1 receptor agonisme, 
naast het verbeteren van de glucosehuishouding, ook in staat is dyslipidemie en 
hepatische steatose te verbeteren.
Omdat onze studies aantoonden dat exendin-4 het vetmetabolisme verbetert en 
vetrijk dieet-geïnduceerde hepatische steatose geheel kan voorkomen (hoofdstuk 8) 
anticipeerden wij dat GLP-1 receptor agonisme mogelijk ook atherosclerose en ziekte 
gerelateerd aan een vette lever zou kunnen behandelen. Echter, de impact van GLP-
1 receptor agonisme op NASH was nog onduidelijk, zeker met betrekking tot het 
effect op hepatische ontsteking. Omdat de ontwikkeling van atherosclerose en NASH 
een gemeenschappelijke etiologie delen hebben we in hoofdstuk 9 het effect van 
exendin-4 op de ontwikkeling van atherosclerose en NASH tegelijkertijd onderzocht 
door wederom gebruik te maken van E3L.CETP muizen op een westers dieet. Hoewel 
vier weken behandeling met exendin-4 slechts een lichte verlaging veroorzaakte van 
het plasmaniveau van lipiden en lipoproteïnen, bracht het een aanzienlijke verlaging 
teweeg in de mate en ernst van atherosclerose, vergezeld van een reductie in de adhesie 
van monocyten aan de vaatwand en het macrofaaggehalte in de atherosclerotische 
plaques. Exendin-4 bleek ook de hoeveelheid cholesterol en CD68+ en F4/80+ 
macrofagen in de lever te verlagen, wat aangeeft dat exendin-4 de dieet-geïnduceerde 
ontwikkeling van NASH remt. Dit ging samen met een verlaagde aantrekking van 
monocyten uit het bloed aangezien de hoeveelheid Mac-1+ macrofagen in de lever 
was verlaagd. Tenslotte reduceerde exendin-4 de expressie van chemokines in vivo en 
onderdrukte het de stapeling van oxLDL in peritoneale macrofagen in vitro afhankelijk 
van de GLP-1 receptor, wat suggereert dat exendin-4 zowel atherosclerose als NASH 
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vermindert door verlaagde aantrekking/activatie van macrofagen uit het bloed. Wij 
concludeerden dan ook dat GLP-1 receptor agonisme een waardevolle strategie zou 
kunnen zijn om naast T2DM ook atherosclerose en NASH te behandelen, met name in 
patiënten die lijden aan een combinatie van deze ziekten.
Naast lipidenverlagende strategieën zijn ook anti-inflammatoire strategieën in 
ontwikkeling voor het verlagen van het risico op HVZ. Glucocorticoïden hebben 
een sterk anti-inflammatoir karakter en worden extensief toegepast in de klinische 
praktijk als immunosuppressiva. Echter, een overmaat aan glucocorticoïden kan ook 
negatieve metabole effecten veroorzaken in vetweefsel, zoals centrale obesitas en 
insulineresistentie, die de mogelijke beschermende effecten van glucocorticoïden op 
HVZ kunnen tegengaan. In hoofdstuk 10 onderzochten we de effecten van tijdelijke 
en continue behandeling met glucocorticoïden op de ontwikkeling van atherosclerose 
door gebruik te maken van E3L.CETP muizen op een westers dieet. Hoewel behandeling 
met corticosteron (CORT) gedurende 5 weken (‘tijdelijk’) en 14 weken (‘continu’) het 
lichaamsgewicht en de voedselinname deed toenemen gedurende de duur van de 
interventie, induceerde alleen continue behandeling met CORT een lager bijniergewicht 
en hoger gewicht van gonadale en subcutane vetkussens na 17 weken. Bovendien nam 
de insulinespiegel en HOMA-IR index toe in de muizen die continu werden behandeld met 
CORT, wat erop duidt dat langdurige toediening van glucocorticoïden insulineresistentie 
induceert. Het was opvallend dat zowel tijdelijke als continue behandeling met CORT na 
17 weken atherosclerose in gelijke mate deden afnemen zonder een effect te hebben 
op het plasmaniveau van lipiden en lipoproteïnen. Deze reductie in plaquegrootte ging 
vergezeld van een verlaagde hoeveelheid macrofagen in de atherosclerotische plaque. 
Wij concludeerden dat behandeling met CORT langdurige gunstige effecten heeft op 
de ontwikkeling van atherosclerose. In de klinische praktijk zouden anti-inflammatoire 
strategieën met glucocorticoïden dus aangepast kunnen worden van langdurende 
behandeling met een lage dosis naar kortdurende behandeling met een hoge dosis.
Samenvattend kan gezegd worden dat de studies die beschreven staan in dit 
proefschrift hebben bijgedragen aan de identificatie van CETP als een biomarker voor 
de hoeveelheid macrofagen in de lever, een belangrijke factor in NASH waarvoor nog 
geen non-invasieve diagnostische middelen voorhanden waren, en aan de identificatie 
van mogelijk nieuwe therapeutische handvatten voor atherosclerose en NASH. 
Allereerst verkregen we meer inzicht in de cellulaire bron van CETP (de macrofaag in de 
lever) en het mechanisme waardoor HDL-verhogende geneesmiddelen de plasma CETP 




in staat de associatie tussen de reductie van de hepatische lipidenconcentratie en de 
plasma CETP concentratie na lipidenverlagende interventies te vertalen van de muis 
naar de mens. Ook toonden we de rol aan van CETP in de divergerende effecten van 
rHDL op het VLDL metabolisme in de muis en in de mens, en onthulden een verschil in 
de centrale regulatie van de hepatische VLDL productie tussen muizen en ratten. Deze 
bevinding onderstreept een algemene bezorgdheid over dierproefonderzoek met 
betrekking tot extrapolatie van bevindingen van specifieke dierstudies om observaties 
in mensen te verklaren. Eveneens toonden we aan dat CORT langdurige gunstige 
effecten heeft op de ontwikkeling van atherosclerose, wat een mogelijke toepassing van 
anti-inflammatoire strategieën in HVZ onderstreept. Tenslotte beschreven we continue 
GLP-1 receptor agonisme als een nieuwe strategie om zowel het lipidenmetabolisme 
als leverontsteking positief te beïnvloeden, wat kan resulteren in nieuwe strategieën 
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